GOOD MORNING AND WELCOME.
I WOULD LIKE TO CALL TO ORDER
THE 63rd MEETING OF THE NIH
ADVISORY COMMITTEE ON RESEARCH
ON WOMEN'S HEALTH.
MY NAME IS VIVIAN OTA WANG AND
I'M THE ACTING DIRECTOR OF THE
OFFICE OF STRATEGIC COORDINATION
ON DETAIL FROM ORWH AND THE
DEPUTY DIRECTOR OF THE OFFICE OF
RESEARCH ON WOMEN'S HEALTH.
THIS MEETING IS OPEN TO THE
PUBLIC, VIA LIVE BROADCAST ON
THE NIH VIDEO NETWORK AND IT'S
BEING RECORDED FOR OUR ARCHIVES
AND FOR FUTURE ON DEMAND VIEWING
BY THE PUBLIC.
NEXT SLIDE, PLEASE.
IF YOU ARE A MEMBER OF THE
PUBLIC, PER THE FEDERAL REGISTER
NOTICE, YOU MAY SUBMIT QUESTIONS
IN WRITING TO ME AT A
CRWH@NIH.GOV AS YOU CAN SEE ON
THE SCREEN AND WE WILL ADDRESS
QUESTIONS AFTER THE MEETING.
NEXT SLIDE, PLEASE.
THIS MEETING IS VIRTUAL ISSUE
THE ADVISORY COMMITTEE AND OUR
INVITED GUEST PRESENTERS ARE
PARTICIPATING THROUGH TEAMS.
NOW A MESSAGE TO OUR MEMBERS AND
THIS IS A REMINDER BECAUSE
YOU'RE SPECIAL GOVERNMENT
EMPLOYEES.
AS MEMBERS OF THIS FEDERAL
ADVISORY COMMITTEE, YOU ARE A
SPECIAL GOVERNMENT EMPLOYEES,
WHICH MEANS YOU ARE SUBJECT TO
THE SAME ETHICS RULES THAT APPLY
TO GOVERNMENT EMPLOYEES, THESE
RULES ARE DESCRIBED IN THE
PAMPHLET TITLED STANDARDS OF
ETHICAL CONDUCT FOR EMPLOYEES OF
THE EXECUTIVE BRANCH.
YOU RECEIVED A COPY OF THIS
DOCUMENT WHEN YOU WERE
APPOINTED.
AT EVERY MEETING WE WOULD LIKE
TO REVIEW THE STEPS WE TAKE AND
THE PROCESS WE FOLLOW TO
IDENTIFY AND ADDRESS ANY
CONFLICTS BETWEEN YOUR PUBLIC
RESPONSIBILITIES AND YOUR
PRIVATE INTERESTS.
AS YOU KNOW BEFORE EACH MEETING
YOU PROVIDE US WITH A GREAT DEAL
OF INFORMATION ABOUT YOUR
PROFESSIONAL AND PERSONAL
FINANCIAL INTEREST MPLET WE USE
THIS INFORMATION AS A FOUNDATION
FOR ASSESSING WHETHER YOU HAVE
ANY REAL, POTENTIAL OR APPARENT
CONFLICTS OF INTEREST THAT COULD
COMPROMISE YOUR ABILITY TO BE
OBJECT IN GIVING ADVICE DURING
OUR COMMITTEE MEETINGS.
IF THE NEED FOR YOUR INDIVIDUAL
SERVICE OUTWEIGHS THE POTENTIAL
CONFLICTS OF INTEREST THAT WE'VE
IDENTIFIED WE WOULD ISSUE A
WAIVER OR RECUSE YOU FROM A
PARTICULAR PORTION OF THE
MEETING.
WE USUALLY WAVE CONFLICTS OF
INTEREST FOR GENERAL MATTERS
BECAUSE WE BELIEVE YOUR ABILITY
TO BE OBJECTIVE WILL NOT BE
AFFECTED BY YOUR FINANCIAL
INTERESTS.
WE ALSO RELY A GREAT DEAL ON
YOU.
YOU NEED TO BE ATTENTIVE DID O
MEETINGS TO AN ISSUE THAT COULD
ARISE TO EFFECTOR APPEAR TO
EFFECT WITH RESPONSE TO YOUR
SPECIFIC PARTY OR MATTER IN THIS
HAPPENS.
AND IF DOES HAPPEN, YOU WILL BE
ASKED TO RECUSE YOURSELF FROM
THAT PORTION OF THE MEETING.
NEXT SLIDE, PLEASE.
BEFORE INTRODUCTIONS, I JUST
BRIEFLY WANT TO REVIEW BEST
PRACTICES FOR OUR PARTICIPANTS
IN THIS VIRTUAL SETTING.
FIRST IF YOU COULD PLEASE MUTE
YOUR MICROPHONE IN YOU'RE NOT
SPEAKING.
SECOND IF YOU COULD TRY TO USE A
HEAD SET WITH A MICROPHONE WHEN
SPEAKING THAT REALLY DOES RESULT
IN THE CLEAREST SOUND AND
PROVIDE THE LEAST AMOUNT OF
AUDIO FEEDBACK.
WHEN SPEAKING PLEASE STAYED YOUR
NAME BEFORE MAKING COMMENTS,
MOTIONS OR RECOMMENDATIONS, AND
LASTLY RAISE YOUR HAND FEATURE
OR ENTER YOUR COMMENT OR
QUESTION DIRECTLY INTO THE CHAT
BOX.
NEXT SLIDE, PLEASE EMPLOY AS I
GO THROUGH THE ROSTER WHEN YOU
HEAR YOUR NAME, UNMUTE YOUR
AMERICA IC AND INTRODUCE
YOURSELF BY WHAT NAME AND
INSTITUTIONS YOU REPRESENT.
DR. ANDERSON?
>> GOOD MORNING DR. ANDERSON
FROM THE FRED HUTCHISON CANCER
CENTER.
>> DR. ANUNYA,.
>> GOOD MORNING I'M WITH THE
ASSOCIATE FOR WOMEN'S HEALTH
RESEARCH.
>> GOOD MORNING, DR. ARNOLD?
>> MORNING, I'M ART ARNOLD AT
THE UNIVERSITY OF CALIFORNIA
LOS ANGELES.
DR. BREWER?
OKAY, WE'LL MOVE ON, DR. GIDDY?
>> GOOD MORNING, DR. GIDDY FROM
VANDERBILT UNIVERSITY MEDICAL
CENTER.
>> THANK YOU GOOD MORNING.
DR. HIGGINS?
>> GOOD MORNING STEVE HIGGINS
FROM THE UNIVERSITY OF VERMONT.
>> THANK YOU, GOOD MORNING.
DR. JONES?
>> GOOD MORNING DR. ANDRIEA
JONES FROM THE UNIVERSITY OF
NORTH CAROLINA AT CHAPEL HILL.
>> THANK YOU, GOOD MORNING,
DR. FEISTER?
OKAY, MOVING ON DR. MELANDS?
>> YES, GOOD MORNING FROM
COLUMBIA UNIVERSITY, SCHOOL OF
PUBLIC HEALTH.
>> GOOD MORNING DR. NOEL?
>> GOOD MORNING, I AM ALEXANDRA
NOEL FROM LOUISIANA STATE
UNIVERSITY.
>> THANK YOU AND GOOD MORNING.
>> DR. OFUTOCUN.
AND DR. SHARPS?
OKAY, NEXT SLIDE, PLEASE.
YOU WERE EACH SENT THE MINUTES
FROM OUR LAST MEETINGS THAT WERE
HELD ON ACT EIGHTH AND
DECEMBER 9th FOR REVIEW.
I WANT TO NOTE THAT ONLY FULL
MEMBERS OF THE ADVISORY
COMMITTEE MAY VOTE AND YOU ARE
NOT A MEMBER OF ACRWH, PLEASE DO
NOT VOTE.
IS THERE A MOTION ON THE TABLE
TO ACCEPT THE OCTOBER, EIGHTH,
AS WRITTEN?
>> I HAVE A MOTION.
>> THANK YOU, DO I HEAR A
SECOND?
>> I'LL SECOND.
-- I'LL SECOND THE MOTION, STEVE
HIGGINS.
>> THANK YOU DR. HIGGINS,
DR. HIGGINS HAS SECONDED THE
MOTION, ALL IN FAVOR OF
ACCEPTING THE MOTION PLEASE
RAISE YOUR HANDS NOW.
ALL THOSE OPPOSE TO THE MOTION,
CAN YOU PLEASE RAISE YOUR HANDS
NOW, THANK YOU.
ALL THOSE ABSTAINING FROM THE
MOTION, PLEASE RAISE YOUR HANDS
NOW.
THANK YOU VERY MUCH.
HAVE THE VOTES BEEN RECORDED?
>> YES, THE VOTES HAVE BEEN
RECORDED, WE HAVE 7 VOTES IN
FAVOR.
>> THANK YOU.
THE OCTOBER 8th 2024 MEETING
MINUTES HAVE BEEN ACCEPTED WITH
7 VOTES IN FAVOR.
OKAY, IS THERE A MOTION ON THE
TABLE TO ACCEPT THE
DECEMBER 9th, 2024 MINUTES AS
WRITTEN IN?
>> I'LL MAKE A MOTION, STEVE
HIGGINS.
>> THANK YOU DR. HIGGINS.
DR. HIGGINS SUBMITTED THE
MOTION, DO I HEAR A SECOND?
>> DR. MELANDS, I WILL
SECURITIZATION. THE MOTION.
>> THANK YOU DR. MELLANDS,
DR. MELANDROGENS HAS SECONDED
THE MOTION, ALL IN FEAEVER OF
ACCEPTING THE MOTION, PLEASE
RAISE YOUR HANDS NOW.
THANK YOU.
ALL OF THOSE OPPOSE TO THE
MOTION, CAN YOU PLEASE RAISE
YOUR HANDS NOW?
AND ALL THOSE ABSTAINING FROM
MOTION, PLEASE RAISE YOUR HANDS
NOW.
THANK YOU HAVE THE VOTES BEEN
RECORDED?
>> YES, THE VOTES HAVE BEEN
RECORDED, WE HAD 8 VOTES IN
FAVOR.
>> THE DECEMBER 9th, 2024
MEETING MINUTES HAVE BEEN
ACCEPTED WITH 9 VOTES IN FAVOR.
NEXT SLIDE, PLEASE.
AS AN ORWH UPDATE, I AM TRULY
HAPPY TO SHARE THAT DURING
OCTOBER OF LAST YEAR, THE ORWH
DIRECTOR DR. JANINE CLAYTON WAS
ELECTED TO THE NATIONAL ACADEMY
OF MEDICINE.
CONGRATULATIONS DR. CLAYTON,
WITH THIS I CONCLUDE MY OPENING
REMARKS AND INTRODUCE THE CHAIR
OF THE COMMITTEE DR. JANINE,
CLAYTON.
SOME, THANK YOU SO MUCH
DR. WANG, AND THANK YOU FOR
THOSE WARM CONGRATULATEARY
REMARKS AS WELL AND I ROLELY
APPRECIATE DR. OTA WANG FOR
PARTICIPATING TODAY, YOU WILL
HEAR MORE ABOUT WHAT SHE'S DOING
BUT THANK YOU SO MUCH VIVIAN FOR
BEING WITH US TODAY.
IT'S NOW MY PLEASURE TO
INTRODUCE DR. NICOLE
KLEINSTREUER, HE IS THE NIH
ACTING DEPUTY DIRECTOR FOR
PROGRAM COORDINATION, PLANNING,
STRATEGIC INITIATIVES, AND
FONDLY KNOWN AS DPC PSI WITHIN
THE OFFICE OF THE NIESHES H
DIRECTOR.
SHE OVERSEES, ALL OF THE
INFORMATION AND RESEARCH ON THE
WOMEN'S HEALTH, OTHER OFFICE
SPOKEUS ON AIDS RESEARCH,
BEHAVIORIAL AND SOCIAL SCIENCES,
DIETARY SUMMIT LEPS, TRIBAL
HEALTH AND OTHERS.
I WANT TO INTRODUCE YOU TO
DR. KLEINSTREUER, WHO IS AN
INTERNATIONAL RECOGNIZED EXPERT
ON DEVELOPING HUMAN RELATED
PUBLIC HELT STRATEGIES FOR
PUBLIC HEALTH PROTECTION.
PRIOR TO HER CURRENT POSITION
SHE SERVED AS THE NATIONAL
DIRECTOR OF THE TOXICOLOGY
PROGRAM IN THE AGENCY CENTER FOR
THE EVALUATION OF ALTERNATIVE
TOXICOLOGICAL METHODS, NICETEM,
WITHIN THE NIEHS, AND ALSO
SERVICE'RE SERVED AS DIRECTOR OF
THE INTERAGENCY COORDINATING
COMMITTEE ON THE VALIDATION OF
ALTERNATIVE METHODS, ICVAM.
SHE WAS ALSO THE NATIONAL
COORDINATOR THE OECD TEST
GUIDELINES PROGRAMS AND SHE'S
LED INTERNATIONAL EFFORTS FOR
NIAMS, REDUCE ANIMAL TESTING AND
EPITHELIAL GREAT COMPUTATIONAL
MODELING, INTEGRATIVE SYSTEMS
AND REGULATORY SCIENCE.
HER WORK HAS WORKED ON QUANT
TAIFIVE RISK ASSESSMENT AND
AUTHORED OVER 150 PEER REVIEWED
PUBLICATIONS RECEIVING NUMEROUS
AWARDS INCLUDING THE 2019
SOCIETY OF TOXICOLOGY
ACHIEVEMENT AWARD AND A 2025
ENHANCEMENT OF ANIMAL WELFARE
AWARD AS WELL AS MULTIPLE NIH
DIRECTORS AND NIEHS MERIT
AWARDS.
TO SAY MORE ABOUT HER
BACKGROUND, SHE HOLDS DEAGREES
IN APPLIED PATH MATHICS AND A
Ph.D. IN BIOENGINEERING FROM
THE UNIVERSITY OF CANTERBURY AND
COMPLETED POST DOCS AT THE EPA
AND HAS ADJUNCT FACULTY
APPOINTMENTS, IMPORTANTLY SHE'S
DEEPLY COMMITTED TO MENTORSHIP,
PUBLIC HEALTH PROTECTION AND
SCIENTIFIC INNOVATION THAT
ENHANCE THE TRANSLATION OF
BIOMEDICAL RESEARCH TO WORK REAL
WORLD IMPACT AND IT'S OUR
PLEASURE TO WELCOME HER HERE
TODAY.
DR. KLEINSTREUER.
>> THANK YOU SO MUCH.
IT'S A REAL PLEASURE TO I DIDN'T
EVEN YOU TODAY FOR THIS 63rd
MEETING OF THE NIH ADVISORY
COMMITTEE ON RESEARCH ON WOMEN'S
HEALTH.
REALLY DELIGHTED TO BE HERE
SPEAKING TO YOU ALL.
OKAY, I THINK I SHOULD BE ABLE
TO TAKE CONTROL, HERE WE GO.
SO I CAN ADVANCE MY OWN SLIDES
AND LET'S SEE.
THERE WE GO.
OKAY.
AS DR. CLAYTON MENTIONED, I AM
THE ACTING NIH DEPUTY DIRECTOR
FOR PROGRAM PLANNING
COORDINATION AND STRATEGIC
INITIATIVES AS WELL AS ACTING
DIRECTOR OF DPC PSI AT NIH, NIH
IS MADE UP OF 27 INSTITUTES AND
CENTERS WITH EXCEPTION OF THE
OFFICE OF THE DIRECTOR WHERE DPC
PSI IS HOUSED AND WHERE THE
OFFICE OF WOMEN'S HEALTH
RESEARCH RESIDES WITHIN THIS
DIVISION, SO WHAT DOES DPC PSI
DO, WE ARE THE HOME FOR
COORDINATION, PLANNING WITHIN
THE OFFICE OF THE DIRECTOR AND I
THINK WE ARE INCREDIBLE LOAMACYY
WELL POISED TO ADDRESS EACH OF
THOSE NEEDS AND ACTIVITIES
ACROSS THE NIH AND I WOULD LIKE
TO THINK OF DPC PSI AS THE
SCIENTIFIC NEXUS OF THE NIH AND
OUR OFFICES HAVE MANY ROLES BUT
ORWHH IS A PERFECT EXAMPLE OF AN
OFFICE THAT ADDRESSES A CROSS
CUTTING RESEARCH THEME THAT MANY
IF NOT ALL OF THE ICs ARE
HEAVILY ENGAGED IN.
SO DPC SI IS REALLY TO IDENTIFY
AND CATALOG THAT RESEARCH TO
IDENTIFY SCIENTIFIC GAPS AND
OPPORTUNITIES, FOSTER
COORDINATION AND COLLABORATION,
ACROSS THE DIFFERENT ICs,
DEVELOP NEW METHODS TO ADDRESS
THOSE RESEARCH GOALS AND ENABLE
THEM AND TO SORT OF SERVE AS AN
EXPERIMENTAL TEST BED FOR
INNOVATIVE AND HIGHLY INNOVATIVE
NIH WIDE ACTIVITIES TO IMPROVE
THE PUBLIC HEALTH OF OUR NATION.
OUR SUCCESS REALLY DOES HINGE
UPON THE SINNER GESTIC
COORDINATION OF OUR OFFICES AND
VITAL PARTNERSHIPS WITH OUR NIH
INSTITUTES AND CENTERS, SO THIS
IS THE ORGANIZATION DPC PSI, WE
HAVE NUMEROUS OFFICES WITHIN THE
DIVISION, AND EARLIER THIS YEAR,
ACTUALLY, THE ENVIRONMENTAL
INFLUENCES ON CHILD HEALTH
OUTCOMES OR THE ECHO PROGRAM,
THE ALL OF US RESEARCH PROGRAM,
AND THE INCLUDE PROJECT WHICH IS
THE INVESTIGATION OF CURRENT
CONDITIONS ACROSS THE LIFE SPAN
TO UNDERSTAND DOWNS SYNDROME ALL
3 OF THOSE PROGRAMS WERE
OFFICIALLY ADDED TO DPC PSI AS
CROSS CUTTING NIH PROGRAMS THAT
SERVE COMELEMENTARY AND ROBUST
FASHIONS THAT ARE IN THE OFFICES
THAT ARE IN DPC PSI, SO AMONG
THE MANY OFFICES WE HAVE THE
OFFICE OF RESEARCH ON WOMEN'S
HEALTH, WHICH AS YOU ALL KNOW,
REALLY SERVES AS THE FOLK AT
POINT FOR WOMEN'S HEALTH
RESEARCH AT THE NIH UNDER
DR. CLAYTON'S LEADERSHIP.
AND FOR OVER THIRD 30 YEARS,
ORWHHAS LED A DIVERSE PORTFOLIO
OF RESEARCH PROMULGATES, POLICY,
PLANNING INITTIAIVE ITS,
COORDINATION EFFORTS AND
RESOURCE DEVELOPMENT PROJECTS
THAT REALLY AIM TO ENHANCE AND
EXPAND WOMEN'S HEALTH RESEARCH
THAT PROMOTE THE INCLUSION OF
WOMEN IN CLINICAL RESEARCH, THAT
PROMOTE CAREER ADVANCEMENT FOR
WOMEN IN HEALTH RESEARCH
CAREERS, AND ADVANCE THE
APPLICATION OF THE NIH SEX AS A
BIOLOGICAL VARIABLE POLICY.
SO ORWH YOU KNOW IS ABSOLUTELY
INSTRUMENTAL IN ADDRESSING MANY
KEY NIH PRIORITIES AND HHS
PRIORITIES THROUGH COLLABORATION
WITH ALL THE DIFFERENT
INSTITUTE
ANDS CENTERS.
SO FIRST I WANT TO GO OVER
BRIEFLY IN TERMS OF NIH
PRIORITIES AND KIND OF HOW THOSE
RELATE TO WOMEN'S HEALTH
RESEARCH.
I WILL START WITH THE NIH
DIRECTOR'S PRIORITIES AND THEN I
WILL GO GRANULAR AND TALK ABOUT
MY PRIORITIES AS ACTING DPC PSI
DIRECTOR.
AND DR. BHATTACHARYA HAS
PRESENTED ON THESE AT A HIGH
LEVEL.
FIRST THERE'S STRONG FOCUS ON
IMPROVING POPULATION HEALTH AND
THIS INCLUDES EVERY PERSON THAT
LIVES IN THIS COUNTRY, YOU KNOW
REGARDLESS OF SEX, GENDER,
SOCIOECONOMIC STATUS, ETHNICITY,
ET CETERA AND TO ENABLE US TO
TACKLE THE CHRONIC DISEASE
CRISIS THAT HAS REALLY IMPACTED
THE WELL BEING OF MANY
AMERICANS.
OH DEAR.
THAT WAS NOT RIGHT.
OUR TECH FOLKS TO HELP ME GET
BACK TO WHERE I WAS.
OKAY, THE NEXT PRIORITY, ON
REPRODUCIBILITY AND RIGOR, SO
THANK YOU FOR THAT -- INSURING
THAT THE NIH IS SUPPORTING
SCIENCE THAT IS HIGHLY
DEFENSIBLE, THAT IS RIGOROUS,
REPRODUCIBLE, IT'S UNBIOSED AND
WE HAVE A NUMBER OF INITIATIVES
THAT WE'VE BEEN EXPANDING TO TRY
AND INCREASE THE SUPPORT FOR
REPLICATION SCIENCE AND
REPRODUCIBILITY.
I THINK THAT NO 1 WOULD ARGUE
WITH THE FACT THAT NIH AS THE
LARGEST FUNDER OF BIOMEDICAL
RESEARCH IN THE WORLD HAS A
RESPONSIBILITY TO BE AT THE
FOREFRONT OF BIOMEDICAL
INNOVATION AND USING THE MOST
CUTTING EDGE SCIENCE TO ADDRESS
BOTH EXISTING AND EMERGING
PROBLEMS.
WE HAVE TO INSURE THAT THE
RESEARCH THAT WE SUPPORT IS BOTH
SAFE AND TRANSPARENT AND MEETS
HIGHEST ETHICAL STANDARDS AND
THAT WE ARE SUPPORTING ACADEMIC
FREEDOM AND ENCOURAGING
DISSENTING OPINIONS AND REALLY
CREATING AND FOSTERING AN
ENVIRONMENT WHERE VARIED
PERSPECTIVES ARE VALUED AND
SUPPORTED AND ENCOURAGED.
I THINK ACROSS ALL OF THESE
PRIORITIES INCORPORATING SEX AS
A BIOLOGICAL VARIABLE AND
ABSOLUTELY ESSENTIAL, SO IT, YOU
KNOW TO GO THROUGH EACH OF THEM,
IT STRENGTHENS POPULATION HEALTH
OF COURSE BY INSURING THAT THE
RESEARCH NOT ONLY REFLECTS BUT
ACCOUNTS FOR THE BIOLOGICAL
DIFFERENCES THAT INFLUENCE
DISEASE RISK AND PROGRESSION AND
TREATMENT.
IT IMPROVING SCIENTIFIC RIGOR
AND REPRODUCIBILITY BY
UNCOVERING CRITICAL SEX BASED
PATTERNS THAT WOULD OTHERWISE BE
MISSED, IF SECOND BIOLOGICAL
VARIABLE WAS NOT CONSIDERED OR
IF THE DATA WERE NOT
DEDEGRADATIONGREGATED, IT
ENHANCES RESEARCH SAFETY THROUGH
UNDERSTANDING OF HOW
INTERVENTIONS AFFECT DIFFERENT
POPULATIONS, IF WE DON'T PAY
ATTENTION TO SEX DIFFERENCES, WE
REALLY RISK EXPOSING INDIVIDUALS
TO UNNECESSARY HARM OR FAILING
TO DETECT RISKS THAT ARE SEX
SPECIFIC.
AND IT BUILDS TRANS TRANSPARENCY
REQUIRING CLEAR REPORTING.
SO FOR EXAMPLE, THE 21st
CENTURY CURES ACT REQUIRES
APPLICABLE NIH PHASE 3 TRIALS TO
REPORT RESULTS AND VALID
ANALYSIS BY SEX, RACE, ETHNICITY
IN CLINICALTRIALS.GOV, SO WITH
THAT WE'RE BUILDING TRUST BUT
WE'RE ALSO EMPOWERING OTHER
SCIENTISTS TO BUILD UPON OUR
WORK.
OKAY, NOW THAT I HAVE SHARED THE
NIH DIRECTOR'S PRIORITIES, I
WANT TO SHARE MY PRIORITIES
WHICH ARE VERY CONSISTENT WITH
THE NIH DIRECTORS, BUT ARE A
LITTLE MORE GRANULAR, SO, FIRST,
IDENTIFYING AREAS OF STRATEGIC
INVESTMENT THAT CAN BE USED TO
TRANSFORM THE SCIENCE THAT WE'RE
DOING AND HAVE STRONG POTENTIAL
FOR IMPROVING OUR PUBLIC HEALTH
PROTECTION AND OUR DISDISCOVERY
OF IMPROVED INTERVENTIONS, SO 1
EXAMPLE OF THIS AREA AS YOU
MIGHT HAVE GUESSED FROM MY
BACKGROUND WHEN DR. CLAYTON WAS
INTRODUCING ME IS AN AREA CALLED
NEW APPROACH METHODOLOGIES SO
USING THE MOST ADVANCED
TECHNOLOGY WE HAVE AVAILABLE TO
US TO DEVELOP AND VALIDATE AND
APPLY HUMAN BIOLOGY BASED
INTEGRATED STRATEGIES TO
UNDERSTAND HUMAN HEALTH AND
DISEASE PATHWAYS AND I WILL TALK
ABOUT THAT IN A LITTLE MORE
DETAIL LATER.
STRONGER PARTNERSHIPS SO I CAME
FROM YOU KNOW DIRECTING A
COMMITTEE THAT INCLUDED 18
FEDERAL AGENCIES SO I HAVE A LOT
OF EXPERIENCE IN CULTIVATING AND
STRENGTHENING PARTNERSHIPS AND
COLLABORATIONS ACROSS THE
FEDERAL GOVERNMENT AND ACROSS A
BROAD RANGE OF STAKEHOLDERS BOTH
IN THE SCIENTIFIC COMMUNITY AND
IN THE GENERAL PUBLIC, AND IN
ADVOCACY ORGANIZATIONS AND NG
Os AND THERE'S JUST SO MUCH
THAT CAN BE GAINED FROM
PARTNERSHIPS BOTH WITHIN THE
GOVERNMENT AND ACROSS ACADEMIA
AND PUBLIC-PRIVATE PARTNERSHIPS
TO BE MORE RESPONSIVE TO
NATIONAL HEALTH PRIORITIES AND
TO LEVERAGE OUR SHARED
SCIENTIFIC EXPERTISE AND
RESOURCES.
I AM ALSO A DATA SCIENTIST AT
HEART, THAT'S MY BACKGROUND IS
IN COMPUTATIONAL SYSTEMS BIOLOGY
AND APPLIED MATHEMATICAL
MODELING AND SO DATA IS MY
LANGUAGE, DATA IS MY BREAD AND
BUTTER SO INCORPORATING REALTIME
DATA AND PERFORMANCE METRICS
INTO OUR PROCESSES TO REALLY
INFORM OUR PROGRAMMING AND
PLANNING AND RESOURCE
ALLOCATION.
WORKFORCE DEVELOPMENT IS
INCREDIBLE LOAMACYY IMPORTANT TO
ME, PROVIDING AN ENVIRONMENT
WHERE EVERYONE CAN THRIVE AND
REALIZE THEIR CAREER GOALS AND
OPPORTUNITIES AND IN
ACCELERATING TRANSLATION THROUGH
PRACTICAL SOLUTIONS.
SO THINKING ABOUT NOT JUST WHAT
WE WANT TO DO BUT HOW WE WANT TO
DO IT AND ENGAGING TECHNIQUES
LIKE IMPLEMENTATION SCIENCE TO
DO THAT PLANNING.
OKAY, I PROBABLY DON'T HAVE TO
LECTURE THIS AUDIENCE ABOUT THE
FACT THAT THERE ARE DIFFERENCES
IN HEALTH FOR WOMEN, WE KNOW
THAT ACROSS THE WORLD WOMEN HAVE
LONGER LIFE EXPECTANCYS THAN MEN
IN THE U.S. FOR MORE THAN A
CENTURY WOMEN HAVE ACTUALLY
OUTLIVED MEN WHICH IS
ATTRIBUTABLE TO LOWER
CARDIOVASCULAR AND LUNG CANCER
DEATH RATES, RELATED LARGELY TO
DIFFERENCES IN SMOKING BEHAVIOR
WORLD WIDE, BUT WE ALSO KNOW
THAT WOMEN ARE MORE LIKELY TO
LIVE WITH CHRONIC DISEASE, SO
20% OF U.S. WOMEN AGE 18-64 HAVE
2 OR MORE CHRONIC CONDITIONS,
MULTIMORBIDITY, IN WOMEN THIS
OFTEN INCLUDES BOTH PHYSICAL AND
MENTAL HEALTH CONDITIONS WHICH
OBVIOUSLY REALLY FURTHER IMPACT
THE QUALITY OF LIFE AND THE
HEALTHCARE NEEDS AND BIOLOGICAL
DIFFERENCES IN ADDITION TO
ENVIRONMENTAL FACTORS REALLY
INFLUENCE THE ONSET PROGRESSION
AND TREATMENT OF DISEASES, SO
THAT'S 1 OF THE REASONS IT'S
CRUCIAL TO INSURE THAT WOMEN ARE
INCLUDED IN RESEARCH AND THAT
SEX DIFFERENCES ARE ADEQUATELY
CONSIDERED.
ADDRESSING AMERICA'S EPIDEMIC OF
CHRONIC ILLNESS IS A TOP
PRIORITY OF HHS AND THE
ADMINISTRATION AND AS A MAJOR
PILLAR OF THE MAKE AMERICA
HEALTHY AGAIN COMMISSION AND I
THINK THAT NIH AND DPC PSI AND
ORWH ARE REALLY POISED TO BE
LEADERS IN THIS SPACE.
CHRONIC DISEASE AND
MULTIMORBIDITY ARE MAJOR
COMPONENTS OF THE NIH WIDE
STRATEGIC PLAN ON THE RESEARCH
OF HEALTH FOR WOMEN ON FY24-28,
THIS WAS PUBLISHED LAST YEAR ON
MAY 15 OF 2024 AND THERE ARE
OTHER CROSS CUTTING THEMES IN
THERE LIKE INTERDISCIPLINARY
CROSS COLLABORATION, PRECISION
MEDICINE, INCLUSION OF GIRLS IN
CLINICAL STUDIES, SEX
DIFFERENCES RESEARCH, AND
PREVENTIVE CARE AND SERVICES.
AUTOIMMUNE DISEASES, IS A CLASS
OF CHRONIC DISEASES THAT
DISPROPORTIONATELY AFFECT WOMEN,
AND ABOUT 8 PERCENT OF THE U.S.
POPULATION IS CURRENTLY LIVING
WITH AN AUTOIMMUNE DISEASE AND
NEARLY 80% OF THOSE ARE WOMEN.
AND SO TO ACCELERATE PROGRESS IN
THIS AREA, IN 2022, CONGRESS
DIRECTED NIH TO ESTABLISH AN
OFFICE OF AUTOIMMUNE DISEASE
RESEARCH WITHIN ORWH AND THEY'VE
BEEN WORKING REALLY HARD ON
THEIR INAUGURAL STRATEGIC PLAN
WHICH WILL BE RELEASED SOON.
NOW NIH HAS SUPPORTED NUMEROUS
EFFORTS TO ADDRESS CHRONIC DECS
IN WOMEN, THERE'S JUST A FEW
EXAMPLES ON THE SLIDE HERE, WE
KNOW THAT MORE THAN 250,000
WOMEN IN THE U.S. ARE ESTIMATED
TO BE LIVING WITH HIV, OF WHOM
5000 HAVE ACQUIRED INFECTION AND
DESPITE KNOWN SEX INFLUULENCES
ON DISEASE AND IMMUNE PATHOGENS,
ONLY ABOUT 17% ARE RECRUITED
INTO HAD HIV CLINICAL TRIALS
WHICH HIGHLIGHTS THE URGENT NEED
FOR RESEARCH AND ADDRESSING THE
IMPACT OF HIV IN WOMEN ACROSS
THE LIFE SPAN.
ORWH AND DPC PSI OFFICE OF AIDS
RESEARCH LAWRCHED THE HIV IN
WOMEN SIGNATURE PROGRAM, THE
CORNERSTONE OF THIS PROGRAM IS
THAT IRPT SECTIONAL AND DATA
DRIVEN APPROACH TO RESEARCH ON
HIV AND WOMEN.
AND THE SIGNATURE PROMULGATE
REALLY ADVANCES THE NIH VISION
FOR WOMEN'S HEALTH WHICH REALLY
ENVISIONS A WORLD IN WHICH ALL
WOMEN AND GIRLS RECEIVE EVIDENCE
BASED CARE, PREVENTION AND
TREATMENT TAYLORED TO THEIR
UNIQUE NEEDS, CIRCUMSTANCES AND
GOALS AND A SECOND EXAMPLE IS
CARDIOVASCULAR DISEASE, AND IT
REMAINS THE LEADING CAUSE OF
DEATH FOR WOMEN IN THE U.S. WITH
MORE THAN 60 MILLION LIVING WITH
HEART DISEASE AND WOMEN OFTEN
REPORT VERY DIFFERENT SYMPTOMS
THAN MEN, SO PRESSURE,
DIZZINESS, NAUSEA, THAT CAN LEAD
TO DIAGNOSIS AND UNDERTREATMENT.
IN 2002, NHLBI, THE NATIONAL
HEART LUNG AND BLOOD INSTITUTE
CREATED HEART TRUTH, IT WAS
DESIGNED TO RAISE AWARENESS AS
HEART DISEASE AS A MORBIDITY
ISSUE IN WOMEN.
MENOPAUSE WITH SYMPTOMS ALONG
WITH INCREASED RISK THAT STAGE
IN LIFE OF DEVELOPING 1 OR MORE
CHRONIC DISEASES, POSES REALLY
SPECIFIC CHALLENGES IN
HEALTHCARE FOR WOMEN BUT ALSO
REPRESENTS AN OPPORTUNITY.
SO BUILDING ON INSIGHTS FROM NIH
RESEARCH, THE FIRST EVER
MULTISECTOR MENOPAUSE PATHWAY TO
PREVENTION PROGRAM IS SET TO
LAUNCH THIS YEAR AND IS
COLLECTING EVIDENCE RELEVANT TO
MANAGING MOAN O PAUSE SYMPTOMS
AND MANAGING HEALTH IN THE EARLY
POST MENOPAUSAL PHASE.
SOMETHING ELSE THAT'S NEAR AND
DEAR TO MY HEART IS HOW WE ARE
GOING TO BE RESPONSIBLY AND
ETHICALLY AMRIING AI TO OUR
RESEARCH CAPABILITIES IN
ALIGNMENT WITH THESE NIH
PRIORITIES.
SO, AI IS UNAVOIDABLE, IT'S
EVERYWHERE IN OUR LIVES NOW AND
SO WE REALLY HAVE A
RESPONSIBILITY TO APPLY IT IN
THE MOST INTELLIGENT AND ETHICAL
WAYS TO HELP ADVANCE RESEARCH IN
WOMEN'S HEALTH AND MANY OTHER
AREAS.
SO THERE'S A NUMBER OF DRIVERS
BEHIND THE GROWTH AND AI HEALTH
APPLICATIONS.
THIS INCLUDES LARGE DATA SETS
THAT ARE BECOMING MORE
ACCESSIBLE AND COMPUTATIONALLY
FRIENDLY THAN EVER BEFORE.
VERY DIVERSE MULTIMODAL DATA
SETS, IMPROVEMENTS IN HOW THOSE
DATA ARE CAPTURED AND REPORTED,
DATA STANDARDS, IMPROVED
INTEROPERABILITY BETWEEN THOSE
DAT AINCREASED COMPUTING POWER,
ADVANCEMENTS IN DATA PRIVACY,
PERSEVERING APPROACHES, THIS IS
SOMETHING THAT NIH IS INCREDIBLY
INVESTED IN FOR PATIENT SECURITY
AND PROTECTION.
AND THEN BREAK THROUGH IN
METHODS ON ANALYZE THAT DATA, SO
DEEP NEURAL NETS, REINFORCEMENT
LEARNINGS, ET CETERA, THIS IS
JUST A FIGURE FROM AN ARTICLE
THAT I WROTE WITH A PREGNANT
COLLEAGUE ON HOW AI IS BEING
APPLIED ACROSS SCIENTIFIC
DISCIPLINES WITH A FOCUS ON
TOXICOLOGY AND PUBLIC HEALTH
PROTECTION.
AS PART OF THIS INTEREST IN AI,
THE NIH DIRECTOR INTENDS TO
DEVELOP A OVERALL DATA PLATFORM
TO ACCELERATE DISCOVERY.
THIS IS NOT SOMETHING WE'RE
DOING FROM SCRATCH, WE'RE
BUILDING ON EXISTING THE CURE,
NIH RESOURCES, LIKE THE NATIONAL
CLINICAL COHORT COLLABORATIVE AT
NCATS TO ACTUALLY UNITE DATA
SOURCES FROM SOURCES LIKE HEALTH
ORGANIZATIONS OR CLAIMS OR
ENVIRONMENTAL DATA,
ENVIRONMENTAL EXPOSURE DATA,
SENSORS, WEARABLES AND WE WOULD
LOAMACYIC -- LIKE TO ATTAIN
BROAD COVERAGE OF THE U.S.
POPULATION BY UTILIZING FEDERAL
PARTNERSHIPS AND AI AND WE WANT
TO USE THIS TO OPEN UP
OPPORTUNITIES LIKE REALTIME
HEALTH MONITORING, DRUG
DEVELOPMENT, LINKING
LONGITUDINAL DATA SETS AND
IMPROVING OUR ABILITY TO ADDRESS
PUBLIC HEALTH CRISIS AND IMPROVE
PUBLIC HEALTH PROTECTION.
AI CAN ALSO BE USED AS A TOOL TO
SUPPORT NEW APPROACHES IN HUMAN
ENVIRONMENTAL SAFETY ASSESSMENTS
AND IN DRUG DISCOVERY, DRUG
DEVELOPMENT AND MECHANISTIC
INSIGHT INTO YEEN AND HEALTH
DISEASE PATHWAYS, WE ANNOUNCED A
92 YOU INITIATIVE AT THE END OF
APRIL, ON APRIL 29th, NIH
ANNOUNCED SORT OF A RENEWED
COMMITMENT TO DEVELOPING
VALIDATING AND SCALING THE USE
OF NEW APPROACH METHODS ACROSS
THE AGENCIES BIOMEDICAL RESEARCH
PORTFOLIO.
SO THESE ARE LAB OR COMPUTER
PAITIONED TECHNIQUES THAT ARE
DESIGNED TO MORE ACALATELY MODEL
HUMAN BIOLOGY, SERVE AS A
COMPLIMENTARY APPROACH TO
TRADITIONAL ANIMAL STUDIES AND
YOU KNOW IN SOME CASES WHERE THE
SCIENCE IS READY SERVE AS
ALTERNATIVES TO ANIMAL TESTING.
BUT REALLY TRY AND LEVERAGE THE
FULL TOOL BOX THAT WE HAVE FOR
RESEARCHERS TO ANSWER VERY
DIFFICULT BIOMEDICAL RESEARCH
QUESTIONS.
AGAIN, THIS IS NOT SOMETHING
THAT'S BRAND NEW, NIH
INVESTMENTS, YOU KNOW ARE WIDE
SPREAD ACROSS THE DIFFERENT
ICs, AND WE HAVE EXISTING
EFFORTS LIKE ICVAAM, THAT I USED
TO DIRECT, THE TISSUE PROGRAM
UNDER NCATS OTHERS ORGANOID
MODELS BUILT ACROSS THE ENTIRE
INTRAMURAL RESEARCH PROGRAM MANY
OF WHICH ARE SPECIFIC TO WOMEN'S
HEALTH AND THEN WE HAVE OTHER
GRANTING PROGRAMS LIKE THE NEW
COMPLEMENT-ARIE AND AN RESEARCH
IN EXPERIMENTATION PROGRAM THAT
ARE GETTING READY TO MAKE AWARDS
NOW.
EXPANDING ONGOING EFFORTS AS
PART OF THIS INITIATIVE, NIH
PLANS TO COORDINATE, VALIDATE
AND SCALE THESE HUMAN BASED
RESEARCH METHODS AND KIND OF
SERVE AS I HUB BOTH WITHIN THE
NIH TO COORDINATE ACROSS THE
VARIOUS EFFORTS, ACROSS ICOs
BUT ALSO ACROSS THE FEDERAL
GOVERNMENT AND ACROSS THE
SCIENTIFIC LANDSCAPE AND EXPAND
FUNDING AND TRAINING FOR THESE
HUMAN BASED APPROACHES AND
EXPAND THE INFRASTRUCTURE TO
CONTINUE TO IMPROVE BOTH THE
ACCESSIBILITY AND RELEVANCE TO
CRITICAL HUMAN HEALTH QUESTIONS
AND ALSO, KIND OF UPDATE HOW
GRANT ARE BEING REVIEWED TO
INTEGRATE MORE CUTTING EDGE
HUMAN BIOLOGY BASED METHODS INTO
CONSIDERATION AND REVIEW PANELS
AND STUDY SECTIONS SO WE'RE ALL
VERY EXCITED ABOUT NIH'S
COMMITMENT TO EXPAND AND FURTHER
INTEGRATE THESE HUMAN BASED
RESEARCH TECHNOLOGIES.
WE ALSO RECOGNIZE THAT IT'S VERY
IMPORTANT TO BE THOUGHTFUL AND
TO BE GOOD STEWARDS OF SORT OF
HOW WE ARE USING NEW
TECHNOLOGIES AND THAT THERE ARE
RISKS TO APPLY THINGS LIKE AI IF
THEY ARE IMPROPERLY TRAINED OR
CONTROLLED OR APPLIED.
SO WE HAVE 2 RFIs, OUT RIGHT
NOW, THE FIRST IS ON RESPONSIBLY
DEVELOPING AND SHARING
GENERATIVE ARTIFICIAL
INTELLIGENCE TOOLS USING NIH
CONTROLLED ACCESS DATA THAT'S ON
THE BOTTOM OF THE SLIDE THERE.
IT WAS RELEASEDDA THE END OF MAY
AND THE RESPONSE DATE IS
JULY 16th, AND THEN ALSO
INVITING COMMENTS ON NIH
ARTIFICIAL INTELLIGENCE STRATEGY
ON THEMES AND PILLARS AND
SPECIFIC ACTIONS THAT COULD
SHAPE THE FORTH COMING NIH AI
STRATEGIC PLAN.
BOTH OF THOSE RFIs CLOSE IN
JULY, SO PLEASE SCAN THE QR
CODES ON THE SCREENS AND FIND
MORE INFORMATION AND DISSEMINATE
THEM AMONG YOUR NETWORKS
BROADLY, WE REALLY WANT TO A
ROBUST RESPONSE TO THESE RFIs.
SO INTEGRATING TECHNOLOGY AND
FOSTERING INNOVATION ARE PIVOTAL
IN ADVANCING WOMEN'S HEALTH
RESEARCH AND I THINK THAT A LOT
OF THE EMERGING TOOLS WE HAVE
AVAILABLE TO US, LIKE DIGITAL
PLATFORMS OR WEARABLE SENSORS,
ADVANCING ANALYTICS, THEY ALL
REALLY ENABLED MORE PRECISE AND
PERSONALIZED AND REALTIME
INSIGHTS INTO CONDITIONS THAT
DISPROPORTIONATELY AFFECT WOMEN.
SO, YOU KNOW WE CAN LEVERAGE
THESE INNOVATIONS AND THESE NEW
TECHNOLOGIES TO UNCOVER
SEX-SPECIFIC DISEASE MECHANISMS,
AND CLOSE GAPS IN HEALTH AND
DEVELOP MORE EFFECTIVE
INTERVENTIONS.
I THINK THAT EMBRACING
TECHNOLOGY NOT ONLY ACCELERATES
DISCOVERY, BUT IT INSURES THAT
WOMEN'S HEALTH NEEDS ARE
ADDRESSED WITH THE RIGOR AND
URGENCY THAT THEY DESERVE AND
SO, YOU KNOW NIH IT REALLY HOLDS
IT AT THE FOREFRONT OFAUR MINDS
AND WE'RE IMPLEMENTING SEVERAL
INITIATIVES TO HARNESS THE
TECHNOLOGICAL ADD VANCES WOMEN'S
HEALTH RESEARCH SPECIFICALLY.
ONE IS UNDER THE RAD-X PROGRAM,
IS ADVANCING TOURS AND
FURTHERING THERAPIES AND ENDING
ENDOMEET RIOSEIS DIAGNOSTIC
DELAYS OR ACT ENDO, CHALLENGE,
THIS IS OFTEN A DEBIL TIGHTING
GYNECOLOGICAL DISEASE, NIH
SELECTED 4 WINNERS FOR THIS
COMPETITION, FOR THE
ENDOMETRIOSIS TECHNOLOGIES, AND
THIS IS FOR VARIOUS FORMS OF
IMAGING, ANOTHER CHALLENGE
COMPETITION IS CALLED DEBUT AND
IT'S BEEN GOING ON SINCE 2013
AND THIS HAS A REAL CAREER
DEVELOPMENT ASPECT TO IT BECAUSE
IT FOCUSES ON JUNIOR
RESEARCHERS, SO CHALLENGES USHED
GRADUATES, STUDENTS TO DEVELOP
TECHNOLOGICAL NEEDS IN SOLUTIONS
TO ANY UNMEET AREA OF NEED IN
HEALTHCARE.
AND IN 2024, THERE WERE QUITE A
FEW AWARDS ACROSS TOPICS
INCLUDING KEY ADVANCEMENTS IN
WOMEN'S HEALTH, A VAGINAL SPEC
LUMTHAT PROVIDES GREATER
FUNCTIONALITY, AND MRI THAT
STREAMLINES THE MRI BREAST
PROCESS, SO BY ADVANCING
TECHNOLOGICAL ADVANCES NIH PLANS
TO REVOLUTIONIZE WOMEN'S
RESEARCH AND LEAD TO MORE
INTERVENTIONS AND IMPROVED
HEALTH OUTCOMES FOR WOMEN ACROSS
THEIR LIFE SPAN.
SO THANK YOU SO MUCH FOR
ALLOWING ME THE OPPORTUNITY ON
SPEAK TO YOU TODAY.
I DO HAVE TIME TO ANSWER ANY
QUESTIONS AND THANK YOU AGAIN TO
DR. CLAYTON AND DR. OTA WANG AND
ORWH AND ALL OF YOU FOR HAVING
ME HERE TODAY.
>> THANK YOU SO MUCH FOR SHARING
YOUR VISION AND YOUR BACKGROUND
AND I'M SURE EVERYONE IS VERY
EXCITED TO HEAR ABOUT YOUR
INTEREST IN WOMEN'S HEALTH AND
AND WE ARE EXCITED TO BRING
WOMEN'S HEALTH TO THE NOW WORLD
AS YOU HIGHLIGHTED THE TRUE
OPPORTUNITY AND POTENTIAL THERE.
DR. OTAWANG DO WE HAVE QUESTIONS
IN THE ROOM FOR
DR. KLEINSTREUER?
>> I'M LOOKING.
>> VIVIAN I THINK THERE IS A
QUESTION FROM DR. JONES ONLINE?
>> HI, CAN EVERYBODY HEAR ME?
THANK YOU.
THANK YOU DR. KLEINSTREUER,
THANK YOU FOR THE WONDERFUL
PRESENTATION, I LEARNED A LOT
AND IT'S VERY EXCITING.
I WONDER IF YOU COULD COMMENT ON
THE SEX IN WOMEN AND ADDICTION
AND PARTICULARLY OPIOIDS BECAUSE
WE KNOW THAT WHILE OUR OPIOID
OVERDOSE DEATHS ARE GOING DOWN,
WE STILL ARE DEALING WITH THIS
CRISIS AS AMERICANS, SO ANYTHING
YOU WILL LIKE TO SAY ABOUT THAT,
I WOULD APPRECIATE LEARNING FROM
YOU, THANK YOU.
>> WELL, THANK YOU FOR THE
QUESTION DR. JONES.
I AM GOING TO PREFACE MY
RESPONSE WITH SAYING THAT IS NOT
MY AREA OF EXPERTISE, I THINK
IT'S AN INCREDIBLE LOAMACYY
IMPORTANT RESEARCH TOPIC, AS YOU
HIGHLIGHTED THERE ARE CLEAR SEX
DIFFERENCES IN ADDICTION AND
SORT OF BEHAVIORS THAT INFLUENCE
ADDICTION.
I WOULD ACTUALLY ASK DR. CLAYTON
IF SHE COULD HELP BACK ME UP ON
THIS ANSWER HERE.
MY UNDERSTAND SUGGEST THAT THERE
IS INTERACTION WITH THE NATIONAL
INSTITUTE ON DRUG ABUSE, THE
NATIONAL INSTITUTE ON ALCOHOL,
SO NIAAA, AT NIDA AND NIMH ARE
STRONG PARTNERS FOR ORWH, AND
JANINE IF YOU COULD PROVIDE MORE
SPECIFICS ABOUT ACTIVITY IN THAT
AREA, I WOULD BE VALID AND
RELIABLE GRATEFUL BECAUSE I
WOULD LIKE TO LEARN AS WELL.
>> SURE, SURE.
DR. JONES, FANTASTIC QUESTION,
SEX DIFFERENCES IN SUBSTANCE USE
HAVE BEEN A LONG-TERM INTEREST
OF ORWH AND WE HAVE A FANTASTIC
COLLABORATIVE RELATIONSHIP WITH
NIDA, AND NIMH AND NIAAA, AND
WE'RE ALSO CONCERNED ABOUT
INCREASING RATES OF ALCOHOL USE
AND THE CONQUENCES BECAUSE WE
KNOW THAT WOMEN TEND TO HAVE
ACCELERATED CONSEQUENCES FROM
ALCOHOL USE IN TERMS OF MEN IN
TERMS OF MULTIORGAN ISSUES.
SO IN ADDITION TO NIDA
COLLABORATING WITH ORWH ON THE
SCORE, THE CENTERS FOR RESEARCH
EXCELLENCE ON SEX DIFFERENCES
WHERE THEY HAVE FUNDED FOR MANY
YEARS WITH US LOOKING AT SEX
DIFFERENCES IN MULTIPLE
SUBSTANCE DISUSE DISORDERS, WE
CONTINUE TO WORK CLOSELY WITH
THEM IN TERMS OF RESEARCH
PRIORITIES AND SEVERAL OF THESE
INSTITUTE VS ISSUED THEIR OWN
FUNDING OPPORTUNITY AKNOWNST
WANTS RELATED TO SEX DIFFERENCES
IN THEIR MISSION AREAS.
SO I ASSURE YOU THIS REMAINS OF
INTEREST TO EVERYONE.
DRIVING IN THIS MORNING I HEARD
ABOUT THE DECREASING RATES OF
OVERDOSE DEATH AND I THINK THAT
THAT'S A FANTASTIC EXAMPLE OF
THE WAY THAT WHEN WE PUT OUR
FORCES TOGETHER, AND I'M SURE,
NICOLE WILL AAGREE, KIND OF A
CROSS GOVERNMENT APPROACH, WE
CAN WHEN WE UNDERSTAND THESE SEX
DIFFERENCES WE CAN IMPLEMENT
STRATEGIES THAT WORK FOR WOMEN
AND MEN.
>> THANK YOU SO MUCH.
>> ABSOLUTELY.
ABSOLUTELY.
>> DR. HIGGINS?
>> AND THEN I WILL TURN IT OVER
TO YOU VIVIAN.
>> YEAH, THANKS FOR THIS
OPPORTUNITY TO ASK A QUESTION.
AND LIKE DR. JONES JUST SAID, I
LEARNED A LOT FROM THE
PRESENTATION.
SO MY QUESTION, I'M AN ADDICTION
SCIENTIST, I FOCUS MORE ON
TOBACCO THAN OPIOIDS BUT THEY --
TOBACCO WAS HAVING A
DISPROPORTIONATE IMPACT ON THE
HEALTH OF RURAL WOMEN, LARGELY
BECAUSE IT'S HARD ON BRING
EVIDENCE-BASED TREATMENT TO
THEM.
WE'RE VERY INTERESTED IN YOU
KNOW DOING -- DEVELOPING DIGITAL
INTERVENTIONS THAT CAN REACH
THEM BUT I WAS JUST CURIOUS HOW
YOU THINK ABOUT RURAL
DISPARITIES?
>> THAT'S A GREAT QUESTION AND
YOU MAY OR MAY NOT BE AWARE OF
OUR CARE FOR HEALTH PROGRAM, IT
WAS FAIRLY NASCENT, IT'S JUST
BEEN LAUNCHED LAST YEAR.
IT IS SETTING UP A NETWORK OF
PRIMARY CARE PROVIDERS THAT CAN
BE USED FOR DECENTRALIZED
CLINICAL TRIALS AND IMPLEMENTING
AND ASKING RESEARCH QUESTIONS
THROUGH THESE PRIMARY CARE
PROVIDER NETWORKS AND THE VAST
MAJORITY OF THEM ARE LOCATED IN
RURAL COMMUNITIES TO ACTUALLY
ADDRESS EXACTLY THE ISSUES THAT
YOU'VE RAISED IN TERMS OF
DISPROPORTIONATE AFFECTS ON
FOLKS THAT LIVE IN RURAL AREAS
THAT MAY HAVE LOWER OR ALMOST
NONEXISTENT READY ACCESS TO HIGH
QUALITY HEALTHCARE AND SO, THEIR
CARE FOR HEALTH IS IN THE STAGE
RIGHT NOW OF REVIEWING A NUMBER
OF CLINICAL TRIAL STUDY CONCEPT
PROPOSALS AND I WILL FOLLOW UP
WITH THIS AND I WILL BE
INTERESTED TO SEE IF ANY OF THEM
ARE ACTUALLY SPECIFICALLY
ADDRESSING, YOU KNOW TOBACCO USE
IN VARIOUS FORMS FROM SMOKING
ALL THE WAY TO VAPING AS WELL.
I THINK ALSO, I'M SURE YOU'RE
FAMILIAR WITH THE TOBACCO
REGULATORY SCIENCE PROGRAM WHICH
IS AN INTERAGENCY PARTNERSHIP
BETWEEN THE NIH AND THE FDA
CENTER FOR TOBACCO PRODUCTS THAT
I KNOW THEY'VE HAD SOME PROJECTS
THAT HAVE FOCUSED ON RURAL
COMMUNITIES, TOO, SO IT WOULD
ALSO, I CAN FOLLOW UP WITH THEM
ON SORT OF THE INCLUSION OF SEX
DIFFERENCES IN THOSE RESEARCH
QUESTIONS AND OUTCOMES.
SO THANK YOU FOR RAISING THAT.
>> YEAH, THANK YOU.
I DIDN'T KNOW ABOUT THE CARES
PROGRAM SO I WILL LOOK IT UP AND
LEARN MORE ABOUT IT.
THANK YOU.
CARE FOR HEALTH.
>> CARE FOR HEALTH IS THE NAME.
>> YES, CARE FOR HEALTH.
>> AND DR. HIGGINS YOU WILL HEAR
A BIT IN MY PRESENTATION ABOUT
THE EXPANSION OF THE IDEA STATES
PROGRAM TO ADDRESS WOMEN'S
HEALTH AND OUR CENTERS OF
BIOMEDICAL RESEARCH EXCELLENCE
ON WOMEN'S HEALTH, COBREs,
THERE IS 1 WE'RE FUNDING WITH
NIGMS LOCATED AT THE UNIVERSITY
OF KANSAS AND THEY ARE LOOKING
SPECIFICALLY AT TELEHEALTH
MEDICINE INTERVENTIONS FOR RURAL
LOCATIONS.
SO WE'RE KEENLY AWARE OF THE
UNIQUE NEEDS OF WOMEN IN RURAL
LOCATIONS AND THOSE GEOGRAPHIC
DIFFERENCES ARE IMPORTANT SO WE
CAN ADDRESS THE NEEDS OF ALL
WOMEN ACROSS THE COUNTRY.
>> THANK YOU.
>> WELL, THANK YOU AGAIN SO MUCH
FOR HAVING ME.
I REALLY, REALLY APPRECIATE IT,
AND I HAVE TO APOLOGIZE THAT I
HAVE TO GO BOARD A PLANE, SO
UNFORTUNATELY I'M NOT GOING TO
BE ABLE TO AT A FOR THE REST,
BUT I KNOW IT'S BEING RECORDED
AND I REALLY LOOK FORWARD TO
VIEWING THE RECORDING LATER OF
THE WEBCAST.
AGAIN, THANK YOU SO MUCH AND I
WISH YOU AN EXCELLENT REST OF
THE MEETING.
>> THANK YOU DR. KLEINSTREUER,
APPRECIATE IT, SAFE TRAVELS.
>> SO LET US TURN TO
DR. CLAYTON'S DIRECTOR'S REPORT.
>> LET ME GRAB CONTROL HERE.
WELL, THANK YOU SO MUCH EVERYONE
AND IT'S EXCITING TO BE WITH YOU
TODAY.
WE HAVE A LOT TO SHARE WITH YOU.
IT'S ALWAYS 1 OF MY FAVORITE
MEETINGS TO BE ABLE TO SHARE
WITH YOU ALL THE WORK THAT'S
BEEN GOING ON ACROSS NIH RELATED
TO WOMEN'S HEALTH AND SO, GIVING
THIS DIRECTOR'S REPORT IS 1 OF
THE WAYS THAT I LOVE TO DO THAT.
I WILL GIVE AN UPDATE ON ORWH
AND NIH IN TERMS OF LEADERSHIP,
I WILL PROVIDE SCIENTIFIC
UPDATES, SOME ORWH PROGRAM
UPDATES AND THEN, CLOSE OUT.
OKAY.
SO I'M GOING TO GO WITH THE
BOTTOM LINE UP FRONT HERE AND
GIVE YOU SOME DATA THAT I REALLY
WANT TO SHARE WITH YOU TODAY.
WE TOOK A LOOK AT ORWH'S CO
FUNDING FROM 1999-2024 TO SEE
THE IMPACT OF THAT CO FUNDING
WITH THE INSTITUTES AND CENTERS
AND IF YOU START AT THE BOTTOM,
CAN YOU SEE, FROM 1999 TO 2024,
WE HAVE SUPPORTED OVER 2000
UNIQUE GRANTS, SOME FUNDED FROM
MULTIPLE YEARS, THOSE HAVE LED
TO OVER 73,000 PUBLICATIONS THAT
SITE AT LEAST 1 ORWH CO FUNDED
GRANT.
NEXT LINE UP, AND THOSE HAVE LED
TO OVER 28,000 PATENT
APPLICATION SIGHTINGS, 7000, 612
PUBLICATIONS.
THE NEXT ROW UP AND AT THE VERY
TOP THERE, YOU CAN SEE 193 DRUG
LICENSES, CITING 406 PATENT
APPLICATIONS SUPPORTED BY ORWH
AND OTHER ICOs TO GIVE YOU A
SENSE OF WHAT THE IMPACT OF ORWH
HAS BEEN IN TERMS OF
COLLABORATING WITH OUR
INSTITUTES AND CENTERS AND
COLLEAGUES.
AND THE CONDITIONS THAT ARE
SUPPORTED BY THESE EFFORTS
EITHER GIVING NEW KNOWLEDGE OF
THE PUBLICATION OR IDENTIFYING
NEW TREATMENTS THROUGH DRUG
LICENSES, ARE HIGHLY RELEVANT TO
THE HELT OF WOMEN INCLUDING
DEMENTIA, HYPER LIP DEEMIA,
EPILEPSY, HYPER CLOOF THE ROL
AND OTHER CONDITIONS, SO BOTTOM
LINE UP FRONT HERE, WE'RE HERE
TO COLLABORATE WITH OUR
COLLEAGUES AND HAVE AN IMPACT TO
IMPROVE THE HEALTH OF WOMEN AND
THIS IS JUST 1 WAY WE DO THAT.
IN TERMS OF NIH AND ORWH UPDATES
I ALWAYS LIKE TO SHARE WITH YOU
THE LEADERSHIP UPDATES, I'M SURE
YOU ARE KEENLY AWARE THAT WE
HAVE WELCOMED RECENTLY THE
18th DIRECTOR OF THE NATIONAL
INSTITUTES OF HEALTH DR. JAY
BHATTACHARYA WE HAVE A NEW
PRINCIPAL DEPUTY DIRECTOR OF NIH
DR. MATTHEW MEMOLI, AND THEN YOU
HEARD FROM DR. NICOLE
KLEINSTREUER FOR DEPUTY DIRECTOR
FOR PROGRAM, COORDINATION,
PLANNING AND STRATEGIC
INITIATIVES AND I AM LOOKING
FORWARD TO EACH AND EVERY 1 OF
THEM AS WE MOVE FORWARD TO
ADVANCE WOMEN'S HEALTH RESEARCH.
WE'VE HAD A FEW CHANGES, YOU
MIGHT HAVE NOTICED, DR. OTA WANG
HAD A DIFFERENT SIGNATURE LINE
TODAY, DIFFERENT TITLE THERE
TODAY, WITH THE CHANGING
LEADERSHIP, THERE HAVE BEEN
SEVERAL OTHER CHANGES,
DR. CAROLYN HUTTER NAMED LAST
YEAR WAS ASKED TO SERVE AS THE
ACTING DIRECTOR OF THE NATIONAL
HUMAN GENOME RESEARCH INSTITUTE
AND LEFT THE OFFICE OF STRATEGIC
COORDINATION WITHOUT LEADERSHIP
DIRECTOR AND DR. OTA WANG WAS
TAPPED TO SERVE AS ACTING
DIRECTOR OF THE OFFICE OF
STRATEGIC COORDINATION WITH LEFT
US WITH AN OPEN DEPUTY DIRECTOR
POSITION AND CINDY CAUGHMAN WITH
THE OFFICE OF PORTFOLIO ANALYSIS
IS SERVING AS THE ACTING DEPUTY
DIRECTOR OF ORWH. AND YOU WILL
SEE THESE NEW NAMES AND FACES
AND I WANT TO MAKE SURE YOU ARE
AWARE OF THE DOMINOES THAT
INITIATES THESE CHANGES.
I'M GOING TO PROVIDE YOU WITH A
COUPLE OF SCIENTIFIC UPDATES,
SINCE WE LAST MET FOR A FULL
MEETING, IT'S MY PLEASURE TO
SHARE WITH YOU, THIS PUBLICATION
THAT I LED ON BEHALF OF NIH
LEADERSHIP ENTITLED RECENT
DEVELOPMENTS OF WOMEN'S HEALTH
RESEARCH AT THE NATIONAL
INTUITYS OF HEALTH AND IT CAME
OUT LAST YEAR AND WE SUMMARIZED
ACROSS THE ENTIRE NIH, THE
WOMEN'S HEALTH RESEARCH EFFORTS
THAT THE INSTITUTES AND CENTERS
INDIVIDUALLY AND HOW WE MOVE
COLLECTIVELY TO HAVE A LARGER
IMPACT TO ADDRESS ALL THE
ASPECTS OF WOMEN'S HEALTH.
WE NOW KNOW OF COURSE WOMEN'S
HEALTH IS EVERYTHING THAT FITS A
WOMAN HEAD TO TOE INSIDE AND OUT
FAR BEYOND FEMALE REPRODUCTIVE
CONDITIONS AS IMPORTANT AS THEY
ARE, WE NEED TO ADDRESS THE
ENTIRE HEALTH OF WOMEN ACROSS
THE ENTIRE LIFE COURSE TO HAVE
THE MOST IMPACT.
WE NOW HAVE INSIGHTS ABOUT HOW
THE DISEASES AND CONDITIONS
AVENGHT WOMEN UNIQUELY,
DIFFERENTLY OR
DISPROPORTIONATELY AND WAYS TO
ACCELERATE TRANSLATION FROM THE
LABORATORY SCIENCE TO PRACTICAL
BENEFITS TO WOMEN AND THIS
PUBLICATION INCLUDES A TABLE AND
SUPPLEMENTARY MATERIAL OF
EXAMPLES OF EACH OF THE ICs
EFFORTS TO IMPROVE THE HEALTH OF
WOMEN AND IT WAS MY PLEASURE TO
CHAT ABOUT THIS WITH
DR. KIRSTEN BIBINS-DOMINGO CITED
THERE.
I ALSO WANT TO HIGHLIGHT A
RECENT REPORT FROM THE NATIONAL
CANCER INSTITUTE ON CANCER DEATH
RATES.
THERE WE GO.
THE 20 -- WHOOPS.
THIS IS MOVING QUICKER THAN I
NEED TODAY TO.
SORRY ABOUT THAT.
A 2025 REPORT LOOKEDDA THE DEATH
RATES AND SAW THE GOOD NEWS,
OVERALL DETH RATES FOR MEN,
WOMEN AND CHILDREN HAVE DECLINED
AND THAT IS FANTASTIC NEWS.
TWELVE OF 19 MOST COMMON CANCERS
IN WOMEN SHOWED DECREASES IN
MORTALITY.
FOURTEEN OF 20 MOST COMMON
CANCERS IN WOMEN SHOWED
DECREASES IN MORTALITY.
OWEVER THERE WAS AN INCREASE OF
CANCER IN WOMEN AT MULTIPLE
SITES EVERY YEAR FROM 2003
THROUGH 2021 WITH THE EXCEPTION
OF 2020.
SO WITH THAT INCREASE IN
INCIDENCE, DESPITE THE DECREASE
IN DEATH RATES WE STILL NEED TO
MAY ATTENTION TO SEX DIFFERENCES
AND MAKE SURE WE FIND A WAY TO
ADDRESS THAT.
RATES OF NEW CANCERS IN WOMEN
INCREASED IN THE BREAST, UTERUS,
COLON AND RECTUM, AND THEN IN
THE PAN KRE TINS KASP A R,
KIDNEY AND LIVER IN YOUNG ADULTS
AND AMONG WOMEN.
AND ALSO RISING RATES OF
ESTROGEN RECEPTOR-POSITIVE
BREAST CANCER AND FERTILITY
RATES, ADVANCING AGENT AT FIRST
BIRTH, RISE AND OBESITY AND
ALCOHOL COMSUMPTION AND NEW
CASES OF DEATHS FROM UTERINE
CANCER.
YOU CAN SEE IN THE GRAPH HERE OF
ANNUAL PERCENT CHANGE FROM
2018-2022, FOR MALES ON THE
LEFT, FEMALES ON THE RIGHT, THE
TICKER OTHERWISE BARS SHOW
REDUCTIONS IN DEATH RATE, THESE
ARE DEATH RATES SO THAT IS GREAT
NEWS TO SEE ALL OF THOSE
REDUCTIONS AND AT THE BOTTOM YOU
CAN SEE THAT LARGEST REDUCTION
IN BOTH MALES AND FEMALES IN
CANCER OF THE LUNG AND BRONCHUS,
NEXT UP FROM THE BOTTOM, FOR
WOMEN YOU CAN SEE OVARY IN
NONHODGKINS LYMPHOMA FOR MEN, SO
WE ARE PLEASED TO SEE THAT
STATISTIC REDUCTION FOR LONG AND
BRONCHUS CANCER IN WOMEN AND
MEN.
I WANT TO DRAW YOUR ATTENTION TO
THE TOP WHERE WE HAVE THE ORANGE
BARS INDICATING INCROSING DEATH
RATES, FOR NONMELANOMA SKIN
KAN--KANAER, BONES AND JOINTS
FOR MALES AND FOR FEMALES, AND
LIVER AND INTERHEPATIC
DEATHERATE FOR WOMEN.
SOPHISTICATEDY WE SEE TREND WEES
WANT TO PAY ATTENTION TO AS WE
LOOK AT THIS DATA ON A ROUTINE
BASIS.
IT'S BEEN A GREAT EXPERIENCE
COLLABORATING WITH THE NATIONAL
CANCER INSTITUTE OVER THE YEARS
AND INVESTMENTS IN THAT
LONG-TERM COLLABORATION HAVE
REALLY PAID OFF IN THE AREA OF
VIROLOGY AND IN TERMS TERMS OFG
TO IMMUNO DOSE INTERVENTIONS FOR
CERVICAL CANCER PREVENTION SO
WE'RE EXCITED TO SEE THAT MOST
RECENT DATA PUBLISHED AND THIS
ACCELERATES CERVICAL CANCER
PREVENTION BY MINIMIZING PATIENT
BURDEN WHILE MAINTAINING
EFFECTIVENESS OF THE
INTERVENTION CAN IT ADDRESSES
DIFFERENCES IN ACCESS TO
CERVICAL CANCER PREVENTION
RESOURCES, A STILL IMPORTANT
ISSUE ACROSS THE WORLD, NEXT.
LET'S GO HERE.
I ALWAYS LIKE TO BRING YOU A
COUPLE EXAMPLES OF SEX AS A
BIOLOGICAL VARIABLE IN ACTION
AND OUR COLLEAGUES ACROSS THE
NIH HAVE DONE A FANTASTIC JOB IN
IMPLEMENTING AND APPLYING THAT
PERSPECTIVE.
HERE'S 1 FROM THE EEUNICE AND
THEY WERE LOOKING AT DNA
METHYLATION PATTERNS INDICATING
DIFFERENTIAL GENE EXPRESSION AND
THEY FOUND OVER 2400 PREVIOUSLY
UNREPORTED DNA SITES WITH
DIFFERENT METHYLATION PATTERNS.
THEY ALSO SHOWED THAT INCREASES
IN METHYLATION PATTERNS RESEARCH
ASSOCIATE WIDE GREATER NEONATAL
SIZE FROM MALE PLACENTAL SIZE
AND GREATER PLACENTAL SIZE FOR
FEMALE PLACENTAS AND THEY FOUND
SPECIFIC GENES THAT THEY KNEW
WERE LINKED TO PRETERM BIRTH,
PREELAMPSIA, AND HYPERTENSION IN
BOTH MALES AND FEMALE PLACENTA
INDICATING THAT MAY PLAY A ROLE
OF CHRONIC DISEASE LEALTER IN
LIFE FROM THESE PERSPECTIVES.
SO THESE EPIDEN GENETIC MODISHS
WE'RE SEEING PLAY A ROLE AND
WE'RE LOOKING AT SEX DIFFERENCES
THERE THROUGH THE NICHD FUNDED
RESEARCH.
HERE'S ANOTHER EXAMPLE FUNDED BY
SEVERAL OTHER INSTITUTES NINDS,
AND NIDDK IN THIS PLACE AND THEY
FOUND A NOVEL ROLE FOR
REGULATORY T-CELLS IN SEX
SPECIFIC PAIN PROGRESSION, WE DO
KNOW THERE ARE SEX DIFFERENCES
IN PAIN PROCESSING AND WOMEN
HAVE HIGHER RATES OF PAIN THAN
DO MEN, AND THIS STUDY LOOKED AT
WHETHER T-CELLS MIGHT PLAY A
ROLE IN PROCESSING, THEY WERE
LOOKING AT TREGULATORY T-CELLS
THAT ARE CONTROLLED BY GENE
LOCATED ON THE X-CHROMOSOME, OF
COURSE WE KNOW THAT T-CELLS PLAY
A ROLE IN IMMUNO MODULATION BUT
THIS IS A DISTINCT ROLE WHERE
T-REGULATORY CELLS WERE FOUND TO
INHIBIT NO SUSCEPTION IN A SEX
SPECIFIC WAY.
WHEN THEY DEPLETED MENINGIAL
T-REGULATORY CELLS IT INCREASED
SENSITIVITY TO A SPECIFIC TYPE
OF PAIN IN FEMALE MICE BUT NOT
MALE MICE AND THEY FOUND TWHA
SOME OF THESE TREG CELLS IN THE
MENING EASE PRODUCED ANNAL
GEEZIC COMPOUND WITH ENKEPH ALIN
AND FEMALE MICE HAD MORE THAN
MALE MICE.
THEY DID A VARIETY OF
INTERVENTIONS TO TEST THE RIGOR
OF THEIR FINDING AND THEY FOUND
OVERALL THAT T-REGULATORY CELLS
MAY BE KEY REGULATORS OF
SEX-SPECIFIC MECHANICAL PAIN
INFLAMMATION AND MAY EXPLAIN WHY
MEN AND WOMEN DIFFER IN THEIR
SENSITIVITY OF PAIN.
I WOULD LIKE TO END THIS LITTLE
SECTION BY HIGHLIGHTING THE
CONGRESSALLY MANDATED MEDICAL
RESEARCH PROGRAM WHO IS RELEASED
RESEARCH ON SEX AS A BIOLOGICAL
BARRIERS LAST YEAR WHICH EXTENDS
ACROSS CLINICAL RESEARCH TO
INCLUDE CLINICAL TRIALS WITH
REQUIREMENTS FOR CONSIDERATION
OF SEX AS A BEOLOGICAL VARIABLE
AND WE'RE REALLY EXCITED TO SEE
OUR PARTNERS IN D.O.D. MOVING
FORWARD IN THIS WAY.
IN TERMS AS SEX AS A VARIABLE,
THIS EXPLAINS HOW FUNDERS HAVE
MOVED FORWARD IN ADVANCING
REQUIREMENTS FOR SEX AS A
BEOLOGICAL VARIABLE AND
DISAGGREGATION OF DATA BY SEX.
AND YOU KNOW INCLUSION OF COURSE
IS NOT SYNONYMOUS WITH COUNTING
FOR SEX AS A BEOLOGICAL VARIABLE
AND WE'VE SEEN ACROSS NORTH
AMERICA FOR EXAMPLE, OVER THE
PAST FEW YEARS ALMOST A 3 TIMES
INCREASE IN THE PROPORTION OF
SEX STUDIES COMPARED TO SINGLE
SEX STUDIES AGAIN ACKNOWLEDGING
SEX CAN HAVE CHROMESOME HORMONE
AND MULTIPLE ORGAN LEVELS.
SO EXCITING TO SEE POLICIES
EXIST NOTHING MULTIPLE COUNTRIES
ACROSS THE WORLD AND INTERESTED
TO SEE WHAT THE UNITED KINGDOM
WILL COME UP WITH NEXT, COMING
SOON.
I'M ALSO EXCITED TO SHARE WITH
YOU A WORKSHOP IN GREECE BY THE
IRPT SECTION OF REGENERATIVE
MEDICINE IN MEN AND WOMEN'S
HEALTH.
YOU CAN SEE DR. OTA WANG CHAIRED
WITH ALONG WITH DR. KIMBERLY
POTTER AND OUR CONTRIBUTORS ARE
LISTED FOR THE REPORT.
REGENERATIVE MEDICINE IS A
PARTICULARLY EXCITING ASPECT OF
BIOMEDICINE IT HAS THE POTENTIAL
TO BRIDGE GAPS AND UNDERSTAND
THE ROLE OF SEX IN HEALTH AND
DEC AS YOU LOOK FORWARD TO
MODULATING REPAIRING, REBOOTING
THESE TISSUES TO A VARIETY OF
NEEDS AND TRANSLATING THAT
KNOWLEDGE INTO IMPROVED CARE FOR
WOMEN AND MEN AND A COUPLE OF
THE THEMES ARE LISTED HERE BUT
ON THE NEXT SLIDE, I'M GOING
SHOW YOU A COUPLE OF ADDITIONAL
PIECES OF INFORMATION FROM THAT
WORKSHOP, A COUPLE QUOTES HERE
ON THE RIGHT NOW THAT POLICIES,
AND PATIENTS WITH DISEASES SUCH
AS SICKLE CELL ARE LIVING LONGER
MORE RESEARCH IS NEEDED BEYOND
THAT FOR QUALITY OF LIFE AND
MATERNAL HEALTH, FROM 1 OF THE
ATTENDEES AS WELL AS INCREASED
RESEARCH ON THE FEMALE MILIEU
AND HORMONAL INFLUENZS AND SEX
INFLUENCES IN THE CARE AND
TREATMENT AND HOW THEY
EXPERIENCE HEALTH AND DISEASE,
SO MODEL SYSTEMS, NOVEL
ALTERNATIVE METHODS, THE NEED
FOR MULTIDISCIPLINARY
APPROACHES, THE OPPORTUNITY TO
BETTER UNDERSTAND, UNDERLYING
BIOLOGY AND THE IMPACT OF SEX
AND HORMONES AND THE NEED FOR
EMERGING THERAPIES TO TARGET
BEYOND THE SYMPTOMS OF ISOTOPE
ORDERS BUT THE CAUSES WERE
SEVERAL THEMES THAT WERE
HIGHLIGHTED.
TO GIVE YOU A LITTLE BIT OF AN
UPDATE ON SOME OF THE ORWH
PROGRAMS THAT OCCURRED SINCE WE
LAST MET IN FULL, IT'S ALWAYS
OUR PLEASURE TO ON BEHALF OF
NIH, LEAVE THE ANNUAL SYMPOSIUM,
IN ADDITION TO A REALLY ROBUST
AND AMAZING PANEL YOU CAN SEE
HERE WE ALSO HAD A CAP STONE
PRESENTATION, FROM DR. RAQUELL
HEALTH CHAIR OF INFORMATION
SCIENCES AND PROFESSOR SPELL MAN
AT THE COLLEGE, IT'S AVAILABLE
BY VIDEOCAST IF YOU MISS TODAY
EMPLOY --
MISSED IT.
I ALSO WANT TO UPDATE ON A
COLLABORATION WE'VE HAD WITH THE
INTRAMURAL PROGRAM.
THE BENCH TO BEDSIDE PROGRAM WAS
CREATED TO SEE NEW PART MERSHIPS
AMONG INSTITUTES AND CENTERS
BETWEEN BASIC SCIENCE AND
CLINICAL INVESTIGATORS AND THEN
IN 2006, THE PROGRAM WAS
EXPANDED TO INCLUDE EXTRAMURAL
COLLABORATIONS AND SINCE 2006,
ORWH HAS CO FUNDED 19 BENCH TO
BEDSIDE PROJECTS AT ALMOST
$5 MILLION AND WE'RE CO FUNDED
OF COURSE WITH THE DEPUTY
DIRECTOR FOR INTRAMURAL RESEARCH
AND OTHER ICOs.
SPECIFICALLY THIS PROGRAM ADDED
THE STRATEGIC PLAN, THE NIH-WIDE
STRATEGIC PLAN FOR RESEARCH ON
HEALTH ON WOMEN CALL TO
PROPOSALS WHEN WE BECAME
PARTNERS.
SO THIS IS 1 OF THE WAY WHAT'SY
ARE IMPROVING WOMEN'S HEALTH BY
COLLABORATING WITH THE
INTRAMURAL PROGRAM.
AN EXAMPLE OF 1 OF OUR RECENT
SUPPORTED PROGRAMS IS THE NOVEL
GUT MICROBIOME FACTORS AND
PREGNANCY AND EARLY CHILDHOOD OR
ETCHED STUDY.
AND THE INVESTIGATORS SUPPORTED
BY THAT RECENTLY FEATURED IN OUR
NIH REMETABOLISM'S HEALTH
RESEARCH SCIENTIFIC INTEREST
GROUP THAT WE CONVENE QUARTERLY,
AT LEAST QUARTERLY AROUND THE
NIH COMMUNITY TO PROVIDE UPDATES
AND DR. SINHA AND DR. HOURIGAN,
PRECEPTED ON THE LONG-TERM
METABOLIC HEALTH AND SHAPING THE
MICROBIOME IN SHAPING FUTURE
HEALTH RESPECTIVELY OUR OWN
DR. OTAWANG WAS THE MODERATOR
FOR THAT SESSION.
I AM ALSO PLEASED TO SHARE WITH
YOU THAT JUST RECENTLY WE WERE
PLEASED TO COLLABORATE WITH THE
UNIFORM SERVICES UNIVERSITY
MILITARY WOMEN'S ELGT RESEARCH
PROGRAM TO KICKOFF A NEW WEBINAR
SERIES, THE FIRST SESSION WAS ON
MENOPAUSE AND MIDLIFE HEGHT AND
DR. HADINE JOFFE AND HAD MIRANDA
JANVRIN AND THEY PRESENTED ON
MILITARY WOMEN ACCESSING
TREATMENT FOR MENOPAUSE SYMPTOMS
IN A PILOT STUDY RESPECTIVELY.
SO TUNE IN FOR FUTURE SESSIONS.
WE'VE BEEN VERY BUSY ACROSS THE
LAST YEAR COLLABORATING AND
DISSEMINATING OUR EFFORTS WITH
OUR PARTNERS AND I'VE BEEN SO
PLEASED TO BE INVITED TO PRESENT
AT MANY INSTITUTE AND CENTER
OFFICES, COUNCILS AND OTHER
SESSIONS AND JUST A FEW OF THEM
ARE LISTED HERE.
LAST YEAR THE NIH PAIN
CONSORTIUM WHICH IS AN NIH-WIDE
EFFORT TO STUDY PAIN, SO IN THE
2024 ANNUAL PAIN CONSORTIUM
MEETING, SEX DIFFERENCES IN
PAIN, DIFFERENT ACCESS TO PAIN
AND MANAGEMENT CARE AND PAIN
ACROSS THE LIFE SPAN WERE TOPICS
THAT WERE PRESENTED IN THAT MAY
2024 PRESENTATION CONSORTIUM
MEETING AND DR. OTA WANG
PROVIDED OPENING REMARKS AND
WE'RE THRILLED TO CONTINUE TO
SUPPORT THIS PAYING CONSORTIUM
AS IT MOVES FORWARD AND WE ARE
EXCITED THEY CHOSE TO FOCUS ON
SEX DIFFERENCES IN PAIN IN 2024.
AVAILABLE ON VIDEOCAST, YOU
HEARD FROM DR. KLEINSTREUER, ON
HER APPROACH TO NIAMS TO ADVANCE
SIGNIFICANT SCIENCES IN HEALTH.
THERE ARE MANY.
THE MOLECULAR TRANSDUCERS OF
PHYSICAL ACTIVITY SON SORTIUM,
10 YEAR PROGRAM, LARGEST
TARGETED NIH INVESTMENT WITH THE
MECHANISMS WITH HOW PHYSICAL
ACTIVITY IMPROVES HEALTH AND
PREVENTS DISEASE, IT'S
CATALOGING BIOLOGICAL MOLL QUEUE
KIEWLS THAT ARE AFFECTED BY
EXERCISE IN PEOPLE, LOOKING AT
HOW THEY ALTERED BY AGE, SEX,
BODY COMPOSITION, FITNESS LEVEL
AND EXPOSURE TO EXERCISE AND
THIS HAS THE POETIC TEBTIAL TO
HELP US UNDERSTAND WAT -- AT A
MOLECULAR LEVEL, INFLUENZS OF
PHYSICAL ACTIVITY THESE ARE
IMPORTANT STUDIES AND THEY'VE
ALREADY SHOWN EXDIFFERENCES IN
THE PUBLISHED INFORMATION.
IN TERMS OF FEMALE SCIENTIFIC
CONDITIONS, NCATS AND SUPPORTING
DRUG DEVELOPMENT TOOLS FOR
PREGNANCY AND WOMEN'S HEALTH.
WE KNOW PREGINANCE
SEPARTICULARLY CHALLENGING TO
STUDY AND THIS IS 1 WAY TO MOVE
FORWARD WITH NIAMS TO DO STUDIES
WE COULD BT DO OTHER WISE SO
WE'RE LOOKING FORWARD TO THEIR
RESULTS.
THE NATIONAL INSTITUTE OF MENTAL
HEALTH HAS LAUNCHED A NOTICE
LOOKING FOR APPLICATIONS AROUND
EXPLAINABLE ARTIFICIAL
INTELLIGENCE RESEARCH INCLUDING
FOR THE DESIGN AND TESTING OF
COMPUTATIONAL MODELS TO IMITATE
SEX DIFFERENCES IN CLINICAL
PHENOTYPES.
IT'S A PARTICULARLY IMPORTANT
APPROACH AS WE MOVE TO MORE
COMPUTATIONAL APPROACHES, IT'S
IM PERRATIVE WE ACCOUNT FOR SEX
AS A BIOLOGICAL VARIABLE AT THE
OUT SET AS WE MOVE FORWARD.
AND THEN NIDCR CLEARED A CONCEPT
AT THEIR COUNCIL RECENTLY
LOOKING AT OPTICAL IMAGES
MIEGZAL DENTAL ORAL,
CRANIOFACIAL MEDICINE, WE ARE
THRILLED TO SEE THE WORK AND
LOOK FORWARD TO COLLABORATING
WITH OUR COLLEAGUES ON THESE
EFFORTS.
THESE ARE JUST A FEW OF THE
MAMs EFFORTS UNDERWAY TO HELP
WOMEN'S HEALTH.
WE CONTINUED TO ADVANCE AND
HEALTH WOMEN'S HEALTH THROUGH
STRAY JECTORY TEENLIC
PARTNERSHIPS.
I WILL HAWAII HIGH -- HIGHLIGHW
MUCH THOSE HERE.
WE WILL SEE AND HERE FROM
DR. DINA P A LTOO, LATER IN THE
PROGRAM, CENTRALIZED FUNDING
OPPORTUNITIES ARE AVAILABLE AT
THAT WEBSITE.
THE NATIONAL HEALTH INTERVIEW
SURVEY LED BY CDC REACHING OVER
35,000 HOUSEHOLDS, WE
COLLABORATED TO ADD QUESTIONS OF
MENOPAUSE TO THAT EFFORT FOR
THIS YEAR.
WE HEARD FROM DR. K ABOUT THE
MENOPAUSE PREVENTION PROGRAM, A
CRITICAL EFFORT FOR MULTIPLE
AGENCIES INVOLVED IN LOOKING AT
MIDLIFE HEALTH AND MENOPAUSE
SYMPTOMS AND HOPEFULLY
PRIORITIZATION OF FUTURE
RESEARCH BASED ON SCIENTIFIC
DISCOURSE IN THIS VERY IMPORTANT
SPACE.
WE ARE COLLABORATING WITH THE
OFFICE OF EXTRAMURAL SEED, SEED
OFFICE AND OUR IC COLLEAGUESAs
WELL AS CDC AND FDA ON THE SMALL
BUSINESS INNOVATION TRANSFER,
FUNDING OPPORTUNITY WHICH IS A
MULTIAGENCY EFFORT IN WOMEN'S
HELT RESEARCH HAS NOW BEEN
ADDED
FOR THE FIEVERLT -- FIRST TIME.
WE ARE ADDING THAT IN 2025, HELP
US GET WORD OUT ABOUT THIS
AMAZING OPPORTUNITY IN THE
RESEARCH SPACE AND WE CONTINUE
TO COLLABORATE ACROSS NIH AS NIH
MOVES FORWARD INICISM ELEMENTING
THE SIMPLIFIED REVIEW FRAMEWORK
OR SRF, SABV IS SUPPORTING THAT
RELATED TO RIGOR AND
REPRODUCIBILITY AND CONTINUES TO
SCORE THE APPLICATIONS AND
INCLUDED PROMINENTLY TO TRAIN
AND UPDATE THE SABV RUVIEWERS
AND FRAMEWORK.
SO EXCITED TO CONTINUE OUR
COLLABORATION WITH CSR IN THAT
REGARD AND OER.
IN ADDITION TO OFFICE
INFRASTRUCTURE PROGRAMS WE
INITIATED A COLLABORATION WITH
THEM TO OTHER SHARED INSTRUMENTS
PROGRAM.
THIS PROGRAM IS PIVOTAL IN
ENABLING CLINICAL TRANSLATIONAL
RESEARCH INCLUDING IN WOMEN'S
HELT AND AS WOMEN'S HEALTH AS
NOW BEEN EXPLICITLY ADDED TO THE
FUNDING OPPORTUNITY THEY WENT
BACK AND TOOK A LOOK AT THE
PUBLICATIONS AND WERE ABLE TO
DEMONSTRATE OVER A THOUSAND
PUBLICATIONS REEL KEEPSAKES VABT
TO WOMEN'S HEALTH FROM
FY22-FY24.
A VARIETY OF INSTRUMENTS RANGING
FROM IMAGING TO SALES ORDERS AND
OTHERS IMPLEMENTATION ARE
SUPPORTED THROUGH THIS PROGRAM.
IT SUPPORTS MULTIPLE INSTITUTE
AND CENTER GRANTEES ON MULTIPLE
POPPICS WHO USE INSTRUMENTS SO
THIS IS 1 OF THE WAYS WE CAN
LEVERAGE ON AND CAPITALIZE ON
INVESTMENT FROM OUR
ICO PARTNERS, TOPICS INCLUDING
BREAST CANCER, UTERINE CANCER
AND HETEROZYGOTTIC OUTWOMANS AND
I CAN'T WAIT TO SEE WHAT THIS
SUPPORTS NEXT.
YOU HEARD FROM DR. KLEINSTREUER,
HOW IMPORTANT IT IS TO ADDRESS
THE CHRONIC DISEASES WE'RE
SEEING IN OUR COUNTRY.
AND SHE HIGHLIGHTED HOW THOSE
RATES DIFFERENT FROM OTHER
COUNTRIES AND YOU MAY RECALL
SEFORT MEMBERS OF THE ADVISORY
COMMITTEE WERE PART OF
ACWRSEVERAL YEARS AGO WHEN NIH
CALLED ON CONGRESS TO ELECTRIC
AT OUR INVESTMENTS ACROSS
INVESTMENTS IN CHRONIC
DEBILITATING CONDITIONS,
SURVIVAL RATES AND MATERNAL
MORTALITY AND AS WE LOOK AT
CHRONIC CONDITIONS WE SUPPORTED
A NATIONAL ACOOED MES REPORT ON
ADVANCING RESEARCH AND CHRONIC
CONDITIONS IN WOMEN, THAT
DEVELOPED, THAT LED TO A REPORT
THAT HIGHLIGHTED A FRAMEWORK
THATY WE COULD USE GOING FORWARD
TO ADDRESS BIOLOGICAL AND
SOCIETAL FACTORS THAT INFLUENCE
DISEASE PREVALENCE, DIAGNOSIS
AND MANAGEMENT, FOR WOMEN AND
PROVIDE A PULTY DIMENSIONAL
RESEARCH DRIVEN STRATEGY TO
UNDERSTANDING CHRONIC DISEASES
IN WOMEN.
WE BUILT UPON THAT AND ISSUED
FUNDING OPPORTUNITIES FOR AN
RO-1 AND R21 WITH 7 ICO PARTNERS
AND FY23, AND 24, AND I'M
HIGHLIGHTING THE 24 DATA HERE
WITH OUR 7 ICO PARTNERS, WE'RE
ABLE TO FUND 21 AWARDS, 9 RO-1S
AND 12 R21S AND YOU CAN SEE THE
FUNDING HERE ON THE RIGHT IN THE
GRAPH IN MILLIONS, SO HERE ARE
THE TOTAL AMOUNTS TOTAL
$8.4 MILLION IN FY24, NEARLY
8.4.
AND A LITTLE BIT MORE
INFORMATION HERE, IN TERPS OF
THE SPECIFIC CONDITIONS THAT ARE
BEING ADDRESSED IN THIS REALLY
UNIQUE PROGRAM, FIRST OF ITS
KIND, LOOKING AT ISSUES THAT
AFFECT WOMEN AND MEN SUCH AS
AORTIC STENOSIS, CARDIOVASCULAR
DISEASE, PREVENTION, HIV
INFECTION, SYSTEMIC LUPUS
ARROWTHEMAITOSEIS SO LIGHTING ON
THE LEFT THE INVESTIGATORS AND
ON THE ON THE X-KROMSOME, WE
KNOW OBESITY IS REALLY IMPORTANT
IN A FACTOR OF THE CHRONIC
DECEASED DEVELOPMENT, TARGETING
ESTROGEN SENSITIVE NEURONS
VERSUS FRAILTY IN FEMALES,
FRAILTY IS A CRITICAL ISSUE IN
OLDER AND OBSTRUCTIVE PULMONARY
FEMALES, ALONG WITH NHLBI, WE
SEE RISING COPD RATES AND HIGHER
MORTALITY RATES IN WOMEN AS
COMPARED TO MEN SO WE WANT TO BE
ABLE TO UNDERSTAND THOSE
CONDITION BETTER SO IT'S BEEN AN
OPPORTUNITY TO ADDRESS GAPS IN
UNDERSTUDIED CHRONIC DISEASES IN
WOMEN THROUGH THIS FUNDING
OPPORTUNITY WITH INTUITYS AND
CENTERS.
IN ADDITION I WANT TO SHOW
NUCLEOTIDES TERMS OF MEMBERS OF
APPLICATIONS TD BREAK DOWN OF
NIH EN--STRATEGIESITUTES AND
CENTERS WITH NICHD LEADING WELL,
AND THE DARKER GREEN BARS
INDICATE THOSE APPLICATIONS
FUNDED THAT ARE IN FEMALE
SPECIFIC CONDITIONS AND YOU CAN
SEE THAT RELATED TO THE TOTAL.
AGAIN, REALLY EXCITED TO BE ABLE
TO MOVE THIS RESEARCH FORWARD.
ALSO MY PLEASURE TO SHARE WITH
YOU A RECENT UPDATE ON THE SCORE
PROGRAM WAS PRESENTED AT THE
ORGANIZATION FOR THE STUDY OF
SEX DIFFERENCES ANNUAL MEETING
AND DR. CHAIRED AND MODERATED A
SESSION WITH 3 SCORE
INVESTIGATORS PRESENTING ON
ALCOHOL USE, ON THE BRAIN GUT
MICROBIOME INTERACTIONS AND
OTHER TOPICS.
THE SCORE PROGRAM IS MOVING
FORWARD AND IT'S OUR PLEASURE TO
WORK WITH OSSD ON THEIR EFFORTS.
YOU HEARD FROM DR. HIGGINS
EARLIER ON RURAL HEGHT AND I
WANT TO HIGHLIGHT AND TELL OUR
ADVISORY MEMBERS THAT WE HAVE
BEEN WORKING OVER 5 YEARS IN A
COLLABORATION BUILDING WITH THE
NATIONAL EN--STRATEGIESITUTE OF
GENERAL UPON SCIENCES THAT LEAD
CONGRESSALLY MANDATED IDEA
STATES OR INSTITUTIONAL
DEVELOPMENT ARK WARD STATES.
IDEA STATES ARE THOSE STATES IN
THE U.S. THAT RECEIVE
HISTORICALLY LOWER NIH GRANT
FUNDING AND YOU CAN SEE THEM
INDICATED HERE ON THE RIGHT.
AND OVER THE YEARS, WE INIT I
SHALY STARTED LEVERAGING WITH
THE IDEA STATES PROGRAM WITH
ADMINISTRATIVE SUPPLEMENTS,
OPPORTUNITIES FOR INVESTIGATORS
FUNDED BY IDEA TO ADDRESS
WOMEN'S HEALTH AND FROM THE LAST
4 YEARS WE'VE NOW FUNDED 83
ADMINISTRATIVE SUPPLEMENTS,
ALMOST $23.4 MILLION OF
INVESTMENTS OF OOH RWH, NIGMS
AND OTHER INSTITUTES AND CENTES
IN AREA SO THIS IS AN NIH-WIDE
PROGRAM NOW.
TO DATE TWEEF FUND THE 21 OF THE
23, PLUS PUERTO RICO AND LAST WE
WE EXPANDED THE PROGRAM TO
INCLUDE CENTERS OF BIOMEDICAL
RESEARCH OR COBREs IN WOMEN'S
HEALTH.
WE ALSO KNOW NEW TRICIAN IS
PARTICULARLY IMPORTANT ISSUE FOR
THE HEALTH OF WOMEN AND THERE
ARE GEOGRAPHIC DIFFERENCES IN
MUSEUM TRICIAN AND IT'S
NUTRITION DEFICIENCY
CONSEQUENCES.
AT THE UNIVERSITY OF KANSAS
LEVERAGING BIG DATA TO IMPROVE
WOMEN'S HEALTH AND I MENTIONED 1
OF THE PROGRAMS THERE IS ON
TELEMEDICINE BUT ALSO IN
REFERAGEING BIG DATA IN A
VARIETY OF OTHER WAYS, SEX BASED
PRECISION MEDICINE AT TULANE IN
LOUISIANA IS OUR THIRD C OBRE
AND STAY TUNED FOR NEXT TIME WE
WERE TOGETHER.
LAST YEAR WE WERE ABLE TO HAVE
THE FIRST SYMPOSIUM OF THESE
RESEARCHERS TO TALK ABOUT THEIR
EFFORTS.
SO I HOPE YOU CAN SEE THAT
WORKING COLLABORATIVELY WITH
NIIMRKS MS AND BUILDING ON
MULTIIDEA STATES PROGRAMS THAT
THEY HAVE INVESTED IN AND THE
ICs INVESTED IN, WE HAVE
WORKED TO EXPAND WOMEN'S HEALTH
AND REACH AND EXPANDED THE REACH
ACROSS COUNTRY INTO THESE STATES
TO ADDRESS THE NEEDS ACROSS THE
NATION.
I MENTIONED THIS COLLABORATION
WITH THE SBIR/STTR PROGRAM OFTEN
CALLED AMERICA'S SEED FUND X.
THIS PROGRAM IS FOR SMALL
BUSINESS INFOIVATION.
WOMEN'S HEALTH HAS BEEN ADDED
AND WE'VE HOSTED SEVERAL
WEBINARS WHERE AT EACH OF THESE
WEBINARS THE SEED OFFICE PRESENT
OFFICE OF DIVERSITY THIS
OPPORTUNITY.
WE HIGHLIGHTED A FEW ITEMS BUT
EACH OF THOSE INSTITUTES AND
CENTERS HIGHLIGHTED WOMEN'S
HEALTH RELEVANT ADVANCES THAT
HAVE BEEN FUNDED THROUGH THE
SBIR/STTR PROGRAM, MAKING CLEAR
THE OPPORTUNITY FOR THIS
NONDILUTIVE MANDATORY ISSUING
THAT HAS BEEN HANDED.
THE NEXT 1 IS JUNE 25th.
SO PLEASE JOIN US TO HEAR ABOUT
OPPORTUNITIES FOR SBIR/STTR
FUNDING AND HELP US GET THE WORD
OUT ABOUT THIS AMAZING PROGRAM.
I'M ALSO PARTICULARLY DELIGHTED
TO SHARE WITH YOU THE OFFICE OF
AUTOIMMUNE DISEASE RESEARCH AND
WITHIN THE RWHAS REPORTED THEIR
FIRST REPORT OF ACHIEVEMENT FOR
FISCAL YEAR 23 AND 24, THAT
REPORT IS AVAILABLE ONLINE AND
THAT HIGHLIGHTS THE PROGRESS
THAT'S' BEEN MADE TOWARD THE
CONGRESSIONAL DIRECTIVES SET
FORTH, WITHIN THE ESTABLISHMENT
AND WE ARE EXCITED TO SHARE THAT
NEWS WITH YOU.
PLEAS CHECK THAT OUT.
WE ALSO SUPPORTED THE NATIONAL
ACADEMIES OF SYSTEMIC WORK
ISSUES BECAUSE WE KNOW A HEALTHY
ECOSYSTEM INCLUDES HEALTHY
WORKPLACES AND THAT INCLUDES
PHYSICAL AND MENTAL HEALTH.
PLEASE CHECK OUT RETINAL
LOCATION PORT THERE.
AND I WILL HIGHLIGHT 2 OF OUR
TRAVEL AWARDS.
OUR OSSD ANNUAL ME MEETING
TRAVEL AWARDS DR. AMANDA QUARS
ON SEX DIFFERENCES IN CLINICAL
TRIAL ENROLLMENT IN U.S.
PSYCHIATRIC DISORDERS AND A
THIRD YEAR MEDICAL STUDENT NEFIA
CHACKO, IS LOOKING AT VASCULAR
DYSFUNCTION IN ASSOCIATED WITH
POST MENOPAUSAL MICE, AND THENAD
LYNN ALEXANDER LOOKING AT APOE 4
GENOTYPES AND MEMORY DECLINE IN
MENOPAUSE AND ALSO LOOKING AT
MENOPAUSE CARE IN A NOVEL
FACILITATED GROUP CARE MODEL.
SO CONGRATULATIONS TO ALL OF OUR
TRAVEL AWARDEES AND I WILL WRAP
UP WITH DAT A SHARE WITH YOU
ONCE A YEAR, HERE IS THE BUDGET
HISTORY OF OUR FOUNDING IN 1991,
OUR FOUND NOTHING 1990 AND YOU
CAN SEE IN 2002 A BIG BUMP UP
FOR THE FORMATION OF THE BIRCH
PROGRAM, PLATBUDGET UNTIL ABOUT
2021, INCREING IN 2023, WITH THE
FORMATION OF THE OFFICE OF
AUTOIMMUNE DEC WERE AND OUR 2024
NUMBERS, 77.76 MILLION.
IN TERMS OF HOW THAT BREAKS OUT
IN TERMS OF OUR PARTICULAR
SIGNATURE PROGRAMS, THAT DATA IS
PRESENTED HERE, WE CO FUND WITH
VIRTUALLY ALL THE INSTITUTES AND
CENTERS ENUMERATED HERE AND A
VARIETY OF PROGRAMS HERE ON THE
LEFT HERE, SO WE ARE WORKING
HARD TO COLLABORATE WITH ALL THE
INSTITUTES AND CENTERS ACROSS
ALL OUR PROGRAM IN A WAY THAT IS
VALUE ADDED TO THE INSTITUTES
AND CENTERS THAT ADDRESS GAPS IN
THE NIH PORTFOLIO AND
OPPORTUNITIES FOR TOPICS THAT
OVERLAP MULTIPLE INSTITUTES AND
CENTERS SO THAT WE'RE
COMPLIMENTARY TO THE IC EFFORTS
IN ADVANCING WOMEN'S HEALTH.
WRAPPING THIS UP, WE ARE SMALL
OFFICE, BUT I CAN ARGUE THAT WE
HAVE HAD A BIG IMPACT, I
HIGHLIGHTED FOR YOU AT THE
BEGINNING OUR IMPACT IN CO
FUNDING RESEARCH IN TERMS OF
DRUG LICENSES, WHICH IS ONLY 1
WAY TO MEASURE I -- IMPACT.
THERAPEUTIC INTERVENTIONS,
COMPARATIVE STUDIES CLINICAL
TRIALS ARE ALL OTHER WAY WE HAVE
SUPPORTED AND IMPACTED THE
HEALTH OF WOMEN, IT'S BEEN OUR
PLEASURE TO COLLABORATE WITH
MULTIPLE INSTITUTES AND CENTERS
THROUGH THE YEARS, AND WE TOOK A
LOOK AT 2013-2024 AND SAW WE
SUPPORTED OVER 2000 PROJECTS,
MOST FREQUENTLY CO INVESTING
WITH NICHD, NHLBI, NIAMS, NIAD,
AND NIDDK, AS WE INNERTEND TO
MAKE EVERY DOLLAR WORK AS HARD
AS POSSIBLE TO IMPROVE THE
HEALTH OF WOMEN AND CONTINUE TO
WORK COLLABORATIVELY WITH OUR
COLLEAGUES TO BE ABLE TO
LEVERAGE AND MAKE SURE OUR
INVESTMENTSA THE NIRE H ARE
STRATEGIC AND EFFECTIVE.
IT'S ALSO MY DISTINCT PLEASURE
TO ASK YOU TO SAVE THE DATE FOR
THE LAUNCH OF THE NIH-WIDE
STRATEGIC PLAN FOR AUTOIMMUNE
DISEASE WERE AND THAT IS GOING
TO BE ON JULY 21st AT 1 P.M.
INFORMATION IS AVAILABLE HERE SO
MEAS DO JOIN US FOR THAT --
PLEASE DO JOIN US FOR THAT
EXCITING EVENT.
OTHER EVENTS UPCOMING, I
MENTIONED THE SBIR WEBINAR IN
JUNE.
IN JULY WE'RE HAVING A WOMEN'S
HEALTH RESEARCH ROUND TABLEOT
VAGINAL MICROBIOME AND
IMPLICATIONS ARE WOMEN'S HEALTH.
OUR NEXT MEETING IS ON
OCTOBER 7th, IN-PERSON MEETING
WITH A 35th ANNIVERSARY
SESSION, OUR PROGRAM MEETING OUR
ANNUAL SCORE AND BIRCWH AND THEN
OUR P2 P MENOPAUSE WORKSHOP,
PLEASE MARK YOUR CALENDARS FOR
THOSE EXCITING OPPORTUNITIES AND
EVENTS.
IT IS OUR PRIVILEGE TO BE
CELEBRATING 35 YEARS OF WOMEN'S
HEALTH RESEARCH AT NIH ADVANCING
THE HEALTH OF WOMEN THROUGH
RESEARCH AND INNOVATION, SO
THROUGH THIS YEAR, WE WILL BE
HAVING SEVERAL EVENTS, EPISODES
AND YOU KNOW NOTIFICATIONS, SO
STAY TUNED IF ARE THAT ON OUR
WEBSITE, AND OF COURSE, JOIN US
ON OCTOBER 7th.
AND WITH THAT, I WANT TO THANK
YOU FOR YOUR ATTENTION.
I WENT A BIT OVER, MY APOLOGIES
DR. OTA WANG, THERE WAS SO MUCH
I WANTED TO SHOW WITH OUR
MEMBERS AND SO WHAT WE CAN DO TO
GET BACK ON TIME IF YOU LIKE, WE
CAN DO ANY URGENT QUESTIONS NOW
BUT WE CAN SAVE THEM FOR OPEN
DISCUSSION IF THAT WORKS BETTER
FOR OUR SCHEDULE.
I THINK WE'RE ACTUALLY OKAY.
AND YOU COULD PROBABLY TAKE A
QUESTION OR 2.
>> OKAY.
>> BEFORE WE MOVE ON TO DR. P A
LTOO'S PRESENTATION.
>> GREAT, OKAY.
>> WE ARE OKAY WITH OUR TIMING.
SO ADVISORY COMMITTEE MEMBERS
ANY QUESTIONS OR COMMENTS ABOUT
ANY OF THE UPDATES OR OTHER
TOPICS AND WE STILL ALSO HAVE
TIME LATER IN THE DAY FOR OPEN
DISCUSSION.
>> QUIET GROUP TODAY.
>> I THINK THEY'RE STILL
DIGESTING ALL THE INFORMATION
YOU'VE GIVEN THEM.
IT WAS QUITE SPECTACULAR, I
THINK WHAT A TESTAMENT TO THE
OFFICE AND THE STAFF HERE.
>> YOU KNOW DR. OTA WANG, I AM
SO EXCITED EVERY TIME WE HAVE
THIS MEETING TO SHARE THE AA
MAZING WORK THAT THE TEAM AT
ORWH HAVE DONE AND YOU'RE
ABSOLUTELY RIGHT AND FOLKS WORK
VERY, VERY HARD AND I WANT TO
ACKNOWLEDGE ALL THE FORMER ORWH
STAFF MEMBERS, IT'S BEEN A YEAR
OF CHANGE AND I WANT TO
ACKNOWLEDGE EVERYONE'S EFFORTS
IN ADVANCING ORWH, IT'S BEEN A
TEAM EFFORT.
DR. HIGGINS HAS A QUESTION?
>> NOT A QUESTION, BUT A
COMMENT, I WANT TO COMMEND YOU
ON YOUR ENTIRE PRESENTATION BUT
I REALLY LIKE THE QUANTIFICATION
OF ACCOMPLISH WANTS ISSUES THE
PUBLICATIONS LICATIONS, THE PATD
WHAT NOT, I THINK IT'S AN
IMPORTANT WAY OF SHOWING THE
CONTRIBUTIONS THAT YOU'RE MAKING
AND FOR ME, I LOVE THE
PUBLICATIONS, SO 73,000
PUBLICATIONS IS PRETERM BIRTH
IMPEDIMENTS PRESSIVE, SO, I JUST
WANT TO COMMEND YOU ON THAT.
>> THANK YOU DR. HIGGINS, I
APPRECIATE THE FEEDBACK, WE'RE
ALWAYS LOOKING AT WAYS TO CONVEY
THE IMPORTANCE OF WOMEN'S HEALTH
RESEARCH AND THE IMPORTANCE OF
NIH WIDE COMPREHENSIVE
COORDINATED EFFORTS AS
VALUE-ADDED.
I APPRECIATE THE FEEDBACK.
>> LOOKS LIKE DR. ANDERSON AND
THEN DR. NOEL.
>> YES, DR. ANDERSON,
DR. CLAYTON THANK YOU VERY MUCH,
IMPRESSIVE PRESENTATION OF ALL
ACCOMPLISHED I WAS ENJOYING
THAT.
I WAS WONDERING IF YOU COULD
DESCRIBE SOME OF THE TRANSITIONS
THAT HAVE HAPPENED IN YOUR
OFFICE WHICH I THINK OFTEN
HAPPEN, I WONDER IF THERE HAVE
BEEN OTHER IMPACTS IN THE ORWH
THAT YOU COULD DESCRIBE OR HAVE
THERE BEEN ANY OTHER CHANGES IN
TERMS OF THE SIZE OF YOUR
STAFFING, THINGS LIKE THAT THAT
WOULD AFFECT OUR ABILITY TO MOVE
FORWARD ON OTHER THINGS?
>> SURE.
SO DR. ANDERSON THAT'S AN
IMPORTANT QUESTION AND IN YOUR
ROLE AS AN ADVISORY COMMITTEE
MEMBER, THOSE ARE QUESTIONS THAT
ARE IMPORTANT FOR YOU TO
UNDERSTAND OUR ABILITY TO GET
OUR JOB DONE IN THE
INTERMISSION.
SO THERE HAS -- IT IS A CHANGING
LANDSCAPE AND WE DO HAVE
POSITIONS THAT ARE OPEN AT THIS
TIME AND SO IT'S IMPORTANT FOR
US TO ALWAYS BE AS EFFICIENT AS
POSSIBLE AND FOCUS ON OUR
CRITICAL VALUE ADDED THAT ONLY
ORWH CAN DO, AND WITH FEWER
STAFFING AND OUR TEAM SIZE, THAT
DOES MAKE THAT MORE CHALLENGING
OF OF COURSE WE ARE FIRMLY
COMMITTED TO ADVANCING EVERY
SINGLE ORWH SIGNATURE PROGRAM
AND WE'VE CHOSEN TO FOCUS ON
THOSE SIGNATURE PROGRAMS AS OUR
NUMBER 1 PRIORITY OF OF COURSE
EACH AND EVERY 1 OF THEM ARE
DONE IN COLLABORATION WITH AN
INSTITUTE OR CENTER.
SO WE HAVE GOOD NEWS AS A NEW
PARTNERS, WITH NIAMS, WITH THE
BIRCWH FOR THAT, WE HAVE NEW
NEWS COMING, I CAN'T SHARE JUST
YET, PART MERSHIP OUTSIDE OF
NIH, OUR SCORE PROGRAM CONTINUES
TO BE STRONG, SABB, AS YOU HEARD
FROM DR. KLEINSTREUER, CONTINUES
TO BE SUPPORTED AND WOMEN'S
HEALTH CONTINUES TO BE A
PRIORITY.
AS WE MOVE FORWARD IT WILL BE
IMPORTANT THAT WE ARE ABLE TO
BRING BACK UPDATES TO YOU ON OUR
ABILITY TO MOVE FORWARD WITH OUR
PROGRAMS AND GIVE YOU THE
INFORMATION YOU NEED TO BE ABLE
TO PROVIDE TO US AS OUR ADVISORY
MEMBERS.
SO WE APPRECIATE ANY THOUGHTS
YOU MIGHT HAVE ON WAYS YOU WE
CAN MOVE FORWARD AND WHAT MIGHT
BE TOP OF MIND FOR YOU ALLA THIS
TIME AS MOST CRITICAL TO
ADDRESS.
>> THANK YOU.
>> WAS THERE ANOTHER HAND?
I THOUGHT DR. NOEL HAD HEAR HAND
UP BUT MAYBE THAT WASN'T THE
LEGACY HAND.
>> WELL YOU ACTUALLY -- HI,
ALEXANDRA NOEL, YOUY SPONDY
LIGHTISSED A BIT TO MY QUESTION.
I THINK YOU HAD A NICE
PRESENTATION AND YOU SHOWED THAT
THERE WAS SEX BASED DIFFERENCE
EVEN IN UTERO LOOKING AT THE
PLACENTA FOR MALE FETUSES,
VERSUS FEMALE FETUSES AND I
WANTED TO KNOW WHETHER IT WOULD
BE A RESEARCH PRIORITY TO LOOK
AT EPIGENETIC EFFECTS IN THE
PLACENTA AND SEX BASED
DIFFERENCE IN THE OFFSPRING,
WOULD THAT BE A PRIORITY MOVING
FORWARD?
>> SO EPIGENETIC SEX DIFFERENCES
ARE REALLY, I THINK AN AREA OF
OPPORTUNITY.
I VBT SEEN A HUGE AMOUNT OF
ATTENTION TO THAT WHICH IS 1 OF
THE REASONS I HIGHLIGHTED THAT
PARTICULAR STUDY, AND YOU SAW
HOW IMPORTANT IT IS, I DIDN'T
EMPHASIZE, YOU KNOW WITH TIME
LIMITATIONS THAT THOSE SEX
DIFFERENCES ARE AND METHYLATION
PATTERNS ARE NEAR GENES THAT
REALLY ARE LINKED TO CHRONIC
DISEASE DEVELOPMENT OF THOSE
OFFSPRING SO IF WE CAN BETTER
UNDERSTAND HOW SEX DIFFERENCES
AND METHYLATION PAT
E-PRESCRIBINGS AND MA SENTA OR
OTHERWISE, SET UP, SET US UP
MALES AND FEMALES FOR THE
DEVELOPMENT OF CHRONIC DISEASE,
THAT WOULD BE A HUGE INSIGHT
INTO THE ARC OF CHRONIC DISEASE
DEVELOPMENT AND SO, FROM THE
LIFE FORCE PERSPECTIVE WE SEE IT
AS A PRIORITY AND WE SEE THAT
SABB, -- IT'S REALLY A GREAT
EXAMPLE OF SABB IN ACTION.
SO WHETHER THAT'S TAKEN UP FROM
1 PARTICULAR INSTITUTE'S
PERSPECTIVE, I THINK THIS IS AN
ISSUE FOR ALL OF NIH, FOR ANY OF
THE INSTITUTES THAT HAVE
DEVELOPMENTAL AND HEALTH
DISEASEADS PART OF THEIR MISSION
TO ACCOUNT FOR SABB, THAT NEEDS
TO BE PART OF IT.
SO ONCE WE KNOW SEX HAS AN
AFFECT, YOU NEED TO,A COUNT FOR
IT IN FUTURE STUDIES BECAUSE NOW
WE UNDERSTAND THAT HAS AN AFFECT
WE WANT TO UNDERSTAND HOW YOU'RE
ACCOUNTING FOR THAT IN THAT NEXT
STUDY SO WE CAN BUILD ON THAT
KNOWLEDGE BASE, SO HOPE TO SEE,
YOU KNOW MORE STUDIES BUILDING
UPON THAT AMAZING COVERAGE
FUNDED BY NICHD AND OF COURSE
OTHERS, GTEX AND OTHERS HAVE
LOOKED AT SEX DIFFERENCES IN
GENE EXPRESSION BUT TRYING TO
UNDERSTAND WHAT THE DIFFERENCE
IS, THE ETIOLOGY OF THOSE SEX
DIFFERENCES AND THE UNDERLYING
PATHOGIZZIOLOGY OF COMPLEX
DIFFERENCES IN GENE EXPRESSION
EMPLOY WE REALLY HAVE A LOT TO
LEARN AND OF COURSE GREAT
QUESTION, ALEXANDRA.
>> OKAY, THAIRNG YOU SO MUCH FOR
YOUR INTEREST, YOUR QUESTIONS,
YOUR LONG STANDING ACWRH MEMBERS
I AM ALWAYS EXCITED TO BRING IT
TO YOU.
DR. OTA WANG WOULD YOU LIKE ME
TO MOVE ON AND INTRODUCE OUR
NEXT SPEAKER?
>> PLEASE DO.
>> I AM VERY EXCITED TO
INTRODUCE DR. DI NA P A LTO,
EACH OF THESE MEETINGS WE WANT
TO PRESENT THEIR PERSPECTIVE SO
YOU CAN UNDERSTAND HOW ALL THE
INSTITUTES AND CENTERS ARE
WORKING TOWARD IMPROVING THE
HELT OF WOMEN.
DR. DINA P A LTOO, IS THE ACTING
DEPUTY DIRECTOR OF POLICY AND
EXTERNAL AFFAIRS AT NLM, IN THIS
ROLE, SHE IS THE ROLE TO THE
SENIOR ADVISORY DIRECTOR OF NLP
AND ESTABLISHES FRAMEWORK
THAGOREAN GUIDES NLM'S RESEARCH,
OPERATION AND PUB LIBRARY
FOUNDATION SERVICES AND WORKING
ALONG NLM'S DEPUTY DIRECTOR FOR
OPERATIONS AND INNOVATION.
SHE ALSO OVERSEES NLM'S
RELATIONSHIPS ACROSS THE NIH
INCLUDING ORWH AND WITH EXTERNAL
GROUPS.
SHE WAS RENTLY DIRECTOR FOR
SCIENTIFIC STRATEGY AND
INNOVATION AT NHLBI WHERE SHE
SERVED AS SENIOR ADVISOR TO THE
NHLBI DIRECTOR AND SHE HAS
PREVIOUSLY SERVED AS NLM AS THE
ASSISTANT DIRECTOR FOR PRIORITY
DEVELOPMENT.
PRIOR TO JOINING NLM, SHE WAS
DIRECTOR OF THE SCIENTIFIC
POLICY AND HEALTH AND SOCIETY
PROGRAM WESTBOUND THE NIH OFFICE
OF THE DIRECTOR'S OFFICE OF
SCIENCE POLICY, RSP AND WAS
RESPONSIBLE FOR MNIH POLICY
EFFORTS AND ETHICAL
CONSIDERATIONS IN SCIENTIFIC
DATA SHARING AND MANAGEMENT,
OPEN SCIENCE, AND GENOMICS AND
HEALTH.
SHE HAS SERVE AS A PROGRAM
DIRECTOR AT NHLBI AND MAINTAINS
SCIENTIFIC PORTFOLIOS IN THE
PAST RELATED TO GENETICS PHARMA
CO GENETICS AND PERSONALIZED
MEDICINE AND YOU CAN SEE WHY WE
INVITED HERE HERE TODAY, SHE DID
RECEIVE HER BACHELOR OF
SUBSTANCE IN MICROBIOLOGY AND
Ph.D. IN PHYSICS FROM HOWARD
UNIVERSITY AND MD FROM JOHNS
HOPKINS SCHOOL OF PUBLIC HEALTH
AS WELL AS CERTIFICATES AND
MEDICINE AND NEW JERSEY AND
ALUMNI OF THE CANCER PREVENTION
FELLOWSHIP PROGRAM HERE AT THE
NATIONAL CANCER INSTITUTE.
PLEASE JOIN ME IN WELCOMING
DR. DINA P A LTOO.
>> THANK YOU SO MUCH
DR. CLAYTON.
AS DR. CLAYTON MENTIONED MY NAME
IS DINA P A LTOOI AM THE DEPUTY
DIRECTOR FOR POLICY AND EXTERNAL
AFFAIRS AT NLM.
I AM VERY HAPPY TO BE HERE AND
EXCITED TO HAVE THE OPPORTUNITY
TO SHARE WITH YOU A LITTLE
BACKGROUNDOT NATIONAL LIBRARY OF
MEDICINE.
I KNOW A LOT OF YOU MAY NOT BE
FAMILIAR WITH WHO WE ARE AND
WHAT WE DO, BUT I WOULD ALSO
LIKE TO TAKE TO YOU A LITTLE BIT
ABOUT HOW NLM ADVANCES
BIOMEDICAL RESEARCH AT THE
INTERSECTION OF DATA SCIENCE AND
INFORMATION.
NEXT SLIDE, PLEASE.
I KNOW A LOT OF YOU KNOW THIS
ALREADY BUT TO PROVIDE A BIT OF
CONTEXT, UP IN THE WOMEN'S
RIGHTS MOVEMENT OF THE 1960INGS,
HEALTHCARE FOR WOMEN AND
RESEARCH INTO WOMEN'S HEALTH
ISSUES HAD HISTORICALLY LACKED
BEHIND THOSE FOR MEN AND AS
THOSE MOVEMENTS REACHED THE
NATIONAL STAGE, SO DID THE
ENTRENCHED DISPARITIES OF WOMEN
SPECIFIC CARE, ACCESS AND
RESEARCH, HOWEVER, DISSPITE THE
VISIBILITY AND HELP OF VOCAL
ADVOCATES ACROSS COMMUNITIES IN
RESEARCH MEDICINE AND POLICY
THESE DISPARITIES REMAIN EVEN
TODAY.
FOR EXAMPLE, IN 2019, WOMEN
ACCOUNTED FOR ABOUT 40% OF
PARTICIPANTS IN CLINICAL TRIALS
ON CANCER, KASHEDIO VASCULAR
DISEASE AWELL AS PSYCHIATRIC
DISORDERS AND AS YOU HEARD
PREVIOUSLY TODAY, THESE 3
DISEASES PRIMARILY OR
DIFFERENTLY AFFECT WOMEN DESPITE
WOMEN REPRESENTING OVER HALF THE
POPULATION.
BUT WHAT'S MORE, BECAUSE MANY OF
THESE TRIALS DIDN'T ACCOUNT FOR
THE INTERSECTION OF SEX AND
RACE, WOMEN WERE LESS LIKELY TO
BE REPRESENTED IN CLINICAL
TRIALS AT ALL.
NEXT SLIDE, PLEASE.
SO THIS SLIDE PROVIDES IMPORTANT
MILESTONES IN SUPPORT OF
RESEARCH ON WOMEN'S HEALTH THAT
YOU'RE ALL FAMILIAR WITH.
THE SLIDE IS FAR FROM
COMPREHENSIVE BUT AS YOU KNOW
NIH ESTABLISHED THE NIH OFFICE
OF RESEARCH ON WOMEN'S HEALTH IN
1990 TO SERVE AS A FOCAL POINT
TO ENHANCE AND EXPAND WOMEN'S
RESEARCH AND INCLUDE RESEARCH
POPULATIONS AND ALSO CONSIDER
SEX AS A FACTOR IN HELT AND
DISEASE.
SEVERAL YEARS LATER, THE U.S.
FOOD AND DRUG ADMINISTRATION
OFFICIALLY MANDATED THE
INCLUSION OF WOMEN IN RESEARCH
AND THEN WITH THE NIH
REVITALIZATION ACT, THIS MANDATE
WAS EVENTUALLY SIGNED INTO LAW.
AND TO COMPLY WITH THIS ACT, NIH
PUBLISHED GUIDELINES THAT
RESEARCH REQUIRED RESEARCHERS TO
INCLUDE WOMEN AND MINORITIES IN
THEIR SUBPOPULATIONS IN THEIR
CLIENICAL RESEARCH.
AND AS DR. KLEINSTEURER, WITH
THE 21st CENTURY CURES ACT,
THESE GUIDELINES EXPANDED TO
INCLUDE RESEARCHERS AND
INCLUDING INFORMATION ON SEX,
RACE AND ETHNICITY IN PHASE 3
CLINICAL TRIALS ON CLINICAL
TRIALS .GOV.
IT IS MAINTAINED BY NLM, AND IT
A SOURCE FOR INFORMATION ON
RESULTS.
IN 2023, CONGRESS DIRECTED NIH
TO ESTABLISH THE OFFICE OF
AUTOIMMUNE DISEASE RESEARCH IN
ORWH AND NLM PARTICIPATES IN
THEA BEINGIVITYS OF THE THIS
OFFICE AND THERE'S ALSO THE
DEVELOPING THE REPORT AND
STRATEGIC PLAN THAT YOU HEARD
HEARD ABOUT.
NEXT SLIDE.
SO OVER THE YEARS AND AS
HIGHLIGHTED BY DR. CLAYTON, ORWH
HAS WORKED IN PARTNERSHIP WITH
INSTITUTES AND CENTERS ACROSS
THE NIH INCLUDING THE NATIONAL
LIBRARY OF MEDICINE WHICH IS 1
OF NIH'S 27 INSTITUTES AND
CENTERS, AND NLM SERVEs AS A
PLATFORM FOR BIOMEDICAL
DISCOVERY AND DATA POWERED
HEALTH BY ACCELERATING EXCUSE
ME, DISCOVERY AND ADVANCE HEALTH
DATA DRIVEN RESEARCH, AND
REACHING MORE PEOPLE AND MORE
WAYS THROUGH ENHANCED
DISSEMINATION AND ENGAGEMENT AND
ALSO BY BUILDING A WORK FOR FOR
DATA DRIVEN EXPRCH HEALTH.
AND TODAY WE WOULD LIKE TO TALK
A LITTLE BIT ABOUT HOW NLM'S
HISTORY AND ITS EVOLVING ROLE IN
DATA DRIVEN APPROACHES TO
ADVANCING WOMEN'S HEALTH AS WELL
AS FROM MAKING THAT RESEARCH
MORE DISCOVERABLE, AND
ACCESSIBLE AND ALSO INSURING
THAT WOMEN ARE REPRESENTED NOT
JUST IN THE DATA AND
INFORMATION, BUT ALSO BEHIND THE
SCIENCE.
NEXT SLIDE, PLEASE.
NLM IS DIVIDED INTO 5 OFFICES,
AND DIVISIONS THAT EACH MANAGE
OUR RESOURCES FROM DIVISION OF
INTRAMURAL RESEARCH IN WHICH WE
HOUSE PRINCIPLE INVESTIGATORS
AND THEY SHOWCASE THEIR
INNOVATIVE SPIRIT AND PASSION
FOR BIOMEDICAL RESEARCH TO OUR
LISTER HILL CENTER FOR
BIOMEDICAL COMMUNICATIONS WHICH
FOCUSES ON ADVANCEMENT AND
RESEARCH, AND ACHIEVING
INCREDIBLE AREY SULTS ACROSS
INFORMATION AND DATA
BIO-INFORMATICS.
NLM IS A LITTLE DIFFERENT THAN
MOST INSTITUTES AND CENTERS AT
NIH IN THAT OUR BUDGET FOR OUR
WORK IS APPROXIMATELY 80% FOR
IMPOSSIBLE TO BUILD RAMURAL AND
20% FOR EXTRAMURAL RESEARCH.
NEXT SLIDE, PLEASE.
UNDER THE ACTING DIRECTORSHIP OF
STEF SHERRY, NLM'S SUCCESS IS
DRIVEN IN PART BY DEDICATED
SENIOR LEADERSHIP TEAM WHO
COORDINATE AND SEE THE EXECUTION
OF OUR PRODUCT SERVICES AND
OTHER OFFERINGS.
WE WORK ACROSS NIH TO
COLLABORATE ON IMPORTANT
INITIATIVE ANDS PROVIDE SUBJECT
MATTER EXPERT EEDZ INIARYS SUCH
AS HEALTH IT, STANDARDS,
BIO-INFORMATICS, PUBLIC ACCESS
TO DATA AND PUBLICATIONS AND AS
WELL AS DATA SCIENCE.
NEXT SLIDE, PLEASE.
NLM WAS ESTABLISHED IN 1836 AS A
SMALL COLLECTION OF MEDICAL
BOOKS IN THE OFFICE OF THE
SURGEON GENERAL OF ARMY AND HAS
EVOLVED INTO A NATIONAL RESOURCE
FOR BIOMEDICAL INFORMATION AND
THE WORLD'S LARGEST BIOMEDICAL
LIBRARY AND DEVELOPER OF
ADVANCED BIOMEDICAL INFORMATION
SERVICES THIS INCLUDES
INFORMATION TO ADVANCE
TREATMENTS OUTCOMES DIAGNOSIS
AND MAINTAIN HISTORICAL
COLLECTIONS INCLUDING RARE BOOK
ANDS YOWRNALS.
NEXT SLIDE, PLEASE.
SO THE EXPERTISE THAT NLM HOLDS
SUPPORTS NIH'S EFFORTS TO
ADVANCE RESEARCH ON WOMEN'S
HEALTH AND I WOULD LIKE TO SERE
SPECIFIC EXAMPLES OF THE ROBUST
COLLECTIONS WE HAVE THAT WE
MAINTAIN.
THE GROUND BREAKING RESEARCH
INITIATED AS WELL AS THE
RESEARCH PROJECTS WE FUNDED IN
SUPPORT OF WOMEN'S HEALTH.
NEXT SLIDE.
NLM'S GLOBALLY APPRECIATED
COLLECTIONS SPANS 11 CENTURIES,
AND ORIGINATES FROM NEARLY EVERY
PART OF THE FLOAB.
WITHIN IT ARE A VARIETY OF
SOURCES ABOUT THE HISTORY OF
WOMEN'S HEALTH FROM ARCHIVEAT
COLLECTIONS OF MANUSCRIPTS,
PHOTOGRAPHS AND FILMS TO RARE
AND UNIQUE BOOKS, AS WELL AS
JOURNALS PASMMENTS AND EFEMRA.
NEXT SLIDE.
THE NLM DIGITAL COLLECTIONS
CONTAIN A FRACTION OF VAST
COLLECTION ON TOPICS SUCH AS
WOMEN'S HEALTH.
THIS SITE INCLUDES A SEARCH BAR
WHERE YOU ENTER KEY WORDS AND
GET BACK A HEALTH OF INFORMATION
INCLUDING JOURNALS, PHOTOGRAPHS
AND HISTORICAL BROCHURES.
FOR EXAMPLE, A SEARCH FOR FEMALE
SCIENTISTS BOOK CALLED WOMEN'S
PHYSICAL FREEDOM AND AUTHOR
PROMOTED SCIENTIFICALLY FOUND
IDEAS AND TREEPTS FOR
DISABILITIES THAT AFFECTED WOMEN
AND IN EARLIER THIS YEAR, TO
MARK WOMEN'S HEALTHRY MONTH NLM
POPULAR BLOG CALLED CIRCULATING
NOW, PUBLISHED A POST THAT
INVITED READERS TO VIRTUALLY
TOUR ORIGINAL COLLECTIONS
SPECIFICALLY THOSE ABOUT WOMEN'S
HEALTH HISTORY, THE TOUR WALKS
YOU THROUGH THE HISTORY OF HOW
WOMEN HAVE EXPERIENCED HEALTH
AND ILLNESS AND, PRACTICED
MEDICINE AND WELL AS ADVOCATED
FOR THE HEALTH AND HEALTH OF
THEIR FAMILIES SO WE INVITE TO
YOU REALLY CHECK OUT THESE
RESOURCES AND ALSO SUBSCRIBE TO
OUR BLOG, TO RECEIVE WEEKLY
POSTS OF A VARIETY OF DISCIPLINE
WRITTEN BY RESEARCHERS WHO HAVE
PERSONALLY STUDIED AND ACCESSED
THE NLM COLLECTIONS.
NEXT SLIDE, PLEASE.
AND HERE'S A SAMPLE OF WHAT YOU
WILL FIND IN OUR COLLECTIONS, OF
THE MATERIALS ARE CURATED, AND
THE 1S IN THIS POST DOCUMENT
HAVE EXPERIENCED HOW WOMEN
EXPERIENCE HEALTH AND MEDICINE,
PRACTICE MEDICINE, AND ADVOCATE
FOR THEIR HEALTH AND THEIR
FAMILIES.
IN THEIR RESEARCH THEY DOCUMENT
SCIENCE BY WOMENS AND PUBLIC
HELT AND DEBATES ON DECISIONS
AFFECTING WOMEN AND THEY ALSO
REVEAL STORIES ABOUT THE
PERSONAL RESPONSIBILITY AND
INDIVIDUAL PUBLIC HEALTH.
IF YOU'RE LOOKING FOR A MORE
GUIDED TOUR THROUGH THE ANNALS
OF WOMEN'S HISTORY WE HAVE
SEVERAL ONLINE EXHIBITS THAT
DISCUSS WOMEN AND WOMEN'S HEALTH
IN A VARIETY OF HISTORICAL
CONTEXT, SOME OF OUR EXHIBITS
INCLUDE THE VOICES OF ACTIVIST
EXPTION REFORMERS IN THE U.S.
WHO HAVE LONG RECOGNIZED THE
HARM OF DOMESTIC VIOLENCE AND
THOUGHT TO IMPROVE LIVES OF
WOMEN IN THOSE ENVIRONMENTS AND
A UNIQUE NURSING POST CARD
COLLECTION THAT IS LITERALLY
ILLUSTRATED AND SHOWS HOW
NURSING WAS SCENE IN THE 20th
CENTURY SOCIETY IN CULTURE.
OUR NEWEST EXHIBIT CALLED RISE,
SERVE AND LEAD, INCLUDES
MENTORSHIP AND ACTION MADE BY
SELECTION OF WOMEN'S PHYSICIAN
ORIGINALLY FEATURED IN THE
CHANGING SPACE.
YOU WILL SEE HERE MUCH
INFORMATION ON DR. VIRGINIA
APGAR FOR THE SCORE THAT BEARS
HER NAME, AND OTHER NOTABLE
WOMEN IN SCIENCE SUCH AS
DR. HELEN OCTAVIA DICKENS, AND
YOU CAN FIND MORE INFORMATION ON
THESE PEOPLE -- ON THESE WOMEN
IN OUR EXHIBITS.
NEXT SLIDE, PLEASE.
SO MOVING ON TO OUR PRODUCTS AND
SERVICES, THESE ARE THE -- THESE
PRODUCTS AND SERVICES CONNECT US
TO ACCURATE TUSTED AND CURRENT
HEALTH AND RESEARCH INFORMATION,
NLM MANAGES AND MAINTAINING
BIOMEDICAL INFORMATION SERVICES
THEY MAKE BIOMEDICAL DATA AND
INFORMATION AVAILABLE IN SUPPORT
OF HEALTH INCLUDING SUPPORT ON
RESEARCH WOMEN'S HEALTH.
WE ARE CURRENT LOAMACYY WORKING
TO UNIFY OUR PLATFORMS AND
DATABASES TO IMPROVE
INTERORPERABILITY AND DISCOVERY
ACROSS MULTIPLE DATA
REPOSITORIES INCLUDING THOSE
THAT HOLE INFORMATION ON
CLENICAL TRIALS, DATA, GENOMICS
AND MORE.
THEY COLLECT FEEDBACK AND
TRANSLATE IT INTO INTUITIVE
PERSONALIZED BIOMEDICAL
INFORMATION DISCOVERY AND THE
BEST PART ABOUT ALL OF OUR
PRODUCTS AND SERVICES, THEY'RE
AVAILABLE FOR FREE.
I WOULD LIKE TO HIGHLIGHT THAT
EVERY DAY, MILLIONS OF
SCIENTISTS HELP PROFESSIONALS
AND MEMBERS OF THE PUBLIC USE
OUR ONLINE SERVICES TO SUBMIT
DAT ATRANSLATE RESEARCH, RESULT
IN A NEW TREATMENT, ACCESS OUR
COLLECTIONS, DEVELOP NEW
PRODUCTS, AND INFORM CLINICAL
DECISION MAKING AND IMPROVE
HEALTH.
IN FACT, NLM RECEIVED 10S OF
TERRA BYTES DATA DAILY
PROCESSING ON AN AVERAGE OF 2
PEDABYTES OF DATA PER DAY.
WE ALSO HAVE 4-10 MILLION USERS
THAT ACCESS HUNDREDS OF TERRA
BYTES OF DAILY FROM NLM MANAGED
ISHT ACTIVE WEBSITES AND
1000th OF DERRA BYTES ARE
DOWNLOADED DATAY SOPHISTICATED
WE'RE IN THE BUSINESS OF PAIKING
DATA AND INFORMATION AVAILABLE
AND WE HAVE A LOT OF PEOPLE
COMING TO OUR SITE.
OUR PRODUCTS AND SERVICES ARE
WITHIN THE TOP 3 DEPARTMENT OF
HEALTH AND HUMAN SERVICES
WEBSITES THAT ARE ACCESSED DAILY
BY THE PUBLIC.
NEXT SLIDE.
OUR MOST WIDELY USED RESOURCE
WHICH MANY OF YOU MAY BE
FAMILIAR WITH IS PUB MED, IT'S A
SEARCHABLE BIBLIOGRAPHIC
DATABASE THAT'S AVAILABLE TO
ANYONE WHETHER RESEARCH,
CLINICIAN OR MEMBER OF OUR
COMMUNITY, IT'S AVAILABLE TO
PUBLIC -- IT'S BEEN AVAILABLE TO
THE PUBLIC SINCE 1996, AND IT
CONTAINS MORE THAN 37 MILLION
CITATIONS AND ABSTRACTS OF
BIOMEDICAL AND LIFE SCANSES
LITERATURE, THAT SUPPORT
RESEARCH INCLUDING THE LATEST
BIOMEDICAL RESEARCH AND STUDIES
FOCUSED ON WOMEN'S HEALTH.
PUB MED, MAKE ITS SIMPLE TO FIND
HIGH QUALITY RESEARCH ON TOPICS
SUCH AS REPRODUCTIVE HEALTH,
PREGNANCY, MENOPAUSE AND CANCERS
AND USES FILTERS AND SEARCH
TOOLS TO 0 IN ON WHAT MATTERS
MOST TO THE USER.
AND BY SUPPORTING ACCESS TO A
DIVERSE AND UPTO DATE
INFORMATION PUB MED HELPS
ADVANCE RESEARCH, GUIDE CLINICAL
CARE AND INFORM POLICY TO HELP
IMPROVE THE OUTCOMES OF WOMEN.
MED LINE PLUS IS A PORTAL THAT
PROVIDES HIGH QUALITY RELEVANT
CONSUMER HELT AND WELLNESS
INFORMATION TO THE PUBLIC.
AND THIS SERVICE OFFERS HEALTH
INFORMATION THAT'S EASY TO READ,
AND UNDERSTAND IN BOTH ENGLISH
AND SPANISH MAKING THE LATEST
INFO AND HEALTH ON WELLNESS
SUCCESSFUL TO EVERYTHING, IT
COVERS SPECIFIC HEALTH TOPICS
AND WOMEN'S HEALTH, INCLUDING
PREGNANCY, HEALTH SCREENINGS,
HUMAN GENETICS AND ANATOMY,
MEDICAL TESTS AND MEDICATIONS.
AND WHILE SOME OF THE
INFORMATION IS PRODUCED BY NLM,
WE ALSO PROVIDE CURATED LINKS TO
OTHER AUTHORITATIVE HEALTH
INFORMATION INCLUDING OTHER NIH
INSTITUTES, WEBSITESES ARE,
GOVERNMENT AGENCIES AS WELL AS
REVIEWED AND NONEMBEDDED
RESOURCES.
BUT THE PROVE OF NLM IS THE
IMPACT IN NUMBERS MUCH IT'S 1 OF
THE MOST VISITED U.S. GOVERNMENT
WEBSITES WITH OVER 400 MILLION
USERS LANDING ON THESE WEBPAGES
EACH YEAR.
PUB MED CENTRAL ON THE OTHER
HAND, IS NLM'S FULL TEXT ARCHIVE
OF BIOMEDICAL JOURNAL LITERATURE
AND INCLUDES OVER 7 AND HALF
MILLION FULL TEXT ARTICLES, MOST
OF THE CONTENT COMES FROM
JOURNALS OR PUBLISHERS THAT HAVE
AGREED TO DEPOSIT THE ARTICLES
THEY PUBLISH IN PMC AND IN FACT
OVER 25,000 JOURNALS CURRENTLY
DEPOSIT THEIR ENTIRE CONTENT IN
PMC, WE'VE ADDED ANOTHER MILLION
ARTICLES THROUGH OUR
DIGITIZATION PROJECTS, AND PMC
ALSO SUPPORTS THE NIH PUBLIC
ACCESS POLICY AS WELL AS THE
SHARING OF ARTICLES FROM OTHER
FEDERAL PARTNERS.
NEXT SLIDE.
CLINICALTRIALS.GOV IS THE PLACE
TO GO TO FIND INFORMATION ABOUT
ONGOING AND COMPLETED CLIBICAL
TRIALS INCLUDING MANY ON
PREGNANCY, CONTRACEPTION, BREAST
CANCER AND OTHER WOMEN'S HEALTH
CONDITIONS, IT LETS YOU EASILY
SEARCH FOR STUDIES TO SEE WHAT'S
NEW, AS FAR AS TREATMENTS AND
INTERVENTIONS ARE CONCERNED OR
EVEN FIND OPPORTUNITIES TO
PARTICIPATE IN CLINICAL TRIALS.
BAY MAKING THE INFORMATION
WIDELY AVAILABLE, WE HAVE HELP
PROMOTE TRANSPARENCY OF CLINICAL
RESEARCH, SUPPORT EVIDENCE BASED
CARE AND ALSO ADVANCE RESEARCH
THAT CAN LEAD TO BETTER HEALTH,
HEALTH OUTCOMES FOR ALL.
NIN 2017 NEW REGULATIONS WERE
RELEASED THAT REQUIRED MOST
CLINICAL TRIALS OF FDA REGULATED
DRUGS BIOLOGICS OR DEVIETIONS IN
ALL CLINICAL TRIALS FUNDED BY
NIH TO BE REGISTER INDEED THE
DATABASE.
AND THESE REGULATIONS REQUIRE
DEPOSITORS TO LEAVE THE
PUBLICATIONS IN THIS, BUT HAVING
THE REGISTRY PUBLICLY AVAILABLE
CAN INFORM OTHER FUTURE RESEARCH
AND FUNDING DECISIONS TO HELP
IMPROVE THE RESEARCH ECOSYSTEM
SUCH AS BY REDUCING TRIAL
DUPLICATION AND UNSAFE OR
INEFFECT -IVE ISHT VENTIONS,
MEET ETHICAL OBLIGATIONS TO
HUMAN TAR PARTICIPANTS IN RESE.
AND IN THE PAST SEVERAL YEARS
WHICH YOU'VE HEARD DR. CLAYTON
MENTION, WE'VE ALSO ADOPTED
CLINICAL TRIALS .GOV TO MEET THE
NEEDS OF OUR COMMUNITY.
NEXT SLIDE, PLEASE.
ANOTHER AREA UNDER NLM'S PURVIEW
IS MAINTAINING AND STANDARDIZING
THESE.
THESE STAND AWRPDS INSURE THAT
RESEARCH IS ACCURATE, CONSIST
AND THEN THE CAN BE COMBINED
ACROSS STUDIES MAKING IT EASIER
TO IDENTIFY TRENDS AND GAPS.
NLM ALSO DEVELOPS, MAINTAINS,
PRODUCES OR DISTRIBUTES OTHER
MEDICAL TERMINOLOGIES THAT ARE
USED FOR CLINICAL OR RESEARCH
PURPOSES AND THESE TERMINOLOGIES
DISAMBUTIGATE DRUG NAMES,
IDENTIFIED PROCEDURES FOR EHRs
AND MUCH MORE, THE STANDARDS
INSURE THAT INFORMATION ABOUT
HEALTH, SUCH AS DIAGNOSIS,
TREATMENTS AND OUTCOMES, CAN BE
ACCURATELY RECORDED, SHARED AND
ANALYZED ACROSS DIFFERENT
STUDIES AND SETTINGS.
SO BY ENABLING RELIABLE AND
COMPARABLE DATA WE HELP
RESEARCHERS AND CLINICIANS WORK
TOGETHER, MORE EFFECTIVELY, TO
IMPROVE HEALTH OUTCOMES,
INCLUDING THOSE FOR WOMEN.
NEXT SLIDE.
NLM OFTEN MANAGES SEVERAL
MOLECULAR BIOREPOSITORY FOR
ASSOCIATED METADATA GENERATED BY
RESEARCHERS PUBLIC HEALTH LABS,
SEQUENCING CENTERS AND OTHERS.
MANY OF THESE YOU PROBABLY HAVE
HEARD ABOUT, AND THESE
REPOSITORY STORE, PRESERVE AND
ORGANIZE DATA FOR SUBMITTERS,
AND THOSE WHO REUSE THE DATA FOR
ADDITIONAL ANALYSIS AND
RESEARCH, AS WELL AS CARRY OUT
ADDITIONAL TYPES OF ANALYSIS TO
ADD VALUE TO DAT THAT HAVE
ALREADY BEEN SUBMITTED.
THESE REPOSITORY PROVIDE
SERVICES THAT ENABLE RESEARCHERS
AND OTHERS TO ANALYZE, ACCESS,
SEARCH, VIEW AND DOWNLOAD THE
DATA.
FOR EXAMPLE, SEQUENCE DATA IS
MORE REUSABLE WHEN RESEARCHER
HAS ADDITIONAL METADATA SUCH AS
INFORMATION ABOUT TD SOURCE, THE
NAME OF THE ORGANISM AND THE
NAME OF THE LOCATION WHERE THE
ORGANISM WAS COLLECTED.
NEXT SLIDE, PLEASE.
AND SOME OF THESE REPOSITORIES
ARE COLLECTING AND MAINTAINING
GENETIC SEQUENCE INFORMATION
THAT CAN BE USED TO
SIGNIFICANTLY IMPACT BY O
MEDICAL RESEARCH AND ARE BROADER
UNDERSTANDING OF THE WORLD
AROUND US, SEQUENCE DATA SUCH AS
THIS ARE BEING USED TO
ILLUMINATE THE STUDY OF
ECOSYSTEMS, POPULATIONS,
BIODIVERSITY AND PUBLIC HEALTH
THROUGH UNDERSTANDING TENOAMS,
GENES, TRANSCRIPTS AND PROTEINS.
AND AS SUCH THE TYPE OF DATA
HOUSED IN THESE REPOSITORIES
INCLUDE DNA, RNA AND PROTEINS.
NEXT SLIDE.
MANY OF YOU HAVE PROBABLY HEARD
ABOUT GEN BANK AND THE SEQUENCE
READ ARCHIVE.
GENBANK IS THE NIH SEQUENCE
REPOSITORY THAT PROVIDES,
COLLECT FOR ALL DOMAINS OF LIFE.
IT PROVIDES ACCESS TO THE MOST
UPTO DATE AND COMPREHENSIVE
SEQUENCE INFORMATION THAT'S
ANALYZED CURATED AND ASSEMBLED
INTO LONGER MOLECULES, FOR MORE
THAN 4.75 BILLION SEQUENCE
RECORDS AND OVER 228 TERRA BYTES
OF DATA.
BY CONTRAST, SRACONTAINS THE RAW
DATA, DATA THAT HAS NOT BEEN
ANALYZED, CURATED OR ASSEMBLED
INTO LONGER MOLECULES AND ACCESS
TO THE DAILY BASIS THEA IN THESE
REPOSITORIES FOR EXAMPLE CAN
HELP TO FACILITATE THE
DEVELOPMENT OF NOVEL AND DATA
SCIENCE METHODS INCLUDING AI TO
SUPPORT DATA SHARING AND
REPRODUCE ABILITY RESEARCH AND
ALSO HELP TO URGT IFER
UNDERSTAND THE HEALTH OF WOMEN.
NEXT SLIDE, PLEASE.
SO THROUGH THESE PROGRAMS, NLM
LAYS A CRITICAL ROLE IN
ADVANCING DATA SCIENCE AND
BIO-INFORMATICS RESEARCH FOR THE
BENEFITS OF UNDERSTANDING
RESEARCH AND HEALTH.
IN ACCIDENT SLIDE.
NLM'S INVESTIGATORS ARE
CONDUCTING NOVEL RESEARCH IN OUR
DIVISION OF INTRAMURAL RESEARCH.
OUR DIVISION OF INTRAMURAL
RESEARCH IS MADE UP OF TALENTED
RESEARCHERS WHO DEVELOP AND
APPLY COMPUTATIONAL APPROACHES
TO A BROAD RANGE OF INFORMATION
PROBLEMS AND BIOLOGY,
BIOMEDICINE AND HUMAN HEALTH
INCLUDING THOSE THAT DIRECTLY
IMPACT WOMEN'S HEALTH.
OUR INTRA MIEWR WILLA RESEARCH
HAS A COMPARATIVE ADVANCAGE IN
IMPLIED WORK AND AIMED AT
IMPROVING HUMAN HEALTH AROUND
THE WORLD.
IT ALSO PROVIDES CRUCIAL
TRAINING AND RESEARCH
OPPORTUNITIES FOR OPPORTUNITIES
AND TRAINEES SETTING THE STAGE
FOR THE SUCCESS OF THE NEXT
GENERATION OF RESEARCHERS.
AND IN THE NEXT 2 SLIDES I JUST
WANT TO GIVE A FEW EXAMPLES OF
WHAT NLM'S RESEARCHERS DO.
NEXT SLIDE.
SO THE FIRST EXAMPLE IS A YEAR'S
LONG COLLABORATION WITH
COUNTERPARTS AT THE NATIONAL
CANCER INSTITUTE TO RELIABLY
DETECT CERVICAL CANCER IN WOMEN
LIVING WITH AND WITHOUT HIV
USING AI AND MEDICAL IMAGING.
THE RESEARCH INCLUDES
PARTICIPATION OF SEVERALUS
ACADEMIC INSTIEWGS,
INTERNATIONAL ORGANIZATIONS,
CLINICAL CENTERS IN VARIOUS
COUNTRY AND INDUSTRY.
AND AN OBSERVATIONAL STUDY OF
DEEP LEARNING AND AUTOMATED
EVALUATION OF CERVICAL IMAGES
FOR CANCER SCREENING, THE
RESULTS SUGGEST THAT THE METHOD
OF USING THE IMAGES FROM
CERVICAL CANCER SCREENINGS TO
TRAIN LARGE LANGUAGE MODELINGS
COULD POTENTIALLY HELP CATCH
CERVICAL CANCER EARLIER AND MORE
EASILY.
NEXT SLIDE.
ANOTHER STUDY FROM A DIFFERENT
LAB AT NLM, IS WHERE NLM
RESEARCHERS WERE STUDYING THE
REGULATORY GENOMICS OF
POLYCYSTIC OVARIAN SYNDROME
USING A RESEARCH FRAMEWORK THAT
INTEGRATES GENOMICS STATISTICAL
ANALYSIS OF PATIENT DATA AND
ALSO AI TO UNRAVEL THE MECH
NICHES AND GENOMIC COMPONENTS
UNDERLYING PC OS, BY TAILORING
THEIR WORK TO THIS SPECIFIC
DISORDER, THE LAB IS LOOKING TO
IDENTIFY KEY GENETIC VARIANTS
ASSOCIATE WIDE PC OS, AND THE
WORK DOES HAVE THE POTENTIA WILL
TO LAY THE GROUND WORK FOR NOVEL
DIAGNOSTICS EXPERIMENTAL
VALIDATION AND DRUG DORPHY TO
BEST TREAT PC OS.
NEXT SLIDE.
NLM RESEARCH FUNDING THROUGH OUR
DIVISION OF EXTRAMURAL PROGRAMS,
SUPPORTS HEALTH WERE THAT
CENTERS ON WOMEN'S UNIQUE HEALTH
NEEDS PARTICULARLY ON DEVELOPING
TOOLS AND QUANTITATIVE METHODS
TO ADDRESS WOMEN'S HEALTH
ISSUES.
BY FUNDING INSTRUMENTAL RESEARCH
NLM CONTRIBUTES TO THE
ADVANCEMENTS IN BIOMEDICAL AND
DATA SCIENCE WITH IMPLICATIONS
THAT IMPROVE HEALTH AND WELL
BEING AND I WILL LIKE TO SHARE A
FEW EXAMPLES OF THE TYPE OF
RESEARCH THAT NLMSUPPORTS
THROUGH ITS EXTRAMURAL RESEARCH
PROGRAM.
NEXT SLIDE.
SO IN THIS STUDY, PREDICTION OF
PRETERM BIRTH AND WOMEN, THE
PROJECT IS FOCUSING ON -- IT'S
FROM A JOINT PROGRAM WITH THE
NATIONAL SCIENCE FOUNDATION,
SMART HEALTH AND BIOMEDICAL
RESEARCH IN THE ERA OF AI.
INVESTIGATORS ARE ANALYZING
MULTIPLE DATA SOURCES TO
IDENTIFY THE LIKELIHOOD OF
WHETHER FIRST TIME PREGNANT
WOMEN WILL EXPERIENCE PRETERM
BIRTH.
THE INVESTIGATOR VS ALREADY OOH
DENTIFIED SEVERAL GENETIC AT
THAT TIMA ELEMENTS THAT HELP
PREDICT THESE INDICATIONS AND
ARE CONTINUING TO EXPLORE THE
DATA TO FIND ANSWERS TO
SPONTANEOUS PRETERM BIRTH.
NEXT SLIDE, PLEASE.
AND ANOTHER STUDY, INVESTIGATORS
ACKNOWLEDGE THAT WOMEN WITH
DISABILITIES ARE SIGNIFICANTLY
UNDERSTUDIED AND UNDERRESOURCED
GROUP AND SEEKS TO REDUCE HEALTH
DISPARITIES.
IN THIS STUDY ON PARTNERING WITH
WOMEN, WITH DISABILITIES TO
DEVELOP A HEALTH INFORMATION
WEBSITE, INVESTIGATORS ARE
FOCUSED ON CURATING AND
PROVIDING HEALTH INFORMATION
THAT'S SPECIFICALLY RELEVANT TO
WOMEN WITH DISABILITIES WITH THE
ULTIMATE GOAL OF MEETING THEIR
HEALTH INFORMATION NEEDS AND
EMPOWERING THEM AS THEY MANAGE
THEIR HEALTHCARE.
NEXT SLIDE.
AND IN A DIFFERENT STUDY,
RESEARCHERS ARE EXPLORING THE
BEST INTERVENTIONS TO ADDRESS
INTIMATE PARTNER VIOLENCE OR IPV
AGAINST WOMEN, WHILE GROUP
THERAPY HAS TRADITIONAL BEEN THE
STANDARD OF CARE FOR IPVs,
SOME HAVE EXPERIENCED A
SIGNATURES 95 KAVENT CHANGE IN
RESPONSE AND FOR THIS STUDY
INVESTIGATORS ARE USING A DATA
DRIVEN APPROACH TO IDENTIFY AND
TEST AND CUSTOMIZED
INTERVENTIONS FOR IPVR WITH THE
GOAL OF DEVELOPING A
DISCIPLINARY CISION MAKING TIEWL
WITH THE GOAL OF CLINICIANS THAT
HELP THE DISPARITIES FACED BY
THESE PARTICIPANTS.
NEXT SLIDE.
TO ASSIST THE NLM EXTRAMURAL
RESEARCH PROGRAM WITH ITS FUTURE
VISION FOR RESEARCH, NLM
RECENTLY RELEASEDDA A REQUEST
FOR INFORMATION, LOOKING FOR
FEEDBACK ON RESEARCH GAPS,
TRANSFORMATIVE OPPORTUNITIES,
AND UNEXPLORED AREAS THAT NLM
CAN ADDRESS THROUGH OUR
EXTRAMURAL PROGRAMS.
SO WE'RE LOOKING FOR THOUGHTS ON
BOLD STRATEGIES FOR AREAS SUCH
AS BIOMEDICAL INFORMATICS
EMERGING AI METHODOLOGIES AS
WELL AS FRAMEWORKS FOR SCALABLE
AND INNOVATIVE DATA SHARING AND
INTERDISCIPLINARY COLLABORATION.
SO THE INPUT WE RECEIVE WILL
HELP SHAPE THE FOUNDATION OF OUR
SCIENCE VISION, BY LINING FUTURE
INVESTMENTS WITH UNMET NEEDS AND
EMERGING OPPORTUNITIES INCLUDING
HOW THEY MAY ALIGN WITH RESEARCH
ON WOMEN'S HEALTH.
SO WE INVITE YOU TO SUBMIT
COMMENTS FOR THIS RFI BY
JULY 14th.
NEXT SLIDE.
AND THE FIRST VOICES AREN'T JUST
VALUABLE, THEY'RE ALSO VITAL IN
REPRESENTING WOMEN IN RESEARCH
AND IS JUST AS CRITICAL AS
REPRESENTING WOMEN THROUGH
RESEARCH AND DIVERSE POPULATION
CAN IMPACT BY O MEDICAL
DISCOVERY AS IT NATURALLY BRINGS
DIFFERENT INFORMATION, OPINIONS,
PERSPEBILITYIVES AND
EXPERIENCES TO THE TABLE,
LEADING TO INCREASED CREATIVITY
INNOVATION AND MORE EFFECTIVE
DECISION MAKING.
MORE OPPORTUNITIES EXIST TO
DEVELOP AND ADVANCE THE CAREERS
OF WOMEN IN BIOMEDICAL RESEARCH,
TAKE OUR NLM RESEARCH GRANTS AND
BIOMEDICAL INFORMATICS AND DATA
SCIENCE WHICH SUPPORT INNOVATIVE
RESEARCH DECISION MAKING TO,A
PLIE THERAPY ANDEES AND
ANALYTERAL PROCESSES OR METHODS
TO DATA.
NOT ONLY DO THEY LOOK FOR
INNOVATIVE ANALYTIC METHODS THAT
ARE GENERALIZABLE WITHIN AND
ACROSS UNDERSERVED POPULATIONS
BUT THEY ALSO RECOGNIZE THE
IMPORTANCE OF DIVERSE
POPULATIONS INCLUDING THOSE FROM
WOMEN'S.
WE ALSO HAVE NLM CODE-A-THONs
WHERE RESEARCHERS AND COMPUTER
PROGRAMS FROM DIVERSE TECHNICAL
GABBING BROWNEDS COLLABORATE TO
CREATE SOFTWARE TOOLS FOR TO
SOLVE PROBLEMS IF ARE THE
BIOMEDICAL COMMUNITY.
IN 20 ARE 19 AFTER 5 YEARS OF
MORE THAN 40 CODE-A-THONs IN
NLM, THEY HOSTED THE FIRST ALL
WOMEN LED CODE-A-THON, ACROSS
INSTITUTES AND ACADEMIA AND
PRIVATE INDUSTRY.
SO HAVING THIS EVENT EXCLUSIVE
TO WOMEN EMPOWERED THEM TO
CREATE AN EXPERIENCE AND
CELEBRATED THEIR UNIQUE
PERSPECTIVES AND PROBLEM SOLVING
SKILLS.
THE PROJECTS THAT CAME FROM
THESE TEAMS RANGED FROM OVARIE,
WHICH IS AN OVERSOURCED GENE
PACKAGE TO FAN-RIERKS PACK, A
CODE CONVERTER FOR SCANNING USS
AND DIAGNOSES AND VIRAL-VDAPP,
ANN OITATION PIPELINE FOR VIRUS
VARIANTS.
NEXT SLIDE.
SO AS MENTIONED EARLIER SINCE
ITS INCEPTION, ORWH HAS WORKED
IN PARTNERSHIP WITH INSTITUTES
AND CENTERS ACROSS NIH TO
PRIORITIZE WOMEN'S HEALTH AND
THE RESEARCH PORTFOLIOS, AND
WHEN IT COMES TO WOMEN'S HEALTH,
THE MISSIONS OF ORWH AND NLM
COULD NOT BE MORE INTERTWINED OR
THE PARTNERSHIP OR SEAMLESS,
THIS COOPERATIVE RELATIONSHIP
BETWEEN NLM AND ORWH HAS ABOUT
KNOW INTEGRAL TO ADVANCING INIT
YAIF ITS.
THE CONTINUE CONTINUE TO PARTNER
ON INITIATIVES AND COLLABORATED
MORE CLEARS LOW ON COMMON DATA
DATA ELEMENTS THE VIFIANCE PENS
PROGRAM THAT DR. CLAYTON
MENTIONED AND AS WELL AS
DISCOVER WHR.
NEXT SLIDE.
SO 1 SUCH INITIATIVE WAS A JOINT
EFFORT TO IDENTIFY AND DEVELOP
COMMON DATA ELMETROPOLITANS
WHICH ARE THE STANDARD
STRUCTURE, MACHINE READABLE
DEFINITIONS OF DATA ELEMENTS,
VARIABLES AND MEASURES USED IN
RESEARCH, RELATED TO WOMEN'S
HEALTH.
THE CDEs HELP RESEARCHERS
SHARE AND COMBINE DATA SETS,
IMPROVE ACUREACY, AND THIS IS A
COLLABORATIVE FLAT FORM THAT
PROVIDES ACCESS TO STRUCTURED
HUMAN AND MACHINE READABLE
DEFINITIONS OF CDEs AND FORM
IN RESEARCH.
NLM MAKES THIS REPOSITORY
AVAILABLE FOR FREE TO ANYONE WHO
WANTS TO SHARE STANDARDIZED
DATA, ACROSS VARIOUS NIH FUNDED
RESEARCH PROJECTS, INCLUDING
THOSE ON WOMEN'S HEALTH.
CURRENTLY NLM DEVELOPED AND
MAINTAINS THIS RESOURCE AND
COLLABORATES WITH THE OFFICE OF
DATA SCIENCE STRATEGY IN ORPW
THE AUTOIMMUNE DISEASE RESEARCH
ON STANDARD INTEROPERABLE DATA
COLLECTION FOR PLIE OICITIS
RESEARCH INITIATIVE.
MYOCYTEIS IS A GROUP OF RARE
AUTOIMMUNE DECEASES THAT CAUSE
CHRONIC INFLAMMATION OF THE
MUSCLES AND LAST YEAR, LAST
FALL, NLM HOSTED AN
INTERNATIONAL EXPERT PANEL AT
THE FIRST MYOCYTEIS COMMON DATA
ELEMENTS WORKSHOP CONFERENCE TO
SET A COURSE OF INSTRUMENTS USED
TO DEVELOP A DATABASE OF
MYOCYTEIS CORE SET MEASURES.
PATIENT RECORDED OUTCOME
MEASURES, KEY MIGHT OICITIS
ASSESSMENT TOOLS AND A NATURAL
HISTORY OF CLINICAL TRIAL STUDY
FORMS.
CONSENSUS IN CODING IS EXPECTED
AND THE CDEs TO SERVE AS
PARADIGM FOR AUTOIMMUNE DISEASES
THAT DISPROPORTIONATELY AFFECT
WOMEN.
NEXT SLIDE.
NLM WAS ALSO PROUD TO
PARTICIPATE IN THE PLANNING AND
PRESENTING AT THE NINTH ANNUAL
VIVIAN PEN SYMPOSIUM LAST MONTH,
THIS YEAR'S FOCUS ON ADVANCING
DATA DRIVEN INFORMATION ON THE
HEALTH OF WOMEN WAS ON HOW DATA
SCIENCE SKILLS RESOURCES AND
TRAINING CAN BUILD CAPACITY FOR
INTERDISCIPLINARY DATA,AINAL SIS
FOR RESEARCH ON WOMEN'S HEALTH.
A PART OF THE MEETING INCLUDED
FLASH TALKS ON VARIOUS DATA
RESOURCES FROM ACROSS NIH THAT
ARE AVAILABLE TO THE PUBLIC FOR
RESEARCH AND 1 OF THESE
RESOURCES THAT WAS DESCRIBED WAS
DISCOVER WOMEN'S HEALTH RESEARCH
OR DISCOVER WHR.
AND IT'S AN INNOVATIVE RESOURCE
THAT WAS LAUNCHED BY AN NLM IN
ORWH COLLABORATION.
NEXT SLIDE.
MANY OF YOU HAVE PROBABLY HEARD
DR. CLAYTON DISCOVER WHR, IT IS
A CENTRALIZED RESOURCE FOR
WOMEN'S HEALTH RESEARCH AND
INFORMATION THAT SUPPORTS NIH
WIDE EFFORTS TO CLOSE THE GAPS
IN WOMEN'S HEALTH ACROSS THE
LIFE COURSE.
THIS MAJOR INITIATIVE
DISTINGUISHED ITSELF FROM OTHER
RESOURCES BY OFFERING AN
EXTENSIVE OVERVIEW OF NIH
SUPPORTED WOMEN'S HEALTH
RESEARCH ENCLOUDING THE LATEST
DATA AND LITERATURE ON COMMON
HEALTH ISSUES THAT PRIMEAR LE
AFFECT OR OFTEN PRESENT
DIFFERENTLY IN WOMEN TO DRIVE
IMPACTFUL EVIDENCE BASED
SOLUTIONS THAT IMPROVE THEIR
HEALTH.
DISCOVER WHR ALSO SERVEs AS A
DISCOVERY PORTAL FOR
RESEARCHERS, HEALTHCARE
PROFESSIONALS, PATIENTS,
CAREGIVERS, AND THE PUBLIC, TO
EASILY DISCOVER THE LATEST
FINDINGS AND ONGOING WOMEN'S
HEALTH RESEARCH ACTIVITIES
INCLUDING NIH SUPPORTED
RESEARCH, CLINICAL TRIALS,
LITERATURE AND INFORMATION ON
ISSUES THAT UNIQUELY OR
DISPROPORTIONATELY AFFECT WOMEN
ACROSS THEIR LIFE SPAN, NEXT
SLIDE.
IN ITS INITIAL PHASE WE HAVE
PRIORITIZED 5 RESEARCH AREAS
BASED ON THEIR SIGNIFICANT
IMPACT ON WOMEN'S HEALTH
INCLUDING MENOPAUSE, POLICY
CYSTIC OVARIAN SYNDROME AND
OTHER SELECT AUTOIMMUNE DISEASES
INCLUDING LUPUS, AND AS OF
YESTERDAY, INFORMATION CAN NOW
BE FOUND ON ENDOMEET REOSEIS,
OVER TIME, USERS WILL BE ABLE TO
QUICKLY NAVIGATE TO AND SURVEY
THE LANDSCAPE OF NIH FUNDED
RESEARCH AND INFORMATION FOR
SPECIFIC WOMEN'S HEALTH RELATED
TOPICS.
NLM'S SPECIFIC SUPPORT COMES
FROM OUR RESEARCH PRODUCTS AND
SERVICES, FOR EXAMPLE, VISITORS
CAN STAY INFORMED WITH THE
REGULAR UPDATES FROM THE NIH
GUIDE FOR GRANTS AND CONTRACTS
ABOUT FUNDING OPPORTUNITIES REEL
KEEPSAKES VABT TO WOMEN'S HEALTH
EEXPLORE CURRENT AND PAST NIH
FUNDED PROJECTS, SOURCED FROM
THE NIH REPORTER SYSTEM,
COMPLETE WITH RELATED
PUBLICATIONS AND PATENTS,AX
ASSESSES DETAILED INFORMATION
FROM CLINICALTRIALS.GOV ON BOTH
ONGOING AND COMPLETED CLINICAL
TRIALS THAT ADDRESS WOMEN'S
HEALTH CONDITIONS AND ALSO
DISCUSS RELEVANT RESEARCH PAPERS
AND STUDIES ON WOMEN'S HEALTH
VIA PUB MED, PROVIDING EASY
ACCESS TO CREDIBLE INFORMATION
AND GUIDED BY NIH-WIDE STRATEGIC
PLAN FOR RESEARCH ON HEALTH OF
WOMEN AND USER FEEDBACK,
DISCOVER WHR WILL BE ENHANCED
WITH ADDITIONAL NIH FUNDED
RESEARCH TOPICS AND RESOURCES
COMMON DAT DATA ELEMENTS, DATA
SOURCES, STANDARDIZED
TERMINOLOGIES AS WELL AS
INCORPORATE DATA SCIENCE TOOLS
IN THE FUTURE.
SO PLEASE KEEP YOUR EYE OUT ON
THE LATEST DISCOVERY WHR
WEBSITE.
NEXT SLIDE.
IN THE LAST FEW MINUTES I WOULD
JUST LIKE TO SHARE WITH YOU A
FEW METRICS ON DISCOVERY WHR.
SINCE ITS LAUNCH 9 MONTHS AGO,
IT'S BEEN ACCESSED BY OVER
25,000 UNIQUE USERS AND GARNERED
OVER 56,000 OVERALL VIEWS FROM
OVER 120 COUNTRIES, MOST OF THE
TRAFFIC TO THE WEBSITE HAS BEEN
THROUGH DIRECT LINKS MEANING
THAT DISCOVER WHR HAS BEEN
CREATING A LITTLE BIT OF A BUZZ
AND THE RESEARCH COMMUNITY AND
EVEN IN THE NEWS CYCLES.
NEXT SLIDE.
WE'RE PROUD TO SHOWCASE SOME OF
THE VARIOUS SOURCES WHERE OUR
VISITORS ARE COMING FROM AND THE
IMPACT ITS HAD ON DRIVING
READERS TO OUR SITE.
IN THIS CHART YOU WILL SEE THAT
THE NUMBERS, THE TRACKS IN THE
NUMBERS OF UNIQUE HITS PER WEEK,
YOU WILL NOTICE THAT THERE HAVE
BEEN SUG'RE SIGNIFICANT SPIKES
SINCE MIDDECEMBER, NOTABLY
FOLLOWING THE RELEASE OF
ARTICLES OR PAPERS THAT HAVE
MENTIONED DISCOVER WHR, SUCH AS
THE WASHINGTON POST ARTICLE, AN
ARTICLE IN JAMA, AS WELL AS THE
OFFICE OF WOMEN'S HEALTH AT
WOMENSHEALTH .GOV.
SO WE HOPE THAT OOZE WE ADD NEW
TOPICS AND FEATURES MORE AND
MORE PEOPLE WILL CONTINUE TO USE
THIS INNOVATIVE RESOURCE.
NEXT SLIDE.
SO THE OFFICE OF THE ASSISTANT
SECRETARY FOR HEALTH OASH OFFERS
GUIDENESS ON THE PUBLIC CORPS
AND PUBLIC HEALTH SERVICE
AGENCIES AND EARLY THERAPY AND
YEAR THROUGH THE OFFICE OF
WOMEN'S HEALTH, OASH RELEASED A
WEBPAGE FOCUSED ON PROTECTING
WOMEN AND CHILDREN AND TO
SUPPORT INITIATIVES AIMED AT
IMPROVING THE HEALTH OF WOMEN IN
CHILDREN, THIS PAGE PROVIDES
LINKS TO VARIOUS RESOURCES AND
INFORMATION ENCLUEDING NIH
RESOURCES.
WHILE WE'RE EXCITED THAT BOTH
CLINICALTRIALS.GOV AND GOEVER
WHR ARE FEATURED PROMINENTLYOT
WEBSITE AND PROVIDES DIRECT
ACCESS TO RESEARCH INFORMATION
AND CLINICAL STUDIES ON WOMEN'S
HEALTH FROM NIH.
NEXT SLIDE.
SO RESEARCH ON WOMEN'S HEALTH
ISN'T A SIDE BAR, IT'S CENTRAL
TO THE MISSION OF NIH.
NLM HAS BEEN A HUB OF
INFORMATION AND PROMOTING AND
CHAMPIONING INITTIAIVE ITS THAT
BEST SERVICE WOMEN AND THEIR
HEALTHCARE NEEDS, AND THAT THEY
REQUIRE DATA HISTORY,
INFORMATION, AND THE NEXT
GENERATION OF RESEARCH IN ORDER
TO MOVE ALL OF THIS FORWARD.
SO FROM PIE O NEARING DATA
ACCESS TO ELEVATING INFORMATION,
NLM IS COMMITTED TO CONTRIBUTING
TO BUILDING A FUTURE OF RESEARCH
ON WOMEN'S HEALTH IN ORDER TO
IMPROVE HEALTH OVERALL.
OUR PRIORITIES MOVING FORWARD
ARE TO ADVANCE BIOMEDICAL
INFORMATICS AND COMPUTATIONAL
DATA HEALTH SCIENCE TO SUPPORT
QUALITY AND SUSTAINABILITY OF
BIOMEDICAL INFORMATION SERVICES
TO MODERNIZE NLM INFRASTRUCTURE
AND ORGANIZATION, AND CONTINUE
TO SHARE OUR EXPERT EEDZ AND
CONTRIBUTE TO NIH AND GOVERNMENT
WIDE PRIORITIES MANY OF WHICH
WERE MENTIONED BY
DR. KLEINSTEUER, SO THANK YOU
FOR THE OPPORTUNITY TO SHARE
THIS OVERVIEW OF NLM AND WHAT WE
DO AND FOR YOUR ONGOING SUPPORT
OF THE TEAMS, RESEARCHERS AND
PARTNERS WHO MAKE ADVANCING
WOMEN'S HEALTH POSSIBLE, AND TO
BENEFIT EVERYONE.
YOU WILL HEAR MORE THIS
AFTERNOON, IN DATA SCIENCE AND
WOMEN'S HEALTH PANEL ABOUT
SPECIFIC DATA AND DATA SCIENCE
PROJECTS THAT ARE FOSTERING AND
ADVANCING THE HEALTH OF WOMEN.
NLM IS HAPPY TO BE AMONGST THE
SUPPORTERS OF FACILITATORS OF
DATA DRIVEN APPROACHES TO FOSTER
DATA POWERED HEALTH.
NEXT SLIDE.
SO I WOULD LIKE TO THANK ORWH
FOR THE INVITATION TO PRESENT
TODAY AND FOR ITS ONGOING
MUTUALLY BENEFICIAL PARTNERSHIP
AND I WOULD LIKE TO THANK KEY
MEMBERS FROM MY TEAM, LIZ AMOS,
LIZ FOX, MLM POLICY TEAM AND
OTHERS FOR THEIR CONTRIBUTIONS
TO THIS PRESENTATION.
NEXT SLIDE.
AND WITH THAT I WOULD LIKE TO
CONCLUDE MY PRESENTATIONS AND
I'M HAPPY TO ANSWER ANY
QUESTIONS YOU MAY HAVE, EITHER
NOW OR IN THE DISCUSSION PORTION
OF THE MEETING.
THANK YOU.
>> THANK YOU SO MUCH DR. P A
LTOO, WHAT A WHIRL WIND TOUR.
YOU REALLY WOWED ME HERE, AND
THAT'S NOT EASY TO DO.
SO THANK YOU SO MUCH FOR SHARING
WITH OUR COLLEAGUES AND WITH THE
PUBLIC ALL THE INCREDIBLE WORK
THAT'S HAPPENING AT NLM, WHAT'S
BEHIND ALL THOSE TOOLS THAT WE
USE SO EASILY AND WHAT IT TAKES
TO ADVANCE DATA SCIENCE AND WHAT
IT TAKES TO LEVERAGE ALL THE NIH
RESOURCES TO MOVE INTO THE
FUTURE AND OUR LONG-TERM
NATTERRENERSHIP, WE GREATLY
APPRECIATE THAT.
IT LOOKS LOAMACYIC DR. GARY HAS
HIS HAND UP?
>> THANK YOU SO MUCH, IN
DR. CLAYTON'S WORDS IT WAS AN
ENORMOUS,AMOUNT OF INFORMATION.
IT'S REALLY IMPORTANT TO, YOU
KNOW WE USE PUB MED AND DBGAP, I
USE A VARIETY OF RESOURCES AND I
JUST WANTED TO GIVE A BIG SHOUT
OUT TO YOU GUYS, WE SOMETIMES
TAKE THAT AMOUNT OF GRANTED AND
IT'S AN ENORMOUS AMOUNT OF
STRUCTURALLY TOWER MAINTAIN ON A
REGULAR BASIS SO THANK YOU FOR
MAKING OUR LIVES EASY AND
RESEARCH BETTER AS WELL.
I THINK 1 QUESTION THAT I DID
HAVE FOR YOU WAS, AND I REALLY
LOVE THE DISCOVER WHR PAGE IN
COLLABORATION WITH ORWH, I THINK
THAT'S A REALLY GREAT PLATFORM
TO INFORM THE PUBLIC AS WELL AND
USED FOR RESEARCH AS WELL, I WAS
PLAYING AROUND WITH IT, JUST
RIGHT NOW AS YOU WERE TALKING
AND JUST SO MUCH MORE EASIER TO
FIND GRANTS BASED ON SPECIFIC
TOPICS AND REALLY LOOKING
FORWARD TO SORT OF THAT
EXPANSION OF MUCH MORE, I WAS
WONDERING, I GUESS 1 PERINENT
QUESTION IS, WILL THIS ALSO
INCLUDE PREGNANCY SPECIFIC SORT
OF PHENOTYPES AS WELL OR IS THAT
GOING TO BE CONSIDERED PERVIEW
OF LIKE A DIFFERENT IC?
>> YEAH, WE -- YOU KNOW AS YOU
MENTIONED AND AS I MENTIONED
THIS, THIS IS A PARTNERSHIP WITH
ORWH AND WE'RE ALSO PARTNERING
WITH OTHER STAFF ACROSS THE NIH,
TO KIND OF PRIORITIZE THE
DIFFERENT TOPIC TO ENCLOUD, SO I
WOULD SAY NOTHING IS OFF THE
TABLE.
WE ARE CONSIDERING DIFFERENT
TOPICS BUT WE ALSO, THERE'S ALSO
A BUTTON ON THE WEBSITE WHERE
YOU CAN PROSLIDE FEEDBACK AND IF
THERE'S A PARTICULAR TOPIC
THAT'S OF INTEREST, OR THAT YOU
FEEL THAT WE SHOULD PRIORITIZE,
PLEASE SHARE THAT.
WE REALLY APPRECIATE EVERYONE'S
FEEDBACK AND WE KIND OF DEFER TO
OUR SUBJECT MATTER EXPERTS WITH
REGARDS TO THE WOMEN'S HEALTH
RESEARCH TOPICS TO INCLUDE.
NTHANK YOU.
>> THANK YOU.
>> DR. WELAND, THANK YOU FOR THE
AMAZING OVERVIEW FOR US, REALLY
ENJOYED THAT.
AGAIN, THIS IS A BROAD QUESTION,
I WAS WONDERING, YOU KNOW AS YOU
TOUCH OFFICE OF DIVERSITY THIS
IN VARIOUS PLACES HOW YOU KNOW
DATA SCIENCE AND USING OUR AI
METHODOLOGIES ARE GOING TO BE
APPLIED AND UPDATED.
I WONDERED IF THERE WERE ANY
SPECIFIC INITIATIVES YOU KNOW
FOCUSED ON YOUR PRODUCTS OR
SERVICES YOU KNOW WITH LIKE PUB
MED IS SOMEONE WORKING ON USING
AI OR IS IT ALREADY USING --
JUST WONDERED HOW ALL THAT WAS
-- IF THOSE PRODUCTS ARE BEING
UPDATED OR WILL THEY BE REPLACED
WITH DIFFERENT PRODUCTS.
THANKS.
>> I WOULD SAY WE'RE AUGMENTS
AND UPDATING NOT NECESSARILY
REPLACING.
NLM ALSO LEADS A COMMUNITY OF
PRACTICE OF AI, AT THE NIH AND
ARE INTRAMURAL RESEARCH PROGRAM
LEADS MANY OF THE AI ACTIVITIES
AT NIH, BUT WE ARE ALREADY
INCORPORATING SOME OF THAT
BEHIND THE SCENES FOR SOME OF
OUR PRODUCTS AND SERVICES, BUT
AS WE CONTINUE TO MODERNIZE OUR
PRODUCTS AND SERVICES, WE WILL
BE INCORPORATING MORE OF THAT
MOVING FORWARD.
>> GREAT.
THANK YOU.
>> DR. JONES?
>> YES, THANK YOU DR. P A LTOO,
OH MY GOODNESS I AM IN AWE AND
INCREDIBLE LOAMACYY JUST
OVERWHELMED WITH THE BREDTH AND
DEPRIVATIONTH OF -- DEPTH OF
WHAT YOU ALL DO AND WHAT AN
INCREDIBLE NATIONAL TREASURE
THIS SERVICE IS FOR THE PUBLIC.
I WAS WONDERING, THIS IS A VERY
SMALL SUGGESTION BUT
COMMUNICATING THE NUMBERS THAT
YOU SHARED WITH US, ABOUT THE
NUMBER OF USERS ACCIDENT THE
AMOUNT OF DATA THAT IS PROVIDED
TO THE PUBLIC FOR THE U.S. AND
AROUND THE WORLD, HAVE YOU EVER
THOUGHT OF PUTTING ON YOUR
WEBSITE THOSE NUMBERS, LIKE A
COUNTER, LIKE A DASHBOARD
BECAUSE I FEEL LIKE THAT NEEDS
TO BE A HIGHLIGHTED, CELEBRATED
AND PEOPLE NEED TO KNOW ABOUT
THIS, AND I DIDN'T KNOW ABOUT IT
UNTIL YOU SHARED IT SO THANK
YOU.
>> YEAH, WE PROBABLY COULD DO A
LITTLE BIT OF A BETTER JOB
HIGHLIGHTING SOME OF THAT BUT
THIS IS ALSO 1 OF THE REASONS
WHY I WANTED TO SHARE WITH ALL
OF YOU WHAT NLM DOES AND WHO WE
ARE, KIND OF ALL THE THINGS THAT
WE MAINTAIN BECAUSE MOST PEOPLE
DO NOT KNOW.
AND WE'VE HAD JUST A GRIT
PARTNERSHIP WITH ORWH, AND YOU
KNOW OUR SERVICE TO THE
COMMUNITY IS WHAT WE'RE HERE
FOR, BUT THANK YOU FOR THAT
SUGGESTION.
WE WILL CONTINUE TO STRIVE ON
HOW WE CAN HIGHLIGHT OUR WORK.
OTHER QUESTIONS OR COMMENTS FOR
DR. P A LTOO?
I THINK WE ALREADY LOOKED AT
THAT COMMENT IN THE CHAT, OKAY,
WE'VE GOT SOME SECONDS DEHIND
DR. JONES COMMENTS.
DINA I WANT TO ALSO THANK YOU
FOR ANNOUNCING TODAY THAT
ENDOMEET REOSEIS HAS BEEN ADDED
TO DISCOVER WHR SIGNIFICANT
WOMEN'S HEALTH ISSUE, CHALLENGES
IN GETTING TIMELY DIAGNOSIS,
HIGHLY PREVALENT AND IMPORTANT
TOPIC FOR THE HEALTH OF WOMEN,
SO THANK YOU SO MUCH FOR MOVING
FORWARD AND GETTING ENDOMEET
RIOOSEIS UP AND ON WHR, WE
CONTINUE TO LOOKING FORWARD TO
WORK WITH YOU AND YOUR TEAM ON
THE OTHER TOPIC ANDS ON DORPH
WHR AND ALL THE OTHER AMAZING
PRODUCTS AND EFFORTS UNDERWAY.
I THINK THAT THE LIBRARY OF THE
FUTURE IS SO EXCITING, LIBRARIES
ARE LIKE MY NUMBER 1 FAVORITE
PLACE IN THE WORLD IN REAL LIFE
BUT I THINK WILL I HAVE TO
EXPAND THAT TO THE VIRTUAL
LIBRARY AS WELL AND I JUST AM
PLEASED THAT YOU WERE ABLE TO
SHARE WITH THE PUBLIC THE
AMAZING WORK AND EFFORTS AND
PERSISTENCE AND RIGOR THAT YOU
ALL ARE APPROACHING THESE DATA
RELATED RESOURCES AND I LOVE
YOUR PHRASE, DATA POWERED
HEALTH.
I WROTE THAT DOWN, YOU KNOW,
THAT IS EXACTLY WHEN WE TALK
ABOUT EVIDENCE BASED MEDICINE,
YOU KNOW I THINK WE MOVE TO THE
NEXT LEVEL WITH DATA POWER
HEALTH AND YOU AND YOUR
LEADERSHIP AND DR. SHERRY AND
OTHERS HAVE BEEN IMPORTANT IN
THAT SO THANK YOU SO MUCH FOR
YOUR PARTNERSHIP AND YOU ARE
WELCOME TO STAY BUT WE KNOW
EVERYONE HAS A BUSY SCHEDULE, SO
WE WILL NOT AT ALL BE OFFEND
FEDERAL YOU HAVE TO STEP OFF.
SO THANK YOU GAIN, DINA,
PREECIAL REALLY APPRECIATE IT.
>> THANK YOU F YOUR LEADERSHIP
DR. CLAYTON AND FOR YOUR
CONTINUED PARTNERSHIP,
APPRECIATE IT.
>> MY PLEASURE.
MY PLEASURE.
WITH THAT I THINK WE ARE GOING
TO MOVE TO OUR OPEN SESSION FOR
OUR ADVISORY COMMITTEE MEMBERS.
OF AND SO, THIS IS AN
OPPORTUNITY FOR YOU TO SHARE
YOUR THOUGHTS AND WE REALLY
WELCOME OUR INPUT ON FUTURE
PROGRAMMING, CURRENT
PROGRAMMING, YOUR FEEDBACK ON
ITEMS YOU SEE, THAT YOU WOULD
LIKE TO SEE MORE OF, THINGS THAT
YOU THINKER MISSING, GAPS GAPSD
OPPORTUNITIES WE WELCOME IT ALL.
SO FEEL FREE TO RAISE YOUR HAND
OR COME ON CAMERA IF YOU WOULD
LIKE TO MAKE A COMMENT.
YOU ALL ARE VERY QUIET TODAY, IF
YOU WERE IN PERSON, I WOULD CALL
ON YOU.
I WILL NOT DO THAT.
I CAN STILL CALL BUT YOU KNOW, I
CAN'T GIVE THEM THE EYE.
THERE, ANDERSON AND DR., LET'S
GO.
>> OKAY, THANK YOU.
DR. ANDERSON, BREAK THE ICE I
LITTLE BIT BUT I DIDN'T HEAR --
I CERTAINLY DIDN'T HEAR MUCH
ABOUT MATERNAL MORTALITY AND THE
VERY, VERY IMPORTANT WORK THAT
WE NEED TO DO THERE, CAN YOU
GIVE US AN UPDATE ON WHAT'S
HAPPENING IN THAT REALM?
>> MATERNAL MORTALITY.
>> MATERNAL MORTALITY CONTINUES
TO BE A REALLY IMPORTANT AREA
FOR WOMEN'S HELT.
DATA, THE DATA ARE THE BOTTOM
LINE, WE CONTINUE TO SEE VERY
DISTURBING RATES OF MATERNAL
MORTALITY IN THE UNITED STATES,
SO I WOULD POINT YOU TO OUR -- 1
OF OUR CENTER FEASS AT NIH, NOT
THE ONLY BUT 1 OF THE
CENTERPIECE SYSTEM THE IMPROVE
INITIATIVE WHICH IS NOW
CONGRESSALLY FUNDED FOR THE PAST
FEW YEARS AND WE HAVE MULTIPLE
CENTERS OF EXCELLENCE ACROSS THE
COUNTRY AND ADDITIONAL
COMMUNITY-BASED PROGRAMMING AS
WELL WE PARTNER WIDE NHLBI WITH
OUR CYST COMMUNITY
IMPLEMENTATION PROGRAMS IN
ADDITION WITH THE IMPROVE MOVE
AM, AND THE DIRECTORS, THERE ARE
A VARIETY OF EFFORTS LED BY
INSURE MARKET TOO UTR ALONG
THEIR SPECIFIC MISSION AREAS AS
YOU'VE HEARD FROM THE PREVIOUS
PRESENTATIONS, THERE IS ADDED
VALUE AND POWER IN COMPOUNDING
OUR ACTIVITIES TOGETHER, LIKE
COMPOUNDED INTEREST, SO MATERNAL
MORBIDITY AND MORTALITY IS 1 OF
THOSE TOPICS TO IMPROVE AND WE
ARE HOPING TO GENERATE MORE THAT
EVIDENCE COULD LEAD TO
IMPLEMENTATION AT THE LEVEL OF
COMMUNITIES WHICH IS WHERE WE
NEED TO SEE THE IMPACT.
SO THAT'S JUST 1 PIECE OF WHAT
WE'RE DOING AND I DO WANT TO
MENTION THAT EEUNICE KENNEDY
SHRIVER NATIONAL INTUITY OF
CHILD AND HUMAN DEVELOPMENT IS
THE NIH LEAD FOR MATERNAL AND
MORBIDITY MORTALITY RESEARCH AND
THEY HAVE A VARIETY OF
COMMITTEES AND EFFORTS OF THEIR
OWN, THAT THEY LEAD AS THEY MOVE
FORWARD IN TRYING TO MAP OUT
THEIR STRAY -- STRATEGIC AGEND.
>> THANK TUMOR SPECTRUM DOES
SEEM IT WOULD CROSS
MULTIPETRESSABLE INSTITUTES AND
YOUR GROUP MIGHT BE THE MOST
IMPORTANT 1 IN FACILITATING
THAT.
>> YOU KNOW THEY'RE ALL
IMPORTANT, BUT WE HAVE HEARD
ACTUALLY ABOUT MATERNAL
MORBIDITY AND MORTALITY.
ONE THING IS TO LINK IT TO THE
FULL LIFE COURSE AND WITH YOUR
BACKGROUND GARNET, YOU CAN'T
THINK OF IT JUST AS THIS 1 SLICE
IN TIME THAT MIGHT BE A
ASSOCIATE WIDE REPRODUCTION,
THERE'S AN ENTIRE LIFE FOCUSED
ONS ARE AND WHAT HAPPENS BEFORE,
THE HELT OF WOMEN BEFORE THEY
BECOME PREGNANT IS AN AREA THEY
THINK IS AN OPPORTUNITY AND THE
HEALTH OF WOMEN IN MIDLIFE, SO
CONNECTING THOSE DOTS ACROSS
THAT LIFE COURSE AND PROVIDING A
SCIENTIFIC FRAMEWORK, FOR HOW
THOSE PIECES FIT TOGETHER, IS
YOU KNOW AN OVERALL ORWH
APPROACH TO HOW WE INTERACT WITH
THE ICs.
IT SOUNDS LIKE IT MIGHT BE OF
INTEREST TO YOU TO HEAR AN
UPDATE IN THE FUTURE MEETING
ABOUT SOME OF THOSE ACTIVITIES.
>> ABSOLUTELY.
THANK YOU.
>> OKAY.
WE'RE HAPPY TO DO THAT.
>> DR. INIIE, DID YOU HAVE A
COMEBT OR QUESTION?
>> I DID.
THESE ARE GREAT GREAT TO HEAR L
THE PROGRESS, WE SEE IT IN
PIECES THROUGHOUT THE YEAR BUT
REALLY GOOD TO HEAR AND ALSO THE
NATIONAL LIBRARY OF INSIDE THERE
WERE WITHIN ORWH, THERE WERE
FUNDING OPPORTUNITIES AND
RESOURCES BUT I WANTED TO KNOW
IF THERE WAS ANY POTENTIAL FOR
COLLABORATING FURTHER ON SOME OF
THE ELEARNING MODULES THAT WOULD
HELP RESEARCHERS CONTINUE
LEARNING SEX DIFFERENCES WOULD
WORK AND THEN WORK IN WOMEN'S
HEALTH?
>> THANK YOU SO MUCH FOR THAT
QUESTION IRENE, OUR ELEARNING
MODULES ARE AN IMPORTANT TOOL IN
RESOURCE FOR THE COMMUNITY AS
YOU SAID TO ADVANCE SEX
DIFFERENCES RESEARCH AND WE ARE
IN THE PROCESS OF UPDATING
SEVERAL OF THEM, ARE THERE
COMMUNITIES FOR ADDITIONAL
PARTNERSHIP.
WE'RE ALWAYS INTERESTED IN
EXPANDING OUR REACH AND OUR
IMPACT AND I THINK 1 OF THE
THINGS WE WANT TO MAKE SURE IS
THAT WE'RE NOT DUPLICATING
EFFORTS ACROSS THE RESEARCH
ECOSYSTEM, SO, WITH PARTNERS
SUCH AS SWHR AND OTHERS, AND
REALLY SWHR'S MOVED INTO THAT
SPACE WITH A LOT OF THE
CONTINUING EDUCATION AND OTHER
ORGANIZATIONS AS WELL, AS THEY
REALIZE SEX DIFFERENCES ARE SO
SALIENT TO SO MANY DISEASE
AREAS, THEY'RE EMBEDDING IT,
THEY'RE EMBEDDING IT MORE AND
MORE IN OTHER ACTIVITIES, BUT WE
ARE WELCOME THE OPPORTUNITY TO
COLLABORATE WITH OTHER KEY
INTERESTED AREAS IN THE SPACE
SOPHISTICATED WORK NOR
COLLECTIVELY SO WE DON'T
DUPLICATE OUR EFFORTS AND OUR
EFFORTS SEAMLESSLY BENEFIT
EVERYONE.
SO HAPPY TO FOLLOW UP ON THAT.
>> THANKS.
>> AND KUDOS TO YOU FOR CITING
SOME NEW PROGRAMS I'VE BEEN
SEEING ON WOMEN'S HEALTH I'VE
BEEN SEEING, NEW PROGRAMMING.
OKAY, AND JUST SO FOLKS DIDN'T
KNOW OUR ELEARNING COURSES HAVE
CONTINUING EDUCATION CREDITS ARE
AND FREELYY VAIL -- AVAILABLE,E
WILL LET YOU KNOW WHEN THE NEXT
SET IS AVAILABLE.
AND IT LOOKS LIKE DR. MELAND
WOULD LIKE TO ADD?
>> YES, JUST WONDERING IF THERE
WERE ANY UPDATES ON LONG COVID?
I KNOW THERE WAS AN IMPORTANT
JAMA METE YORK PAPER LOOKING AT
SEX DIFFERENCES IN LONG COVID
PUBLISHED JANUARY 2025, THAT
FOUND FEMALES HAD SIGNIFICANTLY
HIGH RISK OF LONG COVID COMPARED
TO MALES, SO WONDER IF THERE
WERE ANY UPDATES THERE?
>> THANK YOU DR. MELENZ FOR YOUR
QUESTION.
SEX DISAGGREGATION IS SO
IMPORTANT AND FINDING
INFORMATION ON THAT. I DO NOT
HAVE NOW INFORMATION ON LONG
COVID AND I WOULD REFER YOU
PERHAPS TO SOME OF THE WEBSITES
THAT ARE AVAILABLE ONLINE FOR
NIH PERWHAPS THE RECOVER
WEBSITE MIGHT BE 1 YOU COULD GET
MORE UPTO GATE INFORMATION.
>> GREAT, YEAH, THANKS.
>> ARE THERE TOPICS THAT THE
ADVISORY MEMBERS WOULD LIKE TO
SEE AT A FUTURE MEETING?
WE'VE GOTTEN VALUABLE INPUT,
DR. NOEL?
>> I JUST HAD A QUICK QUESTION
AND I GUESS IT COULD GO WITH
ALSO MAYBE SOMETHING WE CAN
MENTION IN THE FUTURE MEETINGS
WOULD BE REGARDING BREAST CANCER
AND THE PRESENCE OF DENSE BREAST
OR AT MAMMOGRAPHY HAVING THE
DENSE BREAST DESIGNATION AND
THAT BEING I THINK A BIT MORE
PRESENT IN UNDERREPRESENTED
MINORITY OR BLACK WOMEN AND HOW
THAT CAN BE ADDRESSED IN TERMS
OF BREAST CANCER RISK AND HOW
MAMMOGRAPHY CAN BE USEFUL FOR
BREAST CANCER DETECTION WITHIN
THAT POPULATION.
IS THERE ANYTHING THAT IS DONE
IN TERMS OF RESEARCH OR IS THAT
SOMETHING THAT COULD BE LOOKED
AT IN FUTURE RESEARCH.
>> THANK YOU SO MUCH DR. NOEL,
THIS ISSUE OF DENSE BREAST
TISSUE AND IT'S AFFECT ON THE
DETECTION OF BREAST CANCER IS A
VERY IMPORTANT 1, EMERGING
EVOLVING 1.
IT DOES IMMEDIATELY ALSO
INTERSECT WITH OUR INTEREST IN
IMPROVING METHODOLOGIES IN
IMAGING AND TECHNOLOGIES.
AND WE HAVE PARTNERS WITH NIBIB
ON THAT AND HAVE SOME WORK IN
THAT SPACE THAT WE'VE SUPPORTED
BUT YOU'RE RIGHT ASTERISKS AN
EEMERGENCYING ISSUE OF
IMPORTANCE AND AFFECTS
POPULATIONS DIFFERENTLY WE WILL
BE HAPPY TO TAKE THAT ON AND HOW
WE CAN INTEGRATE THAT INTO
FUTURE MEETINGS.
IMPORTANT TOPIC AND THANK YOU.
OTHER QUESTIONS OR COMMENTS.
TOPICS YOU WANT TO HEAR ABOUT IN
THE FUTURE?
WE ARE A LITTLE EARLY FOR OUR
BREAK, BUT WE APPRECIATE THE
GIFT OF TIME AND IT'S BUSY, BUSY
TIME AND A BUSY DAY.
WOULD YOU LIKE TO GO AHEAD AND
DO OUR PHOTO AND BREAK EARLY?
>> YEAH, I THINK WHAT WE SHOULD
DO IS MAYBE GIFT OURSELVES A BIT
LONGER LUNCH BREAK.
SO FIRST OF OF ALL I JUST WANT
TO SAY --
>> DR. THERE ARE A COUPLE
QUESTIONS I SAW --
>> I'M SORRY, WE'RE NOT SEEING,
WE'RE ONLY SEEING 1 SCREEN SO WE
DON'T SEE THE FULL GALLERY, GO
AHEAD DR. JONES?
>> OH THANK YOU YEAH, I WAS
GOING TO RAISE THE ISSUE OF
DEMENTIA AND ALZHEIMERS AND JUST
THINKING ABOUT AS THE LIFE
SPANNED, WE'RE LIVING LONGER IT
SEEMS LIKE THAT IS A TOPIC ON
MANY PEOPLE'S MINDS AND THINKING
ABOUT THE UNIQUE RISKS THAT
WOMEN HAVE WITH DEMENTIA AND
ALZHEIMERS SO ANYTHING THAT'S
JUST A TOPIC I THINK WOULD BE OF
INTEREST, THANK YOU?
>> THANK YOU SO MUCH, YES,
ABSOLUTELY.
DR. SHARPS?
WE'RE NOT HEARING YOU
DR. SHARPS, LOOKS LIKE YOU'RE
MUTED?
>> YEAH, I WANTED TO COMMEND YOU
AND THE OFFICE ON THE IMPRESSIVE
WERE PORT FOAL DWROA THAT YOU
AREY PORTED ON -- PORTFOLIO THAT
YOU REPORT OFFICE OF DIVERSITY
IN THESE CHALLENGING TIMES AND I
AM CERTAINLY GRAD TO SEE THE
EMPHASIS ON POPULATION HEALTH
BUT WHAT I'M NOT HEARING AND I
KNOW IT'S PROBABLY A PART OF THE
TIMES BUT WE KNOW WOMEN ARE NOT
HETEROGENIUS GROUP AND DIFFERENT
POPULATIONS WITHIN THE
POPULATION HAVE DIFFERENT
DISEASE BURDEN SO I HOPE WE
CONTINUE -- ARE ABLE TO CONTINUE
TO FOCUS ON THAT AND I THINK IN
THE FUTURE, WE DIPPED A LITTLE
BIT INTO AI, BUT I THINK
CONTINUING LOOKING AT TECHNOLOGY
AND HOW IT'S INFORMING OR BEING
INTERNATIONAL CLASSIFICATION
GRAYED IN WOMEN'S HEALTH
RESEARCH AS WELL AS HOW IT WORKS
IN DIFFERENT COMMUNITIES AND
DIFFERENT POPULATIONS AND I
THINK WOULD BE CONTINUED FOCUS
FOR FUTURE MEETINGS.
>> THANK YOU SO MUCH DR. SHARP,
I APPRECIATE THAT.
CERTAINLY CONTINUE TO BE
PROMOTING AND ADVANCING AND
INCLUSION OF WOMEN AND
INDIVIDUALS FROM RACIAL AND
ETHNIC UNDERREPRESENTED GROUPS
PER LEGISLATION AND IMPORTANT
FOR OUR RESEARCH TO BE ABLE TO
ADDRESS AND INCLUDE ALL
INDIVIDUALS WHO ARE AFFECTED BY
DECS AND CONDITIONS, WE STUDY
AND MAKE SURE WE UNDERSTAND WHO
WHOM OUR RESULTSA, PLIE.
SO HAPPY TO CONTINUE OUR SUPPORT
OF THAT EFFORT, THOSE EFFORTS
AND I APPRECIATE THE SUGGESTIONS
FOR TOPICS.
ARE THERE OTHER SUGGESTIONS FOR
TOPICS FOR OTHER COMMENTS THAT
OUR ADVISORY MEMBERS WOULD LIKE
TO ADD?
AND YOU CAN CERTAINLY DO THAT
LATER IN THE DAY, WE HAVE A
LITTLE BIT MORE TIME RATER IN
THE DAY, SO IF YOU THINK ABOUT
SOMETHING YOU WOULD LIKE TO
COMMENT ON OR ADD, JUST JOT IT
DOWN AND WE WILL BE HAPPY TO
RECEIVE IT LATER IN THE DAY, BUT
I'M GOING TO TURN IT BACK OVER
TO THE EXEC SEC OF ACWHR,
DR. VIF RAN OTA WANG FOR OUR
NEXT STEPS.
>> SO FIRST OF ALL I JUST HAVE
TO SAY, I AM REALLY APPRECIATIVE
OF THE TREMENDOUS
PRESENTEDDATIONS THAT WE'VE HAD
THIS MORNING.
AND REALLY THE GREAT
DISCUSSIONS.
SO AT THIS TIME, WHAT I WOULD
LIKE IS IF ALL OF THE MEMBERS
COULD JOIN US ON CAMERA SO WE
COULD AT LEAST TAKE A VIRTUAL
PHOTO OF US ALL, AND THEN AFTER
THAT WE WILL TAKE A BREAK IF YOU
COULD BE BACK BY 12:30, WE WILL
START WITH OUR AFTERNOON
PRESENTATIONS AND DISCUSSION.
WELCOME BACK EVERYBODY, I
WOULD NOW LIKE TO CALL THE
MEETING TO ORDER AND INTRODUCE
DR. BELINDA SETO WHO WILL BE
MODERATING OUR PANEL ON DATA
SCIENCE AND WOMEN'S HEALTH.
THE INTRODUCTION I HAVE WILL NOT
DO JUSTICE TO THE DR. SET, BUT I
WILL DO MY BEST.
DR. SETO WAS APPOINTED TO THE
OFFICE OF DATA STRATEGY IN 2019.
HER AREAS OF OF AVAILABLE ARE IN
COMMON STANDARDS, COMMON
ELMETROPOLITANS AND REAL WORLD
DATA.
THE FORMER DEPUTY DIRECTOR OF
THE NATIONAL EYE INSTITUTE AND A
NATIONAL INSTITUTE OF BIOMEDICAL
IMAGING AND BIOENGINEERING, SHE
BRINGS ORGANIZATIONAL LEADERSHIP
EXPERIENCE AND SCIENTIFIC
KNOWLEDGE TO THE POSITION.
AFTER EARNING HER Ph.D. IN
BIOCHEMISTRY FROM FROM PURDUE
UNIVERSITY, DR. SETO COMPLETED
OR POST DOCTORAL FELLOWSHIP AT
THE NATIONAL HEART LUNG AND
BLOOD INSTITUTE.
SHE CONDUCKED RESEARCH ON
HEPATITIS B AND VACCINE
DEVELOPMENT AT THE FDA AS WELL.
SHE WAS A PROGRAM DIRECTOR IN
THE OFFICE OF RESEARCH AND
MINORITY HEALTH, WHERE SHE LED
SEMINOLE STUDIES ON INFANT
MORTALITY AND MENOPAUSORRITY
YOUTH BEHAVIOR HEALTH STUDIES.
AS DEPUTY DIRECTOR OF THE OFFICE
OF EXTRAMURAL RESEARCH, SHE ALSO
LED INITIATIVES OF DATABASE
MANAGEMENT, OPEN ACCESS TO NIH
FUNDING TRENDS AND DATA SHARING
POLICY.
HER VAST EXPERIENCE AND
DATABASED MANAGEMENT ANALYSIS
AND INTRAMURAL GRANT POLICIES
HAS LED TO APPOINT AMS BY THE
DIRECTOR AND THE NATIONAL --
EXCUSE ME TO THE SCIENTIFIC DATA
COUNCIL AT NIH IN THE DEPARTMENT
OF HEALTH AND HUMAN SERVICES
DATA COUNCIL.
WELCOME DR. SETO.
THANK YOU VERY MUCH FOR JOINING
TODAY'S PANEL.
>> THANK YOU VIVIAN FOR THOSE
KIND INTRODUCTION.
IT IS MY DISTINCT PLEASURE TO
MODERATE THIS PANEL WITH REALLY
DISTINGUISHED SPEAKERS, I'M SO
LOOKING FORWARD TO IT I GO OVER
THE SLIDES AND I SAY I CAN'T
WAIT TO HEAR THE PRESENTATION.
I WE WILL DO EACH PANELIST WILL
DO A 15 MINUTE PRESENTATION AND
IF THE AUDIENCE WILL HOLD THE
QUESTIONS UNTIL ALL 3
PRESENTATIONS ARE DONE, AND WE
WILL -- I WILL ASK A COUPLE OF
QUESTIONS AND THEN WE WILL OPEN
TO THE AUDIENCE FOR DISCUSSION
AND IF THAT IS OKAY VIVIAN, I
WILL GO AHEAD AND INTRODUCE THE
FIRST SPEAKER DR. MOORE.
GREAT.
THANK YOU.
DR. MOORE JASON MOORE IS THE
CHAIR OF THE DEPARTMENT OF
COMPUTATIONAL MEDICINE AT CEDAR
SINAI MEDICAL CENTER WHERE HE
SERVES AS DIRECTOR FOR
ARTIFICIAL INTELLIGENCE RESEARCH
AND EDUCATION, HE LEADS AN
ACTIVE RESEARCH PROGRAM FOCUSED
ON THE DEVELOPMENT AND
APPLICATION OF ARTIFICIAL
INTELLIGENCE ALGORITHMS FOR THE
ANALYSIS OF BIOMEDICAL DATA.
RECENT WORK FOCUSES ON METHODS
FOR AUTOMATED MACHINE LEARNING
WITH A GOAL OF DEMOCRATIZING AI
IN HEALTHCARE.
HE IS AN ELECTIVE FELLOW OF THE
AMERICAN COLLEGE OF MEDICAL
INFORMATICS, THE INTERNATIONAL
ACADEMY OF HEALTH SCIENCES
INFORMATICS, AND THE AMERICAN
STATISTICAL ASSOCIATION.
SHE'S EDITOR IN CHIEF OF THE
JOURNAL BIODATA MINING.
THE FLOOR AND THE MIC IS YOURS,
DR. MOORE.
>> GREAT.
THANK YOU SO MUCH AND IT'S
REALLY WONDERFUL TO BE WITH ALL
OF YOU TODAY FOR THIS PANEL.
I'M REALLY LOOKING FORWARD TO
IT, AS YOU HEARD I'M AN AI
METHODOLOGIST, I DEVELOPED AI
METHODS AND HAVE MY ENTIRE
CAREER AND I WILL TOUCH A LITTLE
BIT OF THAT ON THE END HAPPENED
OF MY PRESENTATION, WHAT I WANT
TO DO IS COMMUNICATE THE
CHALLENGES WE FACE WORKING WITH
DID THEA ESPECIALLY AROUND THIS
NEW ERA OF AI.
AND LET ME JUST SAY THAT IF YOU
SEE AN OPPORTUNITY TO DLABERATE
OR IF THERE'S SOME WAY I CAN
HELP YOU PLEASE FEEL FREE TO
REACH OUT.
MY E-MAIL ADDRESS IS HERE ON THE
SLIDE.
SO LET ME START WITH THIS
CONCEPT OF LEARNING HEALTH
SYSTEM, I WORK AT A BIG HOSPITAL
HERE IN LA, AND YOU KNOW WE DO
RESEARCH AND WE HOPE THAT THAT
RESEARCH WILL TURN INTO EVIDENCE
AND THAT EVIDENCE WILL LEAD TO
CARE AND GOOD CARE WILL LEAD TO
AN IMPROVED PATIENT EXPERIENCE,
BUT UNFORTUNATELY ALONG THERE
PATH, THERE'S A LOT OF SCIENCE
AND RESEARCH THAT IS PUBLISHED
BUT NEVER FINDS ITS WAY INTO
EVIDENT, THERE'S A LOT OF
EVIDENCE THAT NEVER FINDS ITS
WAY INTO CARE AND THERE'S A LOT
OF CARE STRATEGIES THAT DON'T
NECESSARILY IMPROVE THE IDEA OF
PATIENT EXPERIENCE, SO THE IDEA
IS TO TIGHTEN THIS UP SO THAT WE
HAVE AN EFFICIENT PIPELINE THAT
LEAD TO IMPROVE PATIENT
STRATEGIES AND EXPERIENCES.
THIS IS A DEFINITION OF AN
LEARNING HEALTH SYSTEM FROM THE
INSTITUTE OF MEDICINE 10 YEARS
AGO, A SYSTEM IN WHICH SCIENCE,
INFORMATICS AND CULTURE ALIGN
FOR CONTINUOUS IMPROVEMENT OF
THE HEALTHCARE DELIVERY
EXPERIENCE AND THIS IS THE IDEA
AND I HIGHLIGHTED INFORMATICS
BECAUSE COMPUTATION,
INFORMATICS, DATA SCIENCE,
STATISTICS ALL PLAY AN IMPORTANT
ROLE IN GLEANING DATA SETS OF SO
WE CAN TIGHTEN UP THIS PIPELINE.
THIS IS A PIPELINE OF WHAT WE
WANT TO TALK ABOUT, AROUND THE
CHALLENGES OF LEARN FREE
RADICALS GENERATED DATA IN A
LEARNING HEALTH SYSTEM
ENVIRONMENT.
DATA ARE EXPENSIVE AND THEY ARE
OFTEN STATIC, MESSY, DIFFICULT
TO INTEGRATE, THEY'RE PRIVATE,
DIFFICULT TO ANALYZE AND
DIFFICULT TO PUT INTO PRACTICE
OR OPERATIONALIZE.
SO I WILL TOUCH ON EACH OF
THESE.
IT'S AN EXCITING TIME OF COURSE
BECAUSE WE CAN MEASURE LOTS OF
DIFFERENT KINDS OF DATA ABOUT
HUMAN SUBJECTS RANGING FROM
OMICS DATA TO ELECTRONIC HEALTH
RECORD CLINICAL DATA, IMAGING
DATA AND MOBILE HEALTH DATA FOR
EXAMPLE, BUT AS YOU KNOW,
COLLECTING ALL THESE DIFFERENT
KINDS OF DATA ARE EXPENSIVE AND
TIME CONSUMING AND IT'S
IMPORTANT ONCE IN A WHILE TO
STEP BACK AND APPRECIATE AND
VALUE JUST HOW EXPENSIVE AND
TIME CONSUMING DATA ARE TO
COLLECT.
ONE OF THE BIG ISSUES WE DON'T
THINK ABOUT A LOT BUT SHOULD
THINK ABOUT MORE IS THAT DATA
ARE OFTEN STATIC, THE KINDS OF
THINGS WE CARE ABOUT LIKE THE
KINDS OF THINGS WE CAN MONITOR
WITH MOBILE HEALTH APPLICATIONS,
SMART PHONE ANDS SMART WATCHES
THESE ARE CONTINUOUS
MEASUREMENTS HEART RATE
VARIABILITY, BLOOD PRESSURE
AVAILABILITY, CHOLESTEROL
MEASURES, ALL OF THESE ARE
DYNAMIC AND TIME IN SPACE AND
CHANGE OVER OUR LIFETIME, SECOND
TO SECOND, MINUTE TO MINUTE,
YEAR TO YEAR, ET CETERA AND WHAT
DO WE DO, WE VERY OFTEN TAKE A
SINGLE MEMBER MEASUREMENT FROM
THIS COMPLEK DYNAMIC TRAJECTORY
AND WE CALL THAT A PATIENT'S
MEASUREMENT, SO THIS I WOULD SAY
INACCURATELY CAPTURES WHAT'S
GOING ON IN A PATIENT AND
SOMETHING THAT WE SHOULD THINK
ABOUT MORE.
OF COURSE BACK TO THE FIRST
SLIDE DATA IS EXPENSIVE AND
COLLECTING TIME SERIES DATA IS
EXPENSIVE AND PRESENTS A WHOLE
BUNCH OF OTHER CHALLENGES.
DATA ARE MESSY, OMICS DATA CAN
BE MESSY, CLINICAL DATA FROM THE
ELECTRONIC HEALTH RECORD IS
ESPECIALLY MESSY, THIS IS A
SLIDE I LOVE AS A FIGURE FROM A
PAPER, NATURE PAPER FROM 2018,
ON LOOKING AT EHR DATEDDA FROM
AML PATIENTS.
AND THE COLUMNS IN THE HEAT MAP
ARE PATIENTS AND EACH ROW IS A
DIFFERENT CLINICAL VARIABLE FROM
THE ELECTRONIC HEALTH RECORD
THAT THEY LOOKED AT.
AND THE LIGHT GRAY SQUARES IN
THE HEAT MAP ARE MISSING DATA SO
YOU CAN SEE EVERY PATIENT HAS
QUITE A BIT OF MISSING DATA
ACROSS ALL THESE VARIABLES AND
EACH VARIABLE IN AND OF ITSELF
HAS QUIT A BIT OF MISSING DATA
SO BIG QUESTION IS WHAT DO YOU
DO WITH THAT, WHAT DO YOU WITH
THE OUTLIERS OF THE DATA THAT'S
PRESENT AND WHAT DO YOU DO WITH
ALL THE MISSING DATA?
DO YOU THROW IT AWAY?
DO YOU IMPUTE IT?
THESE ARE THE QUESTIONS WE
STRUGGLE WITH IN THE DAILY BASIS
THEA CLEANING AND QUALITY
CONTROL PHASE OF ANY DATA
SCIENCE STUDY.
DATA ARE DIFFICULT TO INTEGRATE
AND 1 OF THE FIRST THINGS WE
THINK ABOUT ESPECIALLY
WELCOMERRING WITH CLINICAL DATA
IS DEFINING THE PHENOTYPE THAT
WE'RE INTERESTED IN, THAT COULD
BE A WOMEN'S HEALTH ISSUE, AND
DISEASE, A CONDITION, AND
ESPECIALLY IN CLINICAL DATA
PHENOTYPES OFTEN COME FROM ICD
BILLING CODES AND BILLING CODES
ARE THERE FOR BILLS PURPOSES AND
NOT NECESSARILY TO ACCURATELY
DEFINE A FEIGNIE TYPE FOR A
PATIENT, AND SO WE NEED LOTS OF
DIFFERENT KINDS OF DATA DISP WE
NEED LABORATORY TESTS,
MEDICATIONS, WE NEED OTHER
CLINICAL MEASURES, WE COULD HAVE
GENETIC MEASURES HERE, WE COULD
HAVE ENVIRONMENTAL MEASURES THAT
TOGETHER ACCURATELY DEFINE A
PHENOTYPE FOR A PATIENT AND SO
THAT REQUIRES DATA INTEGRATION
AND OF COURSE EACH HELT SYSTEM
COLLECTS DATA IN A DIFFERENT
WAY, WE USE DIFFERENT
INSTRUMENTS, WE USE DIFFERENT
LABORATORY TESTS, DIFFERENT
ASSAYS FROM DIFFERENT VENDORS
AND THAT CREATE AS I LOT OF
HETEROGENEITY FROM SITE TO SITE
IF WE'RE TRYING TO INTEGRATE
DATA FROM DIFFERENT SOURCES AND
SO WE NEED TO THINK ABOUT COMMON
DATA MODELS, THAT ARE DATA
STANDARDS CAN MAP OUR DATA TO SO
THAT WE AT CEDAR SINAI, THIS IS
A PATIENT'S GLUCOSE LEVEL OR A1C
LEVEL OR THIS IS THE MEDICATION
THEY'RE TAKING THAT IT'S EXACTLY
THE SAME AS THOSE THINGS AT YOUR
INSTITUTION AND ONCE WE MAP IT
TO ACCOMMODATE A MODEL, THEN WE
CAN START TO EITHER INTEGRATE
DATA DIRECTLY OR DO A FEDERATED
ANALYSIS OF THE DATA AND
DIFFERENT SITES AND INTEGRATE
THE RESULTS AND AS YOU CAN
IMAGINE, THIS IS A TIME
CONSUMING DIFFICULT PROCESS BUT
NONETHELESS A VERY IMPORTANT
PROCESS, FOR PULLING DATA
TOGETHER TO DO A BETTER
ANALYSIS; NOW OF COURSE 1 OF THE
THINGS WE THINK A LOT ABOUT IS
THE PRIVACY OF OUR PATIENTS, OUR
HUMAN SUBJECTS FOR THE RESEARCH
DATA THAT WE COLLECT, THE
CLINICAL DATA WE COLLECT, AND
THERE ARE DIFFERENT WAYS TO DEAL
WITH THAT, OF COURSE, 1 APPROACH
IS DEIDENTIFY THE DATA, SHARE
THE DATA FROM MULTIPLE SITES,
AND DO A CENTRALIZED ANALYSIS OF
THAT DATA.
SO YOU COULD CLEAN THE DAILY
BASIS THEA, MAP IT TO A COMMON
DATA MODEL, DEIDENTIFY IT AND
SHARE IT IN A CENTRALIZED MANNER
AND THERE ARE PLENTY OF NATIONAL
STUDIES THAT DO THIS, THE
ADVANTAGES, THE DATA'S ALL IN 1
PLACE AND YOU CAN DO 1
INDGREATED ANALYSIS, THE DOWN
SIDE OF COURSE IS THAT A
HOSPITAL SENDING CLINICAL DATA
TO A CENTRALIZED SITE LOOSES
CONTROL IN THOSE DATA COULD BE
COMPROMISED AND EVEN THOUGH THE
DATA IS DEIDENTIFIED, THERE IS
STILL WAYS TO IDENTIFY DATA FOR
A BAD ACTOR WHO'S MOTIVATED TO
DO SO.
SO THERE ARE SOME RISKS WITH
CENTRALIZED ANALYSIS.
THE OTHER APPROACH IS, THIS IS
THE APPROACH THAT I PERSONALLY
FAVOR IS THE FEDERATED APPROACH
WHERE AT SEKDAR SINAI, OUR DATA
STAYS AT OUR OWN INSTITUTION, WE
ANALYZE THE DATA HERE, YOU
ANALYZE YOUR DATA AT YOUR
INSTITUTION BEHIND YOUR SECURE
FIRE WALL AND THEN WE SHARE
MODELS AND GLEAN INSIGHTS FROM
THE MODELS THEMSELVES AND THERE
ARE WAYS FOR EXAMPLE WITH
PARAMETRIC STAT IFORTICICAL
ANALYSIS, LIKE LENOIRIAR OR
STATISTICAL AGGRESSION, CAN YOU
COMBINE THE STATISTICS THAT COME
OUT OF THESE APPROACHES WITHOUT
LOSING INFORMATION AND DO
INFERENCE AND GAIN MORE POWER BY
DOING A FEDERATED ANALYSIS.
SO THINGS ARE -- THERE ARE OTHER
STRATEGIES AS WELL, LIKE
SYNTHETIC DATA THAT CAN BE
GENERATED BUT THIS IS ALSO
SOMETHING WE NEED TO THINK ABOUT
AS WE WANT TO DO STUDIES ACROSS
MULTIPLE SITES.
DATA ARE DIFFICULT TO ANALYZE,
I'M -- I APPROACH HUMAN HEALTH
AS IF IT'S A COMPLEX ADAPTIVE
SYSTEM AND THAT'S WHAT THIS
SLIDE IS SHOWINGA THE BOTTOM, WE
HAVE ALL OF OUR BIOMARKERS, MANY
DIFFERENT INDIVIDUAL FACTORS
THAT WE CAN ANALYZE, THIS COULD
BE GENETIC MEASURES, PROTEIN
MEASURES, METABOLOMIC,
ENVIRONMENT, CLINICAL MEASURES,
SO THESE ARE ALL THE INDIVIDUAL
PIECES AND PARTS OF A COMPLEX
SYSTEM LIKE A PARTICULAR MEASURE
OF WOMEN'S HEALTH, THOSE
INDIVIDUAL COMPONENTS ORGANIZED
THEMSELVES PERHAPS IN THE
PATHWAYS, AND AT A HIGHER LEVEL
INTO CONTROL STRUCTURES AND
THOSE CONTROL STRUCTURES
INTERACT TO ULTIMATELY DETERMINE
A HEALTH OUTCOME AND THE POINT
OF THIS SLIDE IS TO SAY THAT
OFTEN WHAT WE DO IS WE TAKE A
SINGLE BIOMARKER OUT OF THIS
COMPLEX PICTURE, LIKE WHEN YOU
DO A GENOME WIDE ASSOCIATION
STUDY FOR GENETIC ASSOCIATIONS,
YOU TAKE A SINGLE NUCLEOTIDE
POLYMORPHISM OUT OF THIS COMPLEX
PICTURE AND WHETHER IT'S
ASSOCIATE WIDE A CLINICAL END
POINT AROUND SAY WOMEN'S HEALTH.
THAT IGNORES ALL OF THESE
INTERACTIONS, ALL OF THIS
COMPLEXITY, AND SO THIS IS 1 OF
THE REASONS DATA ARE DIFFICULT
TO ANALYZE IS THAT THE PATTERNS
THAT WE'RE LOOKING FOR ARE
COMPLEX AND YOU HAVE TO
UNDERSTAND AND EMBRACE THIS
COMPLEXITY TO DO A GOOD JOB WITH
ANALYSIS AND THIS IS 1 OF THE
AREAS WHERE AI I THINK HAS AN
IMPORTANT ROLE TO PLAY BECAUSE
AI AND MACHINE LEARNING ARE
SPECIFICALLY DESIGNED TO LOOK AT
MANY FACTORS, BIOMARKERS
SIMULTANEOUSLY AND CONSIDER THE
COMPLEX NONINTERACTIONS BETWEEN
THOSE FACTORS AND YOU THROW IN
THE DYNAMIC AND IT IS THE TIME
DIMENSION AND YOU GET A WHOLE
OTHER LEVEL OF COMPLEXITY BUT
THIS IS WHAT WE NEED ON DO TO
FULLY UNDERSTAND THE
UNDERPINNINGS OF COMMON COMPLEX
DISEASES.
NOW ONCE WE CLEAN THE DATA AND
WE'VE MAP TODAY TO ACOMMON DATA
MODEL, WE INTEGRATED IT, WE'VE
DONE A CONFIDENT ANALYSIS, WE
KEPT THE DATA SECURE AND
PRIVATE, THE REAL CHALLENGE
BEGIN ANDS THAT'S HOW TO
OPERATIONALIZE IT, SO YOU HAVE A
MODEL THAT YOU TRUST AND YOU'VE
DONE ALL THE HARD WORK TO BUILD
A GOOD MODEL, THEN YOU HAVE TO
COMMUNICATE THAT THROUGH PEER
REVIEWED LITERATURE, THAT MODEL
NEEDS TO BE REPLICATED AND
VALIDATED AND INDEPENDENT DATA
SETS FOR IT TO BE BELIEVABLE,
AND SO THEN, THAT'S THE TOP
PART, THE PROCESS WE GO THROUGH
TO GO THROUGH THE PEER REVIEW
PROCESS TO CONVINCE OTHERS THAT
THIS IS A GOOD MODEL AND THAT
THEY SHOULD BE INTERESTED IN
DOING MORE WITH IT, BUT LET'S
SAY WE WANT TO DEPLOY IT IN THE
CLINIC, THIS OPENS THE DOOR TO
AN ENTIRE LENGTHY PROCESS, IS
THE MODEL GENERAL?
DOES IT TREAT ALL PEOPLE
EQUALLY?
IS IT SAFE?
DOES IT HAVE THE POTENTIA WILL
TO HARM PEOPLE?
IS IT EFFICIENT, IS IT ENERGY
EFFICIENT FOR EXAMPLE, DO WE
TRUST THE ALGORITHM, CAN WE LOOK
AT THE ALGORITHM AND THE MODEL
AND UNDERSTAND WHAT IT DOES AND
TRUST IT JUST AS WE TRUST A
COLLEAGUE WHEN WE GO AND ASK FOR
AN OPINION ABOUT A PATIENT.
WE INCREASE -- HEALTH SYSTEMS
ARE INCREASINGLY UNDER FINANCIAL
STRAIN AS THE POPULATION AGES
AND HEALTHCARE REIMBURSEMENT
MODELS CHANGE SO WA ALSO THINK
ABOUT RETURN ON INVESTMENT, DOES
THIS SAFE HOSPITAL RESOURCES,
DOES IT SAVE TIME AND MONEY,
DOES IT FREE UP CLINICIANS TO DO
OTHER THINGS, SO THIS IS
SOMETHING THAT WE THINK ABOUT.
AND THEN WE HAVE TO THINK ABOUT,
DECISION SUPPORT, SO YOU WANT TO
PUT A MODEL INTO THE CLINIC, HOW
IS THAT MODEL GOING TO FIT INTO
A CLINICIANS WORK FLOW, DO THEY
HAVE TIME TO EVEN THINK ABOUT
WHAT THE MODEL IS TELLING THEM
ABOUT A PATIENT AND ONCE YOU
DEPLOY A MODEL IN THE CLINIC,
YOU HAVE TO AUDIT IT REGULARLIER
FEW MONTHS OR 6 MONTHS YOU HAVE
TO DO AN ANALYSIS OF THE MODEL,
IS IT STILL A SAFE, EFFICIENT,
EFFECTIVE TRUSTWORTHY MODEL
BECAUSE THE DATA CAN DRIFT AND
CHANGE OVER TIME AND
INSTRUMENTATION CHANGES AND WHAT
MIGHT BE AN EFFECTIVE MODEL
TODAY MIGHT BE LESS EFFECTIVE N
6 MONTHS AS DATA SHIFT AND
CHANGES.
AND THEN OF COURSE THERE'S
CHANGES IN THE LAWS AND RULES
AND REGULATIONS, I'M IN THE
STATE OF CALIFORNIA WHERE WE
HAVE A STATE LEGISLATURES WHO
ARE INTRODUCING LOTS OF NEW
BILLS AROUND THE REGULATION OF
AI, AND MAKING SURE THAT IT IS
SAFE AND EFFECTIVE FOR PATIENTS.
SO SO THIS IS A VERY LENGTHY AND
COMPLICATED PROCESS THAT WE HAVE
TO GO THROUGH TO CREATE A
CLINICALLY EFFECTIVE AND USEABLE
MODEL.
RIGHT, I WILL TAKE MY LAST FEW
MINUTES TO TELL YOU A FEW WORDS
ABOUT WHAT I'M INTERESTED IN
THIS DEVELOPING AI TOOLS TO USE
DATA EFFECTIVELY IN A LEARNING
HEALTH SYSTEM ENVIRONMENT AND
I'M INTEREST INDEED
ACCESSIBILITY AND DEMOCRATIZING
AI, MAKING IT EASY FOR
CLINICIANS AND BIOLOGISTS AND
EVERYBODY TO BENEFIT FROM IT, SO
YOU DON'T HAVE TO BE A DATA
SCIENTIST OR A COMPUTER
SCIENTIST, AND WE'VE DEVELOPED
WHAT WE CALL AN ECOSYSTEM FOR
EXPLAINABLE AI AND THIS COMBINES
A LOT OF DIFFERENT PIECES AND
PARTS BUT BASICALLY WHAT WE'RE
DOING HERE IS PUTTING CURATED
DATA, PUBLIC KNOWLEDGE ABOUT
YEENS AND DISEASE, AND DRUGS AS
WELL AS CODE AND RESEARCH
RESULTS INTO WHAT'S CALLED A
GRAPH DATABASE.
SO WE TAKE CODE AND RESULTS AND
KNOWLEDGE, AND DATA AND WE LINK
IT ALL IN A GRAPH SO WE
UNDERSTAND THE RELATIONSHIPS
BETWEEN ALL OF THOSE ENTITIES,
AND WE'VE BUILT LARGE LANGUAGE
MODEL TOOLS WHERE WE CAN TART TO
ASK QUESTIONS ABOUT THE DATA, WE
CAN LAUNCH WITH JUST A FEW WORDS
A MACHINE LEARNING ANALYSIS.
WE CAN INTERROGATE THE RESULTS
JUST AS WE WOULD A DATA SCIENCE
COLLEAGUE, AND SO THE IDEA IS
THAT THIS WILL MAKE IT EASY FOR
PENAL TO DO COMPLICATED MACHINE
LEARNING ANALYSIS, ASK QUESTIONS
ABOUT THE RESULTS, GAIN AN
UNDERSTANDING OF THE RESULTS AND
ALL OF THIS IS BASED ON AN
ONTOLOGY THAT WE BUILT WHERE WE
CAN MODEL THE RELATIONSHIPS AND
UNDERSTAND THE SEMANTIC
RELATIONSHIPS BETWEEN CODE AND
DATA AND KNOWLEDGE AND RESULTS
AND ANNOTATIONS AND SO THIS IS
WHAT ALLOWS US TO PUT ALL OF
THESE ENTITIES INTO A GRAPH AND
BE ABLE TO BETTER UNDERSTAND HOW
THEY ARE WORK TOGETHER AND ALLOW
A LARGE LANGUAGE MODEL LIKE CHAT
GPT TO ASK INTELLIGENT QUESTIONS
ABOUT IT.
AND THIS IS A PAPER WE PUBLISHED
RECENTLY A METHOD CALLED
ESCARGO, WHICH IS AN EXCELLENT
LANGUAGE BASED MODEL DESIGNED TO
ASK QUESTIONS ABOUT A DATABASE
LIKE THIS.
AND WE SHOWED WITH HUNDREDS OF
DIFFERENT TYPES OF QUESTIONS
ABOUT THE GRAPH, WE SHOWED THAT
OUR ESCARGO METHOD ACHIEVES 80
HEVER 90% ACCURACY AND ANSWERING
THOSE QUESTIONS WHICH IS MUCH
BETTER THAN CHAT GPT WHICH
UNDERSTANDS VERY LITTLE ABOUT
THE KNOWLEDGE WE HAVE IN OUR
GRAPH AND THIS IS ALL PUBLISHED
AND OPEN SOURCE SOFTWARE.
SO I WILL STOP THERE AND LOOKING
FORWARD TO THE REST OF THE PANEL
AND AGAIN, YOU KNOW MY GOAL IS
TO MAKE -- ACCELERATE RESEARCH
BY MAKING IT EASY AND ACCESSIBLE
AND I WILL JUST THANK MY TEAM,
ECOXAI TEAM, MY NIH FUNDING AND
AGAIN THERE'S MY E-MAIL ADDRESS
AND THIS IS WHERE WE'RE LOCATED
IN WEST HOLLYWOOD, THIS IS THE
PACIFIC DESIGN CENTER THAT WE
CALL THE NORTH CAMPUS WHICH IS
ABOUT A 10 MINUTE WALK FROM THE
MAIN CEDAR SINAI HOSPITAL WHERE
WE LEASE RESEARCH SPACE AND ON -
IMON THE FIFTH FLOOR OF THE
GREEN BUILDING.
>> THANK YOU DR. MOORE FOR THE
QUICK WHIRL WIND TOUR OF DATA
SCIENCE AND NONE OF US CAN LIVE
WITHOUT DATA SCIENCE AND I WOULD
LOVE TO GET TO THE DISCUSSION
PORTION OF THIS PROGRAM TO TALK
MORE ABOUT THE EXPLAINABLE AI IN
THE ECOSYSTEM.
SO THANK YOU.
OUR SECOND SPEAKER FOR THIS
AFTERNOON IS DR.A ELHADA D, AND
SHE IS THE CHAIR AND ASSOCIATE
PROFESSOR OF THE DEPARTMENT OF
BIOMEDICAL INFORMATICSAL
COLUMBIA UNIVERSITY VAGELOS
COLLEGE OF PHYSICIANS AND
SURGEONS.
AND DIRECTOR OF THE MEDICAL
INFORMATION SERVICES AT NEW YORK
PRESCRIBING BI TERRION HOSPITAL.
SHE LEADS THE AI AND BPS
INITIATIVE AND IN COLUMBIA'S
UNIVERSITY RESEARCH INIAATIVE ON
DATA POWERED WOMEN'S HEALTH.
HER RESEARCH SITS AT THE
INTERSECTION OF ARTIFICIAL
INTELLIGENCE, HUMAN CENTERED
COMPUTING AND MEDICINE WITH A
FOCUS ON DEVELOPING NOVEL
MACHINE LEARNING METHODS.
SHE DESIGNED AI DRIVEN TOOLS TO
SUPPORT PATIENTS AND CLINICIANS
INSURING THAT THE AI SYSTEM OF
THE FUTURE IS SAFE AND EFFECTIVE
AND ADVANCE MEDICINE,
DR. ELHADAD, I AM REALLY LOOKING
FORWARD TO YOUR PRESENTATION,
THE MIC IS YOURS.
WOULD YOU PLEASE UNMUTE, THANK
YOU?
>> I CAN UNMUTE.
THANK YOU.
HI, EVERYONE.
I WILL TALK TO YOU ABOUT A
ROADMAP THAT WE'VE BEEN THINKING
HERE AT COLUMBIA AND IN MY LAB
IN PARTICULAR ON AI POWERED
WOMEN'S HEALTH.
SO AS DR. SETO SAID I AM REALLY
MUCH AT THE INTERSECTION OF AI
AND WOMEN'S HEALTH.
THESE ARE THE ENTITIES THAT ARE
FUNDING MY WORK AND I'M VERY
GRATEFUL TO THEM AND CLUE THE
MENSTRUAL TRAWK AND ODESSY AND
THE OBSERVATIONAL HEALTH DATA
ARE MY DATA PARTNERS.
SO I WANT TO START BY SAYING
THAT THERE'S THIS PROMISE OF
DATA AI AND TECHNOLOGY, WHICH IS
I THINK ALONG 3 AXIS TO ELUC
DATE THE ROLES OF SEX AND GENDER
IN HEALTH TO IDENTIFY NEW
KNOWLEDGE, ABOUT WOMEN'S HEALTH,
NEW PHYSIOLOGICAL KNOWLEDGE AND
ALSO TO CREATE NEW SOLUTIONS
TECHNOLOGICAL SOLUTIONS TO
SUPPORT WOMEN, BUT IF WOMENS
HEALTH ON ITS OWN WAS A COMPLEX
TOPIC ADDING DATA AND AI
TECHNOLOGY ADDS AN ADDITIONAL
LAYER OF COMPLEXITY.
AND SO, THE BULK OF MY TALK
REALLY IS HOW DO WE GO ABOUT
THINKING ABOUT HOW AI CAN HELP
WITHOUT HARMING AND THE TRDR OF
THE BIG OUTLINE OF THIS TALK IS
AI TECHNIQUES THAT ACCOUNT FOR
THE BIASES OF THE DATA AND ABOUT
WOMEN'S HEALTH IN PARTICULAR
THAT ARE ENCODED IN THE
DALLASCOWBOYS.COM DATA HUMAN
CENTERED AI APPROACHES THAT
INSURES A SOLUTIONS CREATED ARE
ALIGNED WITH THE NEEDS VALUES OF
INDIVIDUALS IN POPULATION AND
TEAM SCIENCE ARE GOING TO BE
CRITICAL TO DELIVERING ON THIS
PROMISE.
AND WE DO OVER ALL MENSTRUAL
HEALTH, ORAL CONTRACEPTION, PC
OS MENOPAUSE BUT I WILL USE
ENDOMETRIOSIS TO TALK ABOUT THE
WORK THAT WE DO.
AND I HOPE I CAN MOTIVATE THE
REASON TO WHERE I'M LOOKING AT
THIS PARTICULAR ASPECTS OF
ENDOMEDE RIRIOSEIS, 1 IS THAT IT
IS AN UNDERSTOOD CONDITION AND
UNDERSTAND STUDIED SO WE WILL
TRY TO DESCRIBE THE DISEASELET
SECONDON IS THAT I DON'T HAVE TO
TELL THIS AUDIENCE BUT THERE'S A
LONG DIAGNOSIS FOR ENDOMEET
RIOSEOSEIS AND COULD WE USE AI
FOR DETECTION, THERE'S A LOT OF
WORK IN BIOMARKERS AND
NONEVASIVE TESTS AND HERE'S THE
IDEA, IS CAN WE USE EXISTING
DATA AND SYSTEMS IN PLACE BUT
NEVERTHELESS EPIABLE PATIENTS TO
ACCESS AN EARLIER DIAGNOSE.
AND THEN THE FACTS THERE'S THIS
COMPLEX SELF-MANAGEMENT TO
ENDOMEET RIAIAL DISEASE I WANT
TO SAY SOMETHING ABOUT TEAM
SCIENCE, IT'S VERY ORGANIZED, I
WAS HONORED TO GELT A WORKSHOP
AND NSF, AND MANY PEOPLE FROM
ORWH IN THE AUDIENCE AS WELL,
AND THAT WAS ABOUT USING AI TO
BETTER UNDERSTAND MENEE PAUSE
AND THE OTHER HALF WHERE THE AI
SCIENTISTS AND IT WAS A
FANTASTIC 2 DAYS AT COLUMBIA
UNIVERSITY THESE ARE 2 THYSELF
ARE 2 INITIATIVE THAT I WILL
MENTION THAT ARE SPECIFICALLY AT
THE INTERSECTION OF TECHNOLOGY
AND EM'S HEALTH WHICH IS WHAT I
LEAD AND EMERGE WHICH SIGNIFY
PARTICIPATE AND IS PART OF
ENGINEERING FOR WOMEN'S HEALTH.
SO THIS ROADMAP I WILL STOP
ENDOMEDE RIOSEIS AND AND HERE I
WILL TELL YOU QUICKLY ABOUT NEW
DATA AND TOOLS AND HOW THAT CAN
HELP US LEAD TO NEW INSIGHTS
IT'S ABOUTEND SO AGAIN I LIKE TO
TELL THE OUTLINE BEFORE I SHOW
YOU EVERYTHING THERE'S 3 TYPES
OF INSIGHT, 1 ABOUT HUMAN
CENTERED APPROACHES, 1 ABOUT AI
TECH INSIGHTS AND 1 ABOUT WHAT
HAVE WE LEARNED ABOUT THE
DISEASE, IN THIS CASE
ENDOMETRIOSIS AND THE HUMAN WITH
INSEAT DISMESS THE AND WANT TO
CONTRIBUTE TO SCIENCE BUT THEY
WANT TO DO SO UNDER SPECIFIC
CONDITIONS AND IN PARTICULAR
PRIVACY IS A REALLY, REALLY BIG
DEAL WORRY PATIENTS WITH ENDOME
RIOSEIS, AND AI IN HIGH-TECH, WE
USE MOBILE HEALTH TO ENGAGE
DAY-TO-DAY PATIENTS TO TELL US
ABOUT THEIR DISEASE AND THAT
ISN'T ACTUALLY USEFUL TYPE OF
TECHNOLOGY ESPECIALLY WHEN THERE
ARE DISEASES THAT HAVE
DAY-TO-DAY VARIATIONSIATIONS IN
SYMPTOMS, AI METHODS THAT ARE
LOOKING TO MIDIGATE DATA ARE
CRITICAL IN THE CASE OF MOBILE
HEALTH, WE NEED TO TAKE INTO
ACCOUNT NOT EVERYONE WILL
RESPOND TO QUESTIONS DAY-TO-DAY,
SOME MIGHT DO IT ONCE IN A WHILE
AND SEVERAL TIMES A DAY AND
MITIGATE FOR THIS POTENTIAL
CHANGES IN HEALTH DATA IS
COLLECTED AND FINALLY AI METHODS
ARE NEEDED BECAUSE WE HAVE THE
PATTERNS OF DISEASE AND SO AND
SO NEWER MOTHERS ARE ACTUALLY
VERY HELPFUL AND FIEBALLY ON
ENDOMITTRYOSE ESTIMATE THAD THAT
WE'VE DONE WITH THE MOBILE HOUSE
TECHNOLOGIES TO CONFIRM THE
ASPECT, BUT ALSO THE FACT THAT
IT'S HIGH -LY HETEROGENEOUS AND
WE CAN PROPOSE NEW SET PROPOSAL
FOR SUBTYPING OF ENDOMETRIOSIS
AND FINALLY THERE'S VALUE IN
LOOKING AT THIS VERY GRANULAR
TEMPORAL VARIATIONS BECAUSE IT
ALSO INFORMS WHAT'S HAPPENING
WITH ENDOMEET RIOSEIS SO WE
CREATED A PROJECT CALLED
CITIZEN-ENDO, THAT ARE PATIENTS
WITH LIVED EXPERIENCES IN
ENDOMETRIOSIS AND AT THE SAME
TIME KNOWLEDGE OF THE CONDITION
AND SECOND BUILT TO SUPPORT THEM
SO WE HAVE A COMMUNITY OF ABOUT
19,000 PATIENTS, 9000 IN THE
U.S., WE WORK ACROSS MULTIPLE
LANGUAGES AND IT'S AN EXTREMELY
REWARDING TYPE OF ACTIVITY AND 1
OF THEM IS TO PARTNER WITH
PATIENTS IN DETERMINING WHICH
QUESTIONS WE'RE ASKING ABOUT
ENDOMIGHT REOSEIS, DECIDING HOW
IT GETS COLLECTED AND
INTERESTED, AND IN ORDINANCE
NUMBER TORE ENGAGE WITH OUR
COMMUNITY WE DO A LOT ADVOCACY
AND DATA MANAGEMENT.
WE DID A LOT OF INTEREST IN HOW
DO YOU DESIGN THAT ASKS PATIENTS
WHAT IS HAPPENING WITH THEIR
DISEASE WHEN IN THE LITERATURE
THERE'S NOT A LOT ABOUT
DAY-TO-DAY DESCRIPTIONS ABOUT
EBD -- EPPED O MEET RIOSEIS, AD
THIS IS AN EXAMPLE WHEN WE HAD
10,000 PARTICIPANTS WE STARTED
CREATING A MAN OF PAIN AND I
HOPE THAT SHES YOU IF ANYTHING
THE SYSTEM ASPECT FROM THE PAIN
LEVEL OF THIS DISEASE.
THERE'S ALSO AND ALSO TEMPORAL
VALID AND RELIABLEINATION, THIS
IS WEEK BY WEEK, THIS IS THIS
CHANGE IN HOW BAD THEY'RE GOING
AND WHEN WE USE AI TO GO AND
RATHER THAN JUST A THING, WE
ALSO SEE THAT PATIENTS HAVE
DRASTIC WEEK BY WEEK CHANGES IN
HEALTH TRAJECTORIES SO THIS IS
ACROSS 50 WEEKS IN SO IT'S A LOT
OF TIME NEARLY A YEAR BUT THESE
ARE INDIVIDUAL PATIENT
TRAJECTORIES AND THE PATIENT
CODE SUGGEST HOW ABOUT BAD OR
WELL THEY'RE DOING THAT WORK
ACCORDING TO AI SUMMARY METRIC
AND AT 1 POINT ABOUT
ENDOMETRIOSIS, IS THAT THINGS
ARE OKAY OUT OF PERIOD AND
THINGS ARE REALLY BAD DURING
PERIOD BUT THAT'S NOT WHAT THE
DATA IS TELLING US AND HOW BAD
OR GOOD OR A WEEK IS FOR A PAT.
SO I SHOWED YOU NEW DATA TYPE
AND GIVING US NEW INSIGHTS, BUT
WE ALSO AND I THINK THAT'S
IMPORTANT FUND FOR WOMEN'S
HEALTH IS THAT YES IS SOMETHING
WE CAN USE IN PARTICULAR
OBSERVATIONAL HELT DATA SO I
WANT TO GIVE A FANTASTIC
OVERVIEW OF ALL THE THINGS WE
HAVE IN OUR RESEARCH BUT THE 1
OF DEFINITION IS PROBLEMATIC AND
PARTICULARLY PROBLEMATIC IN
WOMEN'S HEALTH, SO WHO HAS
ENDOMETRIOSIS, PHENOTYPE
DEFINITION, DEPENDING ON HOW WE
DO SO BASED ON WHICH
GUIDELININGS WE PAY ATTENTION
TO, WE WILL FIND VERY DIFFERENT
TYPES OF PATIENTS AND SO THIS
PAPER, DESCRIBES WHEN WE USE
LAPROSCOPIC SURGERY, PATHOLOGY
AS THE GOLD STANDARD OR WHETHER
WE USE THE MORE RECENT
GUIDELINES THAT ARE SYMPTOMS
BASED TO IDENTIFY WHO ARE
PATIENTS WITH ENDOMETRIOSIS AND
YOU WILL SEE HERE IN THIS
DIAGRAM, IT'S NOT A SUBSET, IT'S
REALLY DIFFERENT COHORTS OF
PEOPLE WE ARE CAPTURE WILL.
NEVERTHELESS, AND THANKS TO A
LOT OF COMMON DATA MODELS AND
AND MANY DIFFERENT PARTNERS IN
THIS LARGE DATA NETWORKS WE'RE
ABLE TO GATHER NEW INSIGHTS
ABOUT ENDOMETRIOSIS AND MORE
IMPORTANTLY REAL WORLD INSIGHT
SO HERE'S THERE'S' COMPARISON OF
2 BHILLION ENDOMETRIOSIS
PATIENTS AND IDENTIFY THE
DEFINITION AND COMPARE THEM TO
EVERY WOMEN WE CAN HAVE OUR
HANDS ON IN REPRODUCTIVE AGE.
SO ABOUT 188 MILLION WOMEN.
AND WE SEE VERY CLEAR PATTERNS,
MAYBE NOT THE 1S THAT WE THINK
OF WHEN WE LOOK AT GUIDELINES
BUT THESE ARE THE REAL PATTERNS
OF DOCUMENTATION OF CARE OF
ENDOMEET REOSEIS PATIENTS AND
NONENDOMEET REOSEIS PATIENTS,
AND I WANT TO TALK ABOUT THE
QUESTION OF EARLY DETECTION IS
SIGNIFICANT IN ENDOMETRIOSIS,
AND THERE'S SIGNIFY 6 YEAR
LAGGING DIAGNOSIS SO HERE WE
ASKING THE QUESTION OF USING
HEALTH RECORD DATA OR CLAIMS
DATA CAN WE GO BACK IN TIME AND
SEE COULD WE HAVE IDENTIFIED THE
PEOPLE WITH ENDOMETRIOSIS AND
I'M SHOWING YOU HERE THE
PERFORMANCE IS AURP, SO IT'S A
PRECISION RECALL CURVE FOR
DIFFERENT CLASSIFIERS OF THE
SAME PATIENTS BUT GOING BACK IN
TIME AND ASKING COULD WE HAVE
GUESSED WHO HAD ENDOMITTRYOSE IN
HERE AND THE RESULTS ARE VERY
PROMISING WHERE EVEN 2.5 YEARS
IN ADVANCE WE COULD HAVE GUESSED
THE 71.9 AUPRC WHO HAD
ENDOMETRIOSIS SO WITH THE HELP
WITH THE WOMEN'S HELT AND
PARTNERSHIP WITH THE NEW YORK
PRESCRIBING BI TERRION HOSPITAL,
WE ARE TESTING THIS -- THE NEXT
PHASE WHICH IS ONCE YOU HAVE AN
ALGORITHM LIKE DR. MOORE
MENTIONED MOW DO WE GO BACK
MAKING IT HAPPEN IN PRACTICE.
SO WE ARE SETTING UP AN
INTERVENTION WHERE WHEN A WOMAN
WHO DID NOT HAVE A DIAGNOSIS OF
ENDOMETRIOSIS COME TO THE
EMERGENCY DEPARTMENT.
IN OUR DATA ANALYSIS WOMEN WITH
ENDOHAVE 3 TIMES OFERATE OF ED
VISIT THAN NONENDO PATIENTS AND
THEY COMPLAIN OF ABDOMINAL PAIN
OR PELVIC PAIN, THERE'S AN AI
MODTHEY'LL DOES AN OPPORTUNISTIC
MODELS THAT LOOKS BACK AT LONG
NUDEINAL EHR DATA AND STAYS, YOU
KNOW MAYBE THERE'S SOMETHING
THAT NEEDS TO BE LOOKED AT HERE,
IT'S NOT A DIAGNOSIS MODEL, IT'S
REALLY A REFERRAL MODEL AND THE
GOAL HERE IS TO BRING THE
PATIENT TO THE RIGHT CLINICIANS
SO THEY CAN INVESTIGATE FURTHER
WHETHER THEY HAVE ENDOMETRIOSIS
OR NOT.
BECAUSE WE KNOW OF OUR WORK ON
THE MORE BETTER HEALTH THAT
PATIENTS LIKE KNOWING AND BEING
PREPARED WHEN THEY GO SEE THEIR
DOCTORS WHAT THEIR PATTERNS OF
DISEASE ARE, WE SEND THEM A
REFERRAL FOR THE FENDO APP.
WHEN IT COMES TO COMPLEX
SELF-MANAGE NLT, I WANT TO
MENTION WORK THAT'S REALLY ABOUT
THE FACT THAT WE NEED TO CO
DESIGN AI SOLUTIONS WITH
PATIENTS AND PROVIDERS AND
THAT'S REALLY THE PART ABOUT
HUMAN CENTERED AI, SO I'M GIVING
HERE SOME OF THE COMPONENTS OF
HUMAN CENTERED AI, THE FIRST 1
IS DO PATIENTS EVEN WANT TO HAVE
INDIVIDUALS SUPPORT FROM AN AI
TECHNOLOGY, WE KNOW THAT MANY
PEOPLE ARE WORRIED ABOUT AI, AND
I THINK IN THE CASE AGAIN OF
STIGMATIZED CONDITION, ACTUALLY
THE OUTLOOK IS POSITIVE AND WE
HEAR THINGS LIKE AI CAN HEAR ME
BETTER THAN MY DOCTOR OR SHOWING
MY DATA GIVES ME A VOICE.
BUT THERE ARE PRINCIPLES WE NEED
TO BE CAREFUL ABOUT, SO, WE IN
THESE PAPERS WE LOOK INTO HUMAN
CONTROLS, WHEN WE WANT TO BUILD
TOOLS THAT GO AWAY FROM
ALGORITHM SUGGESTIONS BUT RATHER
HAVE INTERACTIONS WITH PATIENTS
TO LET THEM DECIDE AND EXPLORE
WHICH RECOMMENDATIONS MAKE THE
BEST SENSE FOR THEM, PRIVACY I
MENTIONED ALREADY, TRUST IN THE
ALGORITHMS BUT ALSO TRUST IN WHO
DESIGNS THE ALGORITHMS ARE
EXTREMELY HIGH CONCERNS FOR
PATIENTS.
AND FINALLY, INTEREST IN SAFETY,
I THINK HERE IS THERE'S AN
OPPORTUNITY FOR AI LITERACY
WHERE PATIENTS JUST ASSUME AI IS
SMARTER THAN IT CURRENTLY IS AND
IT THEY JUST ASSUME IF THERE'S A
RECOMMENDATION, IT WILL BE SAFE
AND I DON'T THINK THAT'S A GIVEN
RIGHT NOW OUR AI TECHNOLOGY AND
THAT'S SOMETHING ARE US AI
RESEARCHERS TO PAY ATTENTION TO.
SO AGAIN, THAT'S REALLY THE
ROADMAP IN VERY GENERAL FASHION,
BUT AI TECHNIQUES THAT ACCOUNT
FOR DIAGNOSIS AND HUMAN CENTERED
APPROACHES AND MOST IMPORTANTLY
TEAM SCIENCE.
I WANT TO THANK THE PEOPLE WHO
ARE WORKING ON THIS
ENDOMETRIOSIS WITH ME, AND ALSO
THE PATIENTS PARTICIPATING IN
OUR RESEARCH.
THANK YOU.
>> THANK YOU DR. ELHADAD, FOR A
PRESENTATION THAT'S UNDERSTUDIED
AND THE ROLE OF AI IN ENGAGEMENT
OF MULTIPLE NATIONS SO I LOOK
FORWARD TO THE DISCUSSION.
THE THIRD PRESENTATION WILL BE
PRESENTED BY D
R. KJIERSTEN FAGNAN, I HOPE
THAT I PRONOUNCE THAD CORRECTLY.
DR. FAGNAN JOINED THE DEPARTMENT
OF ENERGY JOINT GENOME INSTITUTE
IN 2012 AS A NATIONAL ENERGY
RESEARCH SCIENTIFIC BIOCOMPUTING
INFORMATICS COMPUTING
CONSULTANT.
AFTER COMPLETING A PEDASCALE AT
USC, AND THE NATIONAL LAB
CONVERTING DIVISION.
AS A POST DOC HER RESEARCH
FOCUSES ON STABLE AND ACCURATE
COMPUTATIONAL METHODS FOR
REACTING SUBSURFACE FLOWS AND
EVOLVE INTO SCALABLE METHODS FOR
SCIENTIFIC DATA ANALYSIS.
IN 2014, DR. FAGNAN BECAME THE
ENGAGEMENT LEAD FOR JGI, THE
JOINT GENOME INSTITUTE, WITH A
FOCUS ON ADAPTING JGI WORK LOADS
TO RUN ON SUPER COMPUTING
HARDWARE AND WORK CLOSELY WITH
STAFF TO UNDERSTAND THE DATA
INTENSIVE NATURE OF JGI WORK
FLOWS.
DR. FAGNAN WAS ASHES POINTED
CHIEF INFORMATICS OFFICER OF JGI
IN 2016 AND THEN HEAD OF DATA
SCIENCE AND INFORMATICS
DEPARTMENT IN 2018.
ALSO IN 2018, DR. FAGNAN WAS
PART OF THE NOBEL PRIZE WINNING
TEAM, WOW COMGRATTULATIONSA THE
SUPER COMPUTING CONFERENCE.
SC18 MET BY RESEARCHERS AT OAK
RIDGE NATIONAL LABORATORY,
DR. FAGNAN HAS BEEN THE
DISTINGUISHED SPEAKER AT IBM
RESEARCH IN ABUDAN WHERE SHE
PRESENTED WORK FOR DISTRIBUTED
DATA IS AND WORK FLOW
MANAGEMENT.
SHE IS CURRENTLY LEADING A
BIOECHO DATA INTEGRATION EFFORT
TO DEVELOP A GLOBAL SEARCH FOR 5
DOE FUNDED RESOURCES.
THANK YOU I AM SO LOOKING
FORWARD TO YOUR PRESENTATION
MUCH THE MIC IS YOURS.
>> THANK YOU, AND IT'S A LITTLE
TRICKY TO LISTEN TO YOUR OWN
BIO, AND THANK YOU FOR THE
INVITATION.
I WILL PRESENT SOMETHING THAT'S
A LITTLE BIT DIFFERENT BUT I WAS
REALLY BLOWN AWAY BY THE LAST
TALK AND THINKING ABOUT WOMEN'S
HEALTH AND DATA IS NOT ALWAYS
SOMETHING WE GET TO FOCUS ON IN
THE DEPARTMENT OF ENERGY SO I
THINK YOU CAN SEE MY ENTIRE
SCREEN?
AND HOPEFULLY THIS SLIDES AND I
WILL GO UNTIL SOMEONE SAYS THEY
CAN'T.
SO I LINGS BIT OF BACKGROUNDOT
JOINT GENOME INSTITUTE AND HOW I
WANT TO GET INTO THIS TALK, WE
ARE AT LAWRENCE BURKELY NATIONAL
LABORATORY AND WE'RE A FACILITY
FUNDED BY THE DEPARTMENT OF
ENERGY AND OFFICE OF
ENVIRONMENTAL RESEARCH, WE
STARTED AS PART OF HUMAN GENOME
PROJECT AND GOT TO PIVOT TO
SEQUENCING ALL SORTS OF
ORGANISMS WITH BIOENERGY
RELEVANCE AND NONE OF THOSE
ORGANISM VS ANY EXPECTATION OF
PRIVACY SO OUR COMPUTING AND
DATA MANAGEMENT NEEDS HAVE BEEN
HISTORICALLY DIFFERENT, ABOUT
YOU WE HAVE ALMOST 300 STAFF AND
WE GET BETWEEN 80 AND 90 PIL
QULN DOLLARS IN FUNDING PER YEAR
TO PRODUS A TON OF DATA FOR THE
FOLK WHO IS PROVIDE SAMPLES TO
US AS WELL AS MAKING DATA
AVAILABLE TO OUR PRETTY LARGE
DATA USER COMMUNITY.
WE KNOW OUR DATA HAS BEEN
INCREDIBLY USEFUL, SOMETHING I
LOVE TO UNDERSTAND AND EXPLORE
IS HOW SOMETHING THAT WAS
SEQUENCED 10 OR 15 YEARS AGO
MIGHT HAVE APPLICATIONS IN
COMPLETELY DEFINITE FIELDS, SO
WE HAVE A REALLY GREAT IMPACT
ANALYST WHO'S TAKEN A BUNCH OF
OUR DATA AND LIVED ACROSS
PUBLICATIONS FOR REUSE AND WE
HAVE'VE GOT MORE THAN 29,000
STUDIES THAT HAVE LEVERAGED AI
DATA SO EVEN THOUGH WE'RE DOING
SEQUENCING OF ORGANISMS RELEVANT
FOR BIOENERGY AND BIOPRODUCT
DEVELOPMENT, THERE ARE
APPLICATIONS THAT GO ACROSS THE
SCIENCES AND 1 OF MY FIRST
EXAMPLES WAS THERE WAS ACTUALLY
A SET OF JGI MICROBES THAT GOT
USED IN AN ANALYSIS OF 6000
YEAR-OLD CHEWING GUM WHICH IS
KIND OF WILD AND CRAZY AND 1 OF
THE MICROBES THAT'S ABLE TO
SECRETE MANAGE NETS WAS ALSO
USED IN THERAPY TO TARGET CANCER
CELLS.
AND THIS JUST SHOWS THE POWER OF
NOD ONLY GENERATING HIGH QUALITY
DATA AND HIGH QUALITY REFERENCE
INFORMATION ABOUT A VARIETY OF
DIFFERENT ORGANISMS BUT ALSO
MAKING THAT DATA AVAILABLE FOR
FOLKS TO REUSE.
SO THERE'S BEEN, I'M SURE
EVERYONE HERE IS FAMILIAR WITH
THE DATA HUNGRY ALGORITHMS THAT
ARE CALLING ATTENTION TO AI
RESEARCH AND DIFFERENT POSSIBLE
SCIENTIFIC BREAKTHROUGHS.
SO YOU HAVE ALPHA FOLDS WHICH
WAS REALLY ONLY MADE POSSIBLE
BECAUSE HAVE YOU THE PROTEIN
DATA BANK AND THEN HAVE YOU THE
EVO AND EVO 2 WHICH HAVE
ACCEPTED UP ALL OF THEYQUENCE
DATA THEY CAN FIND TO BUILD A
FOUNDATION MODEL BUILT ON DNA
AND THEN WE HAVE OF COURSE THE
NLMs OR GENERATIVE AI MODELS
THAT ARE HELPING FOAMS DO
EVERYTHING FROM WRITE CODE TO
E-MAIL TO CREATING CRAZY IMAGES
THAT STILL DON'T LOOK QUITE
RIGHT TO ME, ANYWAY, BUT THESE
ALGORITHMS REQUIRE A LOT OF
DATA, A LOT OF CURATED DATA AND
A LOT OF STRUCTURE IF WE'RE
GOING TO ACTUALLY GET TO A POINT
WHERE WE TRUST THE INFORMATION
THAT COMES OUT OF THAT, WHICH
WAS MENTIONED IN THE PREVIOUS
TALK.
I HAPPEN TO SEE THIS QUOTE WHICH
I WAS WALKING THROUGH THIS
BUILDING AND IT REALLY RESONATED
WITH ME KIND OF WHAT WE'RE
DEALING WITH.
SO IN THE STATE OF OUR DATA
SYSTEMS, WE ARE DROWNING
INFORMATIONALLY, STARVING PER
WISDOM, WE HAVE SO MUCH DATA
FLOATING AROUND IN DIFFERENT
SOURCES, THERE ARE MORE THAN
3000 DIFFERENT DISTINCT
BIOLOGICAL DATA RESOURCES THAT
EXIST.
AND THAT NUMBER IS PROBABLY
GROWING OR FLUCTUATING, AND
THERE ARE SOME THAT ARE BUILT BY
STUDENTS THAT LEAVE THE LAB BUT
IT DOESN'T CHANGE THE FACT THAT
IT'S EASY TO CREATE A DATA
PORTAL, AND EASY TO POST DATA UP
ON THE INTERNET, WHAT'S
CHALLENGING IS MAKING IT
ACCESSIBLE.
AND THE CONCEPT OF PEOPLE BEING
ABLE TO PUT TOGETHER THE RIGHT
INFORMATION AT THE RIGHT TIME
AND TO THINK CRITICALLY ABOUT
IT, I THINK, THAT'S WHAT WE WANT
TO ENABLE FOR OUR SCIENTIFIC
COMMUNITIES, AT A USER FACILITY,
THIS IS PART OF OUR MISSION,
LIKE, HOW DO WE CREATE THE
SYSTEMS AND LET FOLKS DISCOVER
AND WORK WITH AND UNDERSTAND
DATA SO THAT THEY CAN THINK
CRITICALLY ABOUT IT AND ADVANCE
SCIENCE.
I JUST WAS SO SURPRISED THAT
I'VE BEEN IN THIS BUILDING FOR A
FEW YEARS AND THIS IS THE FIRST
TIME I STOPPED AND NOTICED AND
READ THE QUOTE.
IT FELT REALLY RELEVANT.
-- RESEARCH AND SO THERE ARE A
LOT OF ACRONYMS ON THE SLIDE
THAT I WILL JUST HIGHLIGHT, THE
JOINT GENOME INSTITUTE, THE
ADVANCES OF MOLECULAR SCIENCES
LABORATORY, THESE ARE 2 USER
FACILITIES THAT GENERATE
MULTIOMICS DATA TYPES AND ALSO
PRODUCES A LOT OF IMAGING DATA
AND THEN WE HAVE THE DAILY
SYSTEMS KNOWLEDGE BASE AND NMDC
AND AN EFFORT TO STANDARDIZE
MICROBIOME DATA, WHICH THEY'VE
DONE A REALLY AMAZING JOB
CREATING A NEW COMP REHAPPENSIVE
DATA MODEL THAT LINKS
ENVIRONMENT INFORMATION THAT
LINKS TO GENOMIC AND MULTIOMIC
WHICH IS REALLY USEFUL DEPENDING
ON THE HYPOTHESIS SOMEBODY MIGHT
WANT TO EXPLORE AND THEN ESI IS
A DIFFERENT FOR COMPLEX
MEASUREMENTS SO WHAT WE'RE
TRYING TO DO IS ADDRESS A
PINPOINT FOR A COMMUNITY WHERE
YOU CAN'T NECESSARILY FIND THE
DATA ACROSS THESE SYSTEMS FROM 1
PLACE.
IT'S SIMILAR IN SPIRIT TO THE
3000 DIFFERENT DATA RESOURCES,
EXCEPT THESE 5 RESOURCES ARE ALL
FUNDED BY THE SAME ENTITY AND IN
PRINCIPLE WE SHOULD BE ABLE TO
TACKLE THIS PROBLEM.
IT'S NOT, YOU KNOW, IT'S A VERY
NATURAL DEVELOPMENT, THERE ARE A
LOT OF SOCIOLOGICAL LOGICAL LAWS
THAT DESCRIBE HOW INFRANCIS
COLLINS SPHRUCTURE GETS
DEVELOPED ACROSS OR WITHIN AN
ORGANIZATION AND ALIGNS TO THE
ORG CHART, AND SO IF I WANT TO
USE DATA I HAVE TO SEND A
DIFFERENT QUERY TO EACH OF THESE
RESOURCES AND THEN I WILL GET
BACK SOMETHING IN A COMPLETELY
DIFFERENT STRUCTURE, SO, IT'S
ALL GOING TO BE DIFFERENT, THE
MODEL LIKE THE UNDERLYING SCHEME
AUSHED LYING DATA
REPRESENTATION, WHICH I'M
REPRESENTING WITH THESE AT THE
TIME RISK ASSESSMENTS PLOOKS
WILL BE DIFFERENT EVEN IF I'M
CLEARING, FOR THE SAME TYPES OF
INFORMATION.
SO IT COULD BE CLEARING ACROSS
THESE DIFFERENT RESOURCES BUT I
WILL STILL GET BACK A DIFFERENT
DATA STRUCTURE.
AND THEN, YOU KNOW THE WORK, THE
INTEGRATION WORK THAT IS A
SCIENTIST NEEDS TO DO IS VERY
TIME CONSUMING, HOW DO I PUT
THESE BLOCKS TOGETHER, IN A WAY
THAT LEADS TO SOMETHING USEFUL
FOR THE QUESTION I HAVE, HOW
DOES IT HELP ME UNDERSTAND THE
GAPS IN THE DATA OR WHERE THINGS
ARE MISALIGNED AND THAT'S
REALLY, HOPEFULLY, THIS IS
REALLY THE WORK, THE SCIENTIFIC
WORK THAT'S BEEN DONE.
SO THEY'RE COMBINING THAT DATA,
TO GET THERE TO ADDRESS THEIR
HYPOTHESIS AND SO OUR INITIAL
GOAL WAS TO START WITH A COMMON
SEARCH ENTRY POINT THROUGH
ACCESSING DATA ACROSS ALL OF
THESE RESOURCES.
SO THEY CAN SUBMIT THE SAME
QUERY, AND GET INFORMATION BACK,
THE INFORMATION IS STILL GOING
TO BE IN THOSE DIFFERENT SHAPED
CONTROLLER OF BANKS BUT THIS IS
STILL HELPFUL FOR AT LEAST
KNOWING AND DISCOVERING WHAT
DATA IS AVAILABLE.
WE'VE DONE USER RESEARCH AND
THIS WAS AS A MENTIONED IN THE
PREVIOUS TALK, I THINK THIS IS
ABSOLUTELY CRITICAL WHEN YOU ARE
BUILDING INFRASTRUCTURE OR
BUILDING AERER SOURCE FOR THE
SCIENTIFIC COMMUNITY IS THAT YOU
PUT THE FOLK WHAT'S ARE GOING TO
USE IT AT THE HEART OF YOUR
PLAN.
SO THIS IS A REPRESENTATION ON
THE RIGHT HERE OF THE DATA LIFE
PSYCHE AND HE WILL DIFFERENT
ASSPECS THAT WEB CONNECTED AS A
USER FACILITY NEED TO KEEP IN
MIND TR MAKING SURE THE DATA IS
HIGHLY USE BELIEVABLE, NOT JUST
TO THE PERSON PROVIDING THE
SAMPLE BUT TO OTHER MEMBERS OF
THE SCIENTIFIC COMMUNITY AND WE
NOTICED A FEW DIFFERENT TRENDS,
WHEN WE SPOKE WITH THE USER
COMMUNITY ABOUT WHAT THEY WERE
DOING WITH THEIR DATA AND 1 IS
THAT THEY ARE GENERATING MORE
DATA, AND SPENDING INCREASING
RESOURCES ON DATA MANAGEMENT AND
BUILDING THEIR OWN
INFRASTRUCTURE, SO IN THE FUTURE
THAT 300 MIGHT GO TO 4000, 5000
IF WE'RE NOT -- YOU ACTUALLY
DON'T KNOW WHAT THE MAXIMUM
NUMBER MIGHT BE BUT THIS NUMBER
OF DISCONNECTED DATA RESOURCES
IS NOT SLOWING DOWN.
IT'S NOT, THERE'S NO COALESCE
ENSEL, IT'S VERY EASY THAT YOU
HAVE A NEW DATA RESOURCE
AVAILABLE, OR HAVE A RESULT
THAT'S NEW DATA PORTAL, AND IT
TAKES RESOURCES TO BUILD IT BUT
THEN IT TAIBS EVEN MORE
RESOURCES TO MAINTAIN IT, SO
THEY'RE RESOURCING IT BUT THEN
OVER TIME THIS IS GOING TO GROW.
SO THEY'RE PAYING FOR SOFTWARE,
SOFTWARE DEVELOP AM, ALLOCATING
UP TO 10% OF GRANTS TO COVER
STAFF THAT ARE JUST ENGAGED IN
THESE DATA MANAGEMENT
ACTIVITIES.
AND THEY ARE A COUPLE DIFFERENT
REASONS FOR THIS, SOMETIMES THE
DAILY BASIS THEA ITSELF DOESN'T
HAVE ANOTHER HOME, SO FOR
PROTEIN STRUCTURES, YOU HAVE
PBB, FOR MASS SPEC., YOU MIGHT
USE MASSIVE, FOR PROTEOMICS,
HAVE YOU PRIDE, ASSUMING PEOPLE
KNOW THAT'S REPOSITORIES EXIST,
AND 1 FORT BEST RESOURCES FOR US
AS BEEN THE SEQUENCE READ
ARCHIVE RUN BY NIH, THE NATIONAL
LIBRARY OF MEDICINE, FECS HERE
ARE PROBABLY FAMILIAR WITH IT
AND A LONG TIME AGO EVERYBODY
GOT TOGETHER AND DECIDED THAT
WAS THE POLICE FOR SEQUENCE DATA
TO LAND AND IT WOULD HAVE THE
IDENTIFIERS PEOPLED NEEDED TO
FIND THAT DATA AGAIN AND IT
SEARCHES THIS AMAZING RESOURCE
FOR THE COMMUNITY.
ABOUT YOU WHEN YOU HAVE
SOMETHING THAT LEVERAGES
SEQUENCE DATA BUT THEN BUILDS ON
TOP OF IT, IF YOU HAVE YOU KNOW
YOUR OWN ANNOTATIONS OR YOUR OWN
ASSEMBLIES OR YOUR OWN
METAGENOMIC BINS, THERE ISN'T A
NATIONAL REPOSITORY FOR THOSE
DATA ENTITIES, SO FOLKS ARE
RESPONDING BECAUSE THEY WANT TO
MAKE THAT DATA AVAILABLE BUT
THEY'RE BUILDING THEIR OWN, AND
WELL IS A HUGE WAY FOR FOLKS TO
AUTOMATE.
NO 1 LIKES TO DO THE BOOK
KEEPING, IT'S COMPLEX,
LEVERAGING A MET DATA STANDARD,
IT'S VERY TIME CONSUMING AND NOT
SOMETHING THAT NECESSARILY HELPS
WITH YOUR SCIENTIFIC
EXPLORATION, BUT IT HELPS
SOMEBODY ELSE USE YOUR DATA AND
SO THERE'S A BIT OF AN INCENTIVE
TO MISS MATCH THERE AND IT'S A
PRETTY TEDIOUS PROCESS AND I
ALREADY TO THIS, THERE ARE GAPS
IN THE PREPOSITORY
INFRASTRUCTURE, SO WHAT WE'RE
BUILDING RIGHT NOW IS SOMETHING
TO HELP US SEARCH, IT'S MORE OF
A HARMONIZATION EFFORT THAN A
DATA INTEGRATION EFFORT.
BUILDING THIS SEARCH TOOLING,
HELPS US ACROSS OUR MODEL.
AND THE CORE ISSUE THAT FOLKS
ARE RUNNING INTO WITH METADATA
RESUES ARE METADAILY BASIS THEA,
THEY'RE NOT HARMONIZED AND
THINGS ARE DIFFERENT CROSS
SYSTEMS AND WITHOUT THIS DATA
HARMONIZATION EFFORT, THINGS
WILL CONTINUE TO BE ISOLATED AND
NOT INGRATABLE AND THAT LIMITS
OUR ABILITY TO USE THOSE DATA
HUNGRY ALGORITHMS OR TO BUILD
NIEW MODELS THAT ACTUALLY
LEVERAGE OUR SCIENTIFIC DATA.
SO AS PART OF OUR EFFORT WE
CREATED THIS FOUNDATIONAL SHARED
DATA MODEL, WE LOOKED ACROSS ALL
5 OF OUR RESOURCES AND WE FOUND
VERY FEW TERMS IN COMMON, THINGS
WERE COMMON THOUGH, SO WE USED
THOSE TO BUILD A MAP TO SHOW TO
OUR COMMUNITY ACTUALLY IF
THEY'RE INTERESTED IN NOT JUST
GENOMICS DATA FROM THE JGI, BUT
THEY'RE INTERESTED IN SAMPLES
THAT HAVE MULTIOMICS
MEASUREMENTS, OUR PARTNER VS
TAKEN A LOT OF THOSE
MEASUREMENTS AND IF THEY'RE
INTERESTED IN NOT ONLY
MULTIOMICS DATA BUT ALSO,
GEOCHEMICAL SENSORS OR OTHER
MEASUREMENTS THAT WE HAVE THAT
DATA AS WELL AND SO THIS WAS AN
XERICIZE TO REALLY SHOW THAT WE
COULD BUILD THESE CONNECTIONS,
WE COULD BUILD THE SHARED
UNDERSTANDING OF WHAT EXISTS AND
THERE'S PROGRESS ON OUR INITIAL
SEARCH PROJECT CREATED THIS
GRAPHICAL ENTRY POINT TO THE
DATA AND THEN WE DO HAVE A
VERSION 0 OF THE API THAT WE
BUILD TOGETHER.
AND SO THESE COMPLEX RESPONSES
WE GET BACK ARE STILL MEANS THAT
A USER HAS TO SPEND TIME
HARMONIZING THAT INFORMATION AND
INTEGRATING IT THEMSELVES, BUT
WE'RE KREASESSING THAT FIRST
STEP IN FIGURING OUT HOW DO THAT
TOGETHER.
AND THIS IS IMPORTANT, WE'RE
THINKING ABOUT THE FUTURE OF
BEING ABLE TO USE LARGE LANGUAGE
MODELS AND AI AGENTS.
I THINK THOSE ARE EVERYWHERE.
RIGHT NOW YOU CAN COMBINE DATA
FROM DIFFERENT SOURCES THROUGH
THE APIs THAT ARE MADE
AVAILABLE BUT YOU HAVE TO BUILD
THE KIND OF STRUCTURE THAT SO
THAT YOU KEEP A HUMAN IN THE
LOOP TO ERROR-CORRECT.
AND SO, YOU KNOW, THIS IS JUST A
HIGH LEVEL, SORT OF AN AGENT
MIGHT DECIDE THIS IS THE
IDEALIZED WAY TO PUT THE TETRIS
PLOKS TOGETHER, BUT MAYBE THE
OWNER WANTED SOMETHING DIFFERENT
BECAUSE MAYBE IT MAKES SENSE FOR
THE PURPLE TO ALIEB TO THE BLUE
OR WHATEVER, IT'S A MENTAL MODEL
BUT WITH A HUMAN WORKING WITH
THE AGENT WHO CAN CONSTRUCK
THESE MODELS TOGETHER AND CAN --
THE QUESTION BECOMES CAN WE
ACTUALLY REDUCE THAT TIME TO A
USER TO UNDERSTAND AND STRUCTURE
THE RIGHT DATA MODELS TO ADDRESS
THE QUESTION OF INTEREST?
AND THIS IS THE INFRASTRUCTURE
THAT WE'RE PUTTING IN PLACE
ACROSS OUR 5 RESOURCES TO ENABLE
THIS.
SO THIS A COMPLEX DEC, IF THERE
ARE QUESTIONS I AM HAPPY TO TALK
ABOUT IT, BUT KEY IDEA IS THAT
WE'RE TAKING THIS FAIR SEARCH
WE'RE BUILDING AND WE'RE
BUILDING TO CROSS RESOURCE DATA
MODEL CATALOG, SO THROUGH THAT
ENTRY POINT HAVE YOU AWARENESS
OF WHAT EXISTS ACROSS THESE
DIFFERENT B. E. R. RESOURCES,
BUT THESE DIFFERENT BRE
RESOURCES DON'T HAVE TO ONLY
SUPPORT THIS CATALOG, SO YOU CAN
MAKE TAIN THESE SPECIFIC PROJECT
SCHEMAS, YOU CAN MAINTAIN THE
HISTORY, CAN YOU MAINTAIN THE
SILOS IF YOU WOULD LIKE TO, AND
THE WAY YOU DO THE HARMONIZATION
IS THROUGH THE CROSS RESOURCE
DATA MODEL CATALOG, SO WE BUILD
THE SHARED MODEL TOGETHER, IT
HAS AN UNDERSTANDING OF NOT ONLY
WHAT EXISTS IN THESE DIFFERENT
RESOURCES BUT ALSO THESE ORANGE
DASH LINES THAT SHOW THE
CONNECTIONS ACROSS THEM, SO THE
CANONICLE MODEL THOSE SHOWING
LONG, AND WOULD BE CAPTURED IN
THIS CATALOG AND THE REASON IT
IS BENEFICIAL IS BECAUSE WE CAN
TAKE OUR HANDFUL OF PORTALS, WE
ARE PART OF THE PROBLEM, WE HAVE
3000 BUT THEY PROVIDED VALUE TO
THE COMMUNITY OVER DECADE
SPECIALIZATION OF SPECIFIC
ENDOTHELIAL WE DON'T WANT THOSE
TO GO AWAY WHILE WE TRY TO MAKE
OUR DATA MORE AVAILABLE TO AI
AGENTS.
SO WHAT WE'VE DONE AND WHAT
WE'RE WORKING ON OUR FIRST 1
THAT RUNS, OUR PORTALS THAT RUN
AGAINST DATABASES NOW CAN SUBMIT
THE SAME INQUIRIES TO THE SAME
STRUCTURE AS AN AI AGENT WOULD
OR AS A USER WORKING THROUGH THE
DAILY BASIS THEA THROUGH JUPITER
NOTEBOOK, SO EVERYTHING IS
COMING THROUGH THE SAME CHANNELS
WHICH MEANS THAT WE HAVE
COLLABBATED AND CONSOLIDATED TO
THE ENTRY DATA.
SO EVERYONE CAN HAVE ACCESS TO
THE DAILY BASIS THEA -- DATA IN
THE SAME PLACE EVEN IF IT'S NOT
CO LOCATED OVER TIME.
SOPHISTICATEDY WE'RE HOPING OVER
TIME, EVERYBODY GENERATING DATA
AND PROVIDING NEW MODELS IS
INTEGRATING INTO THE SAME
STRUCTURE AND THAT MEANS WE CAN
FOCUS OUR EFFORTS COLLECTIVE
LOAMACYY TO MAKE SURE THE
INFRASTRUCTURE IS ROLELY ROBUST
BUT IT MEETS DIVERSE USE CASES
AND APIs FOR USE WITH HUMANS
BUT THEN WE HAVE ALSO HAVE
TRAINING EXERCISES BECAUSE THE
DEPARTMENT OF ENERGY CAN SHUNT
THAT DATA, AND WE CAN THEN BRING
THE MODEL BACK INTO THE
INFRASTRUCTURE FOR OTHERS TO
USE.
SO THERE'S A LOT GOING ON IN THE
BOXES BUT THE GOAL IS TO SHOW
HOW THE DATA SITS ON THE BOTTOM,
THE WAYS THAT DATA IS
REPRESENTED AND THOUGHT ABOUT AN
ACCESS, SITS ABOVE IT WITH A
VARIETY OF DIFFERENT SCHEMAS,
YOU MAINTAIN A CROSS RESOURCE
DATA MODEL CATALOG AND YOU HAVE
THIS QUERY INFRASTRUCTURE THAT
ACTUALLY SUPPORTS ALL OF THE
USER INTERFACES.
AND THE WAY I LIKE TO THINK
ABOUT THIS RIGHT NOW, MAYBE THIS
IS A GOOD MENTAL MODEL FOR
EVERYONE HERE, BUT WHAT WE'RE
TRYING TO DO IS BUILD A LIBRARY,
SO RIGHT NOW, ALL OF OUR BOOKS
ARE BASICALLY IN PILES ON A
FLOOR OR MAYBE LOCKED IN
SOMEONE'S CLOSET OR DESK DRAWER
AND WHEN YOU LOOK AT IT SOME OF
THE PAGES ARE BLANK OR THEY'RE
MISSING TITLES OR A BUNCH OF
INFORMATION IS GONE, BUT WHAT A
PERSON WOULD HAVE TO DO IN ORDER
TO USE THOSE BOOKS WILL BE TO
SIT DOWN AND BASICALLY READ THEM
ALL, TO FIGURE OUT WHAT'S IN
THEM AND FIGURE OUT IF IT'S
SOMETHING USEFUL.
SO THIS CROSS RESOURCE DATA
CATALOG, YOU CAN THINK OF IT
LIKE WE'RE BUILDING THE DEWY
DECIMAL SYSTEM THAT CAN
REPRESENT DIVERSE ENVIRONMENTS.
AND ONCE WE HAVE THAT IN PLACE,
THEN WE CAN ESTABLISH THE
SHELVING, WE CAN ESTABLISH ORDER
TO THE LIBRARY AND WE CAN TAKE
THE BOOKS AND WE CAN ASSIGN THEM
THE RIGHT CHARACTERISTICS IN THE
RIGHT MODEL AND SHELVE THEM IN
THE RIGHT PLACE SO PEOPLE CAN
ACTUALLY COME TO THE LIBRARY AND
FIND WHAT THEY'RE LOOKING FOR.
SO IF THEY'RE INTERESTED IN
SOMETHING RELATED TO
METAGENOMICS THEY MIGHT WIND UP
ON THE JGI SHELVES BUT THEY WILL
GET THERE 32 THE SHARED CATALOG.
IT WORKS WELL IN MY BRAIN
BECAUSE IT ALSO EMPHASIZES THE
FACT THAT SOME OF THE DATA AND
INFORMATION MIGHT BE MISSING AND
SO RIGHT NOW, PEOPLE NEED TO SIT
DOWN AND FIGURE OUT THE RYE WAYS
TO PUT THINGS TOGETHER AND OVER
TIME IF WE ACTUALLY DO ALIGN ON
THIS SHARED CATALOG, IF WE DO
ALIGN ON A CANONICLE MODEL, AND
WE HAVE ENOUGH PEOPLE DOING THE
SASMYING AND INFORMATION THEN
THAT'S SOMETHING THAT AI COULD
HELP US WITH OVER TIME, WHICH IS
EXCITING.
SO IN SUMMARY TO WHAT WAS SAID
BEFORE, THE TEAM SCIENCE IS
IMPORTANT.
WE CAN'T OVERLOOK THAT.
NO 1 CAN CONQUER MOST OF THESE
SCIENTIFIC CHALLENGES WE HAVE
ALONE.
AND YOU CAN GET TO AN 80 MRS
SOLUTION WITH AI OR WITH YOUR
CURRENT WORK, AND IT'S FINE BUT
THAT FINAL 20%, THE HARDEST 20%
PUTTING THINGS INTO CONTEXT,
DOING THAT,A LONE IS FEELING
REALLY IMPOSSIBLE, BECAUSE IT'S
TOO MUCH WORK, TOO MUCH
FIDUCIARY FOR ANY SINGLE HUMAN
OR ANY SINGLE TEAM.
SO IF WE WORK TOGETHER, THEN WE
WILL BE ABLE TO CREATE THE KIND
OF CRITICAL MASS IN OUR DATA,
CHARACTER EYATION THAT'S NEEDED
SO THAT EAMENTS AND NLMs AND
OTHER LARGE SCALE DATA SCIENCE
TOOLS BECOME REALLY USEFUL FOR
SCIENCE AND I THINK WE REQUIRE
COLLECTIVE INPUT FOR THAT AND
COLLECTIVE INFRASTRUCTURE AND IT
WILL BE A REALLY INTERESTING AND
EXCITING TIME FOR STUDYING AI
TOOLS AND I KNOW IT WAS
INTERESTING AND DIFFERENT BUT
NOW WE CAN CHAT AS A PANEL.
>> THANK YOU VERY MUCH.
>> YEAH.
>> THAT DEFINITELY WAS
INTERESTING AND AS YOU WERE
TALKING ABOUT THE DATA CATALOG,
IF I NEED TO HAVE THE DISCUSSION
SESSION IN REVERSE, WE WILL
START WITH THE DISCUSSION AND
WORK BACKWARD BA BEING TO
DR. MOORE, IF I MAY ASK, WHEN
YOU WERE TALKING ABOUT THESE 5
DATABASES AND THE CATALOG,
COMING IN MY MIND, OH WHAT ABOUT
RAS, AND SINGLE SIGN ON.
AM I THINKING OFFTRACK HERE?
>> OH, AS AN INFRASTRUCTURE
NERD, 1 OF THE THINGS THAT
DRIVES ME CRAZY IS THE THING WE
DON'T HAVE SINGLE SIGN-ON ACROSS
ALL THESE SYSTEMS AND 1 THING I
DIDN'T CALL OUT IN THE
DISCUSSION IS YOU NEED A SET OF
LIBRARIANS NOT ONLY DECIDING
WHAT BOOKS COME INTO THE LIBRARY
AND HOW THEY'RE CURATED BUT ALSO
WHO HAS ACCESS AND WHAT ACCESS
LOOKS LIKE AND WHAT, YOU KNOW
AND MAYBE BECAUSE LIBRARIES ARE
SUCH A HAPPY PLACE WHEN I WAS A
KID BUT I LIKE THIS ANALOGY FOR
THINKING ABOUT OUR DAT BECAUSE
YOU GO THERE AND YOU COULD HANG
OUT WITH THE BOOKS AS MUCH AS
YOU WANTED BUT IF YOU WANTED TO
TAKE 1 HOME WITH YOU THERE WAS A
PROCESS, YOU HAD TO IDENTIFY
YOURSELF, YOU HAVE TO HAVE A
CARD AND WE WERE GOING TO KEEP
TRACK AND IF YOU DIDN'T BRING IT
BACK ON TIME OR IF YOU MESS IT
UP, THERE ARE FINES AND THERE'S
SOME ANALOGUE THERE FOR HOW WE
THINK ABOUT DATAK ASSESSES
CONTROLS AND IT STARTS WITH A
SHARED IDENTITY FOR ANYBODY WHO
WILL INTEREST THE SYSTEM AND
TAKE THINGS OUT OF IT AND THEN I
THINK THERE ARE INTERESTING
QUESTIONS ABOUT HOW MUCH DATA WE
LET FLOW THROUGH UNSECURED
SYSTEMS TOO, AND THEIR FOCUS ON
THE NUCLEOTIDES CLER SIDE OF THE
DEPARTMENT OF ENERGY THAT HAVE
TO THINK ABOUT IT THIS A LOT
MORE THAN WE DO THE OPEN SIDE.
BUT WHENEVER YOU'RE TALKING
ABOUT PATIENT DATA OR HEALTH
DATA, YOU WANT TO MAKE SMUR
THAT'S LOCKED DOWN AND YOU WANT
TO MAKE SURE PEOPLE AREN'T
ACCESSING IT WHEN THEY SHOULDN'T
AND NOW WE HAVE ALL SORTS OF
OTHER COPYRIGHT ISSUES WITH AI
AND DOING THINGS AT SCALE, BUT
THE ROOT OF THINKING ABOUT THAT
IS HAVING THIS LIKE IDENTITY OR
PASS PORT, RIGHT, SO YOU KNOW
THE PERSON WHO'S ACCESSING IT IS
WHO YOU THINK THEY ARE AND THAT
IS NOT OFF BASE.
I CAN RAMBLE ABOUT THAT FOR A
WHILE BECAUSE IT'S A SOURCE OF
FRUSTRATION THAT EVEN WITHIN THE
DEPARTMENT OF ENERGY IF I WANT
TO LOG INTO ECOSYSTEMS RIDGE, IT
IS A DIFFERENT SET OF
CREDENTIALS THAN IF I LOG INTO
BERKELEY LAB, WHY, WHY IN AND
THEY HAVE REASONS, BUT THEY'RE
NEVER GOOD 1S.
BUT IT'S A POLICY PROBLEM.
OKAY.
SORRY THAT'S A BIT OF A RANT.
>> APPRECIATE THAT.
SO NOW, OPENING UP THIS TALK SO
DR. FEGNAN CAN TALK TO THE
AUDIENCE.
>> LET ME SEE IF THERE ARE
QUESTIONS IN THE CHAT.
NOT YET.
I DON'T DON'T SEE ...
OKAY, I DON'T SEE HANDS, OH
THERE'S YES, DR. ANDERSON?
>> YEAH, THANK YOU ALL FOR
REALLY IMPRESSIVE WORK, REALEY
EXCITING TO SEE IT, THE LOVE THE
ENDOMEET REOSEIS EXAMPLE, IT
HELPED ME CRYSTALLIZE WHAT WE'RE
THINKING ABOUT THIS AND HOW WE
WOULD USE THESE TECHNIQUES, SO
LET ME SAY I'M A STATISTICIAN BY
TRAINING BUT REALLY VERY OLD
SCHOOL, REFLECTING MY AGE, AND
SO, HOW OFF AND ON, I TALK MODEL
CITIZEN MY TRAINEES AND OR
STAFF, I SAY, THE MOST IMPORTANT
THING IN GETTING AN ANALYSIS
RIGHT IS GETTING THE RIGHT DATA
SET OR HAVING THE RIGHT
DENOMINATOR.
YOU WILL NOT GET THE RIGHT
ANSWER IF YOU DON'T START WITH
THE RIGHT DATA SET SO I'M
WONDERING IF YOU COULD RIFF ON
THAT TOPIC ATH BITD WITH REGARD
TO AI, AND WHAT ARE THE LIMITS
OF WHERE WE CAN TRUST AI AND
WHERE WE CAN'T AND FOR THESE
WHAT SOMEONE CALLED DATA HUNGRY
ALGORITHMS, HOW ARE WE GOING TO
REPRODUCE OR REPLICATE THIS WORK
TO CONVINCE OURSELVES OF THE
VALIDITY OF THIS WORK?
>> I'M HAPPY TO JUMP IN FIRST.
SO WONDERFUL WONDERFUL QUESTION.
I JUST WROTE AN EDITORIAL ABOUT
TRUST AND AI, AND AT A
COMMERCIAL, WE HAVE VENDOR WHO
IS WANT TO COME SELL US THEIR
LATEST AND GREATEST PRODUCTS OF
AI, AND 1 OF MY ROLE SYSTEM TO
ASK THE TOUGH QUESTIONS AS AN
ACADEMIC AND RESEARCHERS AND IN
FACT, WE HAD 1 COMPANY TELL US
WE ASK HARDER QUESTIONS THAN ANY
OTHER INSTITUTION THAT THEY TRY
TO SELL TOO WHICH WE WEAR AS A
BADGE OF HONOR.
BUT 1 OF THE PROBLEMS WITH
COMMERCIAL COMPANIES THEY DON'T
SHOW YOU THEIR SOURCE CODE, THEY
DON'T SHOW WHAT YOU'S GOING ON
UNDER THE HOOD AND THAT'S A
BEING PROBLEM IF ARE A HOSPITAL
OR HEALTH SYSTEM WANTING TO
ADOPT AI BECAUSE HOW CAN YOU AS
A CLINICIAN TRUST WHAT THE AI'S
DOING, HOW CAN I AS A AN I
RESEARCHER KNOW IT'S USING
STATE-OF-THE-ART TECHNOLOGY AND
YOU KNOW WHEN YOU'RE A CLINICIAN
AND HAVE YOU A PROBLEM PATIENT
AND YOU HAVE A QUESTION ABOUT
THE BEST TREATMENT OPTION, CAN
YOU WALK DOWN THE HALL AND ASK
YOUR TRUSTED COLLEAGUE AND HAVE
YOU A TRUST RELATIONSHIP.
YOU KNOW THEIR TRAINING AND
TRUST THEIR DECISIONS AND THAT'S
WHY YOU GO ASK THEM, YOU CAN'T
DO THAT OF AN AI BECAUSE YOU CAN
BE THE SEE WHAT IT'S DOING AND I
THINK THIS IS A BIG PROBLEM.
I WILL LET THE OTHERS WEIGH IN
BUT I THINK THAT'S SOMETHING WE
NEED TO THINK ABOUT.
>> AGAIN, I CAN ADD TO WHAT
JASON IS SAYING, I AGREE WITH
EVERYTHING HE IS SAID, I THINK
OF 3 ASPECTS, THE FIRST 1 IS
GOVERNANCE AND I'M EXPANDING A
BIT YOUR QUESTION DR. ANDERSON
BUT IN THE ABSENCE OF
REGULATION, ABOUT AI, WE STILL
NEED GOVERNANCE, AND SO, THERE
ARE BEST PRACTICES ABOUT IT, BUT
I THINK, I'M TAKING THE LENS OF
WOMEN'S HELT FOR A SECOND, I
THINK WE JUST WANT TO MAKE SURE
WE'RE NOT FORGETTING THE WOMEN
THEMSELVES AND POTENTIAL AS
INDIVIDUALS AND PATIENTS AND
HAVE THEM UNDERSTAND THE
GOVERNANCE SIMILARLY, WE WANT TO
MAKE SURE THERE IS EDUCATION
ABOUT WHAT IT MEANS TO BE
RELIABLE AND TRUSTWORTHY FOR
PRACTITIONERS, SO CLINICIANS,
WHO'S GOING TO BE THE MIXTURES
THAT THE DOCTORS ARE OF TOMORROW
ARE EDUCATED CONSUMERS OF AI,
THAT DOES NOT MEAN KNOW HOW TO
CREATE AN AI AND PROGRAM IT,
THAT MEANS KNOW WHAT TO DO WITH
THE RESULTS OF AN AI TOOL AND
HOW TO INTERPERATE, KNOW WHAT
REQUESTYS TO ASK TO PROBE IT AND
FINALLY ON THE METHOD LOGICAL
SIDES, YOU KNOW THERE'S
OBVIOUSLY, IT'S AN ACTIVE FIELD
OF RESEARCH BUT I THINK WE ARE
GETTING IN THAT INTERSECTION OF
AI AND HEALTH TO GOOD METHODS
AND BEST PRACTICES ABOUT WHAT
DOES IT MEAN FOR A MODEL TO BE
ROBUST EMPLOY SO WE'RE THINKING
IN TERMS OF TIME AS PRACTICES
EVOLVE, HOW WELL DOES IT DO OR
THINKING IN TERMS OF GEOGRAPHIC
SCALES AS DIFFERENT POPULATION
OR DIFFERENT SITES, ET CETERA,
ET CETERA BUT YOU KNOW A FEW
YEARS AGO, EVERYONE WAS
THINKING, YEAH, WE NEED TO THINK
ABOUT WHAT IT MEANS TO BE
ROBUST, AND WE DIDN'T REALLY
KNOW HOW TO DECOMPOSE THAT INTO
SPECIFIC EXPERIMENTS AND HOW TO
OPERATIONALIZE IT AND I THINK
IT'S -- THERE'S A FANTASTIC KIND
OF COMMUNITY TO OPERATIONALIZE
IT IN THE HOUSE DOMAIN, SO THAT
WE CAN GO FURTHER OR TRUST IN
THOSE SYSTEMS BUT I WOULD SAY,
THERE'S DEFINITELY A LOT OF WORK
TO DO STILL.
>> WELL, IF I CAN FOLLOW UP, I
CAN SEE FOR PRODUCTION APPROACH
THERE'S OFTEN A GOOD WAY TO
VALIDATE THAT.
BUT THERE ARE TIMES WHEN REAL
WORLD DATA CAN LEAD US ASTRAY,
IT'S THE SAMPLING PROBLEM, OR WE
DON'T HAVE AN ADEQUATE
REPRESENTATIVE OR DATA SET THAT
YOU'RE WORKING FROM, YOU KNOW SO
THAT PATIENT POPULATION, AT
CEDARs MIGHT BE DIFFERENT THAN
THE PATIENT POPULATION AT
CHICAGO RUSH.
AND YOU KNOW IS THIS ALGORITHM
GOING TO MOVE FROM 1 TO OTHER IN
A RELIABLE WAY.
SO, I'M JUST WONDERING HOW WE
DEAL WITH THAT PARTICULAR
PROBLEM.
>> IF I MAY, I WILL GIVE YOU AN
ELEMENT OF ANSWERS, I THINK ALL
OF THE WORK IN THIS DATA
NETWORKS THAT USE A COMMON DATA
MODEL, THAT'S 1 OF THE INCENTIVE
USE FOR THIS IS AS WE GO AWAY
FROM THE DATA HARMONIZATION
ISSUES, WE CAN THEN, YOU KNOW
THAT'S TAKEN CARE OF TO SOME
EXTENT, YOU NOT FULLY BUT TO
SOME EXTENT, THEN WE CAN GO ASK
THE REQUESTYS OF TRAIN ON 1
SITE, TEST ON ANOTHER OR LIKE
YAISON MENTIONED WHERE YOU DO
FEDERATED LEARNING WHERE YOU
EMBRACE THE DIVERSITY OF THE
SITES AND ASK THE AI TO HANDLE
IT FOR YOU, BUT I THINK WHAT I
WOULD SAY IS IMPORTANT IN ALL OF
THESE METHODS IS TO REALLY FOR
EACH QUESTION, THERE'S GOING TO
BE DIFFERENT PROBLEMS, IS IT
TIME, IS IT SCALE THESE KINDS OF
THINGS AND SO, REALLY, THINKING
ABOUT THE QUESTION, WE'RE TRYING
TO ANSWER IS GOING TO BE
CRITICAL, RIGHT?
>> THANK YOU.
DR. FAGNAN?
NYEAH, I JUST COMPLETELY AGREE
ABOUT THE TRUST ISSUES.
I AM WORRIED.
A LONG TIME AGO, I GAVE A TALK
AT A MEETING SHOWING A
SIMULATION OF HIGH INTENSITY
FOCUSED ULTRASOUND TREATMENT DID
IT WAS A SIMULATION AND 2
DIMENSIONAL, NOT AT ALL
REPRESENTATIVE OF REALITY BUT
MOST FOLKS IN THE AUDIENCE
WANTED TO BELIEVE THAT IT WAS
REPRESENTATIVE OF WHAT A
TREATMENT MIGHT LOOK LIKE FOR A
PATIENT.
WE HAVE A DESIRE AS HUMANS TO
WANT TO PUT A LOT OF FAITH IN
THE COMPUTER AND LIKE, THINK
THAT IT'S SMARTER THAN US.
WE HAVE TO REMEMBER THAT IT'S
BUILT BY US ISSUES @ MOMENT.
LIKE THE EMERGENT INTELLIGENT
PROPERTIES THAT WE'RE OBSERVING
AND MAYBE THIS WAS ALREADY
DISCUSSED ARE THINGS THAT ARE
THERE'S THE CONCEPT OF THE
EYEBALL NORM IN MATHEMATICS
WHERE YOU LOOK AT A SIMULATION
AND A PICTURE AND THAT'S PRETTY
GOOD.
AND THEN YOU ACTUALLY LOOK AT
THE FUNDAMENTAL PRINCIPLES OF
LIKE WHAT EQUATIONS AM I SOLVING
AND DID THE COMPUTER DO THIS
ACCURATELY AND YOU SEE IT'S JUST
RIFE WITH ERROR AND RIGHT NOW WE
HAVE THINGS WITH LLMs THAT
WEEM ARE REALLY EXCITED ABOUT
BECAUSE THERE'S LIKE A LOT OF
EYEBALL NORM LOOKS GOOD ENOUGH
AND I WOULD ARGUE FOR SCIENCE
THAT IS NOT THE BAR WE SHOULD BE
USING HOWEVER, I WORRY IT MIGHT
BE THE BAR FOR GETTING A
PUBLICATION OUT, RIGHT?
AND IT MIGHT BE A BAR FOR SORT
OF PLAYING TO THE INCENTIVE
STRUCTURE THAT WE HAVE.
AND SO BALANCING THIS SORT OF
REAL CONCERNS AGAINST FOLKS WHO
ARE GOING TO PUT OUT
PUBLICATIONS BECAUSE THEY NEED
TO, IS REALLY GOING TO BE A
CHALLENGE AND OUR FUNDERS WHO
ARE LOOKING FOR ANSWERS TO SOME
OF THESE REALLY EXPENSIVE
PROBLEMS, DATA HARMONIZATION IS
EXPENSIVE, IT GETS MORE
EXPENSIVE THE MORE LIKE,
EXPERIMENTS YOU DO, RIGHT?
AND THE MORE DATA YOU GENERATE
AND THERE'S NOT NECESSARILY AN
INTEREST IN FUNDING IT, LIKE
IT'S CHALLENGING TO MAINTAIN
FUNDING FOR NATIONAL
REPOSITORIES AND SO THERE IS
SOMETHING HERE WHERE LIKE, I
WORRY ABOUT HOW IT GETS
ADVERTISED AND I WORRY ABOUT THE
HYPE AND I WORRY ABOUT GOING
DOWN THESE RABBIT HOLES WHERE
PEOPLE AREN'T JUST WILLING TO
STAND UP AND SAY THEY HAVE TRUST
ISSUES, TOO AND I THINK YOU HAVE
TO FALL BACK ON LIKE
FOUNDATIONAL STATISTICS TO
REALLY UNDERSTAND THE DATA
ITSELF AND UNDERSTAND IF YOU
WERE DESIGNING AN EXPERIMENT
CORRECTLY AND BE REALLY
JUDICIOUS ABOUT THE TOOLS YOU
USE BUT FOR ANYTHING YOU WANT
ACCURACY AVOID LLMs, FOR NOW,
THAT'S JUST NOT WHAT THEY'RE
BUILT TO DO.
>> DR. MOORE, A QUESTION, YOU
REALLY KINDLY POINTED OUT ALL
THE CHALLENGES OF DATA AND WE
LIVE SOME OF THOSE ON A DAILY
BASIS, THEY'RE HARD TO WORK
WITH, THEY'RE NOT STANDARDIZED,
THEY'RE COSTLY, AND THAT'S TRUE
FOR ALL THE CHALLENGES THAT YOU
POINT OUT, I WONDER IF YOU WOULD
POINT OUT A USE CASE WITH AI-LLM
WHERE THERE'S USE CASE INTERSECT
WHAT THE LEARNING HEALTH SYSTEM?
YOU HAVE THE PRIVILEGE OF
LIVING, HAVING 1 SIDE OF YOUR
BRAIN WORKING WITH DATA AND THE
OTHER SIDE OF YOUR BRAIN WORKING
WITH THE PATIENTS AND THE
CLINICAL SETTINGS SO YOU WOULD
IDEAL TO UNDERSTAND WHERE DO
THEY INTERSECT IN THIS LEARNING
HEALTH SYSTEM?
OH IT'S A GREAT QUESTION, 1 OF
THE GREATLY UNDERAPPRECIATED
AREAS WHERE AI HAS A ROLE TO
PLAY AND IN A HEALTH SYSTEM IS
THE PATIENT EXPERIENCE, WE DON'T
THINK ENOUGH -- WE ALL
EXPERIENCE THIS OURSELVES AS
PATIENTS, YOU KNOW HEALTH
SYSTEMS ARE CONFUSING, IT'S
STRESSFUL, IT'S A HARD TIME WHEN
YOU HAVE A HEALTH ISSUE AND
GETTING THE TO CARE YOU NEED AND
GETTING TO THE RIGHT DOCTOR AND
NAVIGATING THROUGH A HEALTH
SYSTEM IS CONFUSING FOR ALL OF
US THAT WORK IN A HEALTH SYSTEM
AND SO I THINK A LOT ABOUT THE
PATIENT EXPERIENCE AND WE HAVE
AN APP A LARGE LANGUAGE MODEL
BASED APP AT CEDAR SINAI, IT'S
CALLED CS-CONNECT SO IT'S AN APP
ANYBODY IN THE STATE OF
CALIFORNIA CAN DOWNLOAD IN THE
APP STORE AND YOU CAN START
ASKING QUESTIONS AND ENTERING
HEALTH INFORMATION, THE AI WILL
ASK YOU WEB CONNECTEDS AND GIVE
YOU A PRELIMINARY DIAGNOSIS, AND
THERE'S A BUTTON THAT SAYS TALK
TO A DOCTOR, YOU CAN PUSH THAT
BUTTON AND TALK TO A DOCTOR
IMMEDIATELY, A DOCTOR WE EMPLOY
AND WITHIN MINUTES BE TALKING TO
A REAL PERSON ABOUT YOUR HEALTH
SITUATION, THE APP THEN HELPS
YOU SCHEDULE AN ASHES POINTMENT,
GET IN TO SEE A DOCTOR AND WHEN
HAVE YOU GO TO HAVE YOUR FIRST
ENCOUNTER WITH A PHYSICIAN OR
CLINICIAN, THE SUMMARY OF WHAT
THE AI LEARNED ABOUT YOU IS
ALREADY PROVIDED TO THEM, SO TO
SAVE TIME, SO THIS, I THINK THIS
IS AN EXAMPLE WHERE LARGE
LANGUAGE MODELS AND AI GRITTILY,
GREATLY IMPROVES THE PATIENT
EXPERIENCE, GETTING THEM INTO
THE CLINICS SO THEY CAN BINE AND
-- CAN BE SEEN AND HAVE THEIR
CONDITION DEALT WITH.
IT GIVES THEM A HEAD START ON
HOW TO INTERACT WITH THE PATIENT
AND GET THEM THE CARE THEY NEED.
WE'VE BEEN USING THIS FOR ABOUT
A YEAR AND A HALF NOW AND WE'VE
HAD 10S OF THOUSANDS OF PATIENTS
COME INTO OUR HEALTH SYSTEM THAT
HAVE NEVER BEEN PATES BEFORE AND
THE REVIEWS ARE QUITE GOOD.
SO I THINK THERE IS A ROLE FOR
LARGE LANGUAGE MODELS IN HEALTH
SYSTEMS, AND YOU KNOW THEY'RE
BEING EVALUATED ACROSS THE
SPECTRUM OF THINGS CAN YOU
IMAGINE USING LARGE LANGUAGE
MODELS FOR.
SOMETIMES THEY'RE USEFUL,
SOMETIMES THEY'RE NOT BUT I
THINK THAT'S AN EXAMPLE WHERE IT
GREATLY IMPROVES THE PATIENT
EXPERIENCE.
>> PRETTY IMPRESSIVE DATA IN
TERMS OF THE SUCCESS.
I KNOW WE, I WILL CONFESS WE
FUNDED SOME HEALTH EDUCATION LLM
CHAT BOT FOR UNDERSERVED
COMMUNITIES STOCK EXCHANGE
REMIND THEM OF THE NEED TO MAKE
THE MEDICATIONS, AND SAY HYPER
TENSIVE, WHAT I ALWAYS FELT IS
MISSING IS IT DIDN'T FOLLOW UP
WITH, HERE'S TO CONTACT AND MAKE
AN APPOINTMENT BECAUSE JUST AS A
REMINDER THEY MAY MAKE MEDICINE
FOR THAT DAY OR EACH FOR A WEEK
BUT THEY MAY ACTUALLY SHOULD BE
SEEN, AND MAKING IT EASY FOR
THEM TO MAKE AN APPOINTMENT,
WHICH YOU HAVE IN YOUR APP, IT'S
AMAZING.
>> YEAH, IT'S SO EASY TO DO NOW.
WE HAVE THE TECHNOLOGY, WE JUST
HAVE TO PUT IT TO WO, ON BEHALF
OF PATIENTS TO MAKE IT EASY FOR
THEM TO GET THE CARE THEY NEED.
A LOT OF PEOPLE DON'T DO IT
BECAUSE IT'S SO CONFUSING AND
DIFFICULT.
>> RIGHT, RIGHT.
THANK YOU FOR THAT.
NOW I HAVE A QUESTION FOR
DR. ELHADAD, IF OUR AUDIENCE, I
DON'T SEE HANDS UP, IF I MAY
ASK, YOU MENTIONED THE USE OF
MOBILE HEALTH AND AND THE
ENDOMETRIOSIS PATIENTS TEND TO
BE A BIT MORE GUARDED ABOUT
THEIR PRIVACY, THE MOBILE HEALTH
DEVICE ITSELF A CONCERN IN TERMS
OF PROTECTING PRIVACY?
>> NO, THAT'S A GREAT QUESTION
AND I THINK THE MOBILE HEALTH IS
ACTUALLY THE LEAST OF THE
WORRIES OF THE PATIENTS.
IT'S REALLY ABOUT IN THE CASE OF
ENDOMETRIOSIS THERE'S A LOT OF
REPRODUCTIVE HEALTH INFORMATION
THAT THEY'RE GIVING TO
RESEARCHERS AND THEY REALIZE HOW
SENSITIVE THE DATA IS AND SO
THEY'RE JUST WORRIED ABOUT WHO
IS GOING TO ACCESS THE DATA.
WHETHER IT WOULD BE THE -- THE
SAME WAY THEY'RE ACTUALLY
WORRIED FOR ELECTRONIC HEALTH
RECORD AND ROUTINE CARE.
THAT'S 1 ASPECT AND THEN THEY'RE
ALSO WORRY BODY MISUSE OF THE
DATA MAYBE NOT FOR THEM
SPECIFICALLY, BUT FOR
ENDOMETRIOSIS PATIENTS AS A
COMMUNITY IN A SUBPOPULATION
WHERE IT'S MORE ABOUT MISTRUST
OF POTENTIALLY AND I WILL
SEPARATE MYSELF FROM THE
ENDOMETRIOSIS COMMUNITY FOR A
SECOND BUT THAT'S WHAT WE HEAR
IS A BIG MISTRUST IN
PHARMACEUTICAL COMPANIES WHERE
THEY FEEL THEY DON'T HAVE THEIR
INTEREST IN MIND EMPLOY THEY
FEEL THEY'RE NOT LOOKING FOR A
CURE, THEY'RE LOOKING FOR
MITIGATION THAT IS TREATING
THEIR SYMPTOMS, YOU KNOW AND I
THINK WHAT IT TALKS ABOUT IS
JUST THE FACT THAT IT'S AN
UNDERSTUDIED DISEASE MORE THAN
ANYTHING ELSE AND THAT THE WAY
TO PERCEIVED BY PATIENTS IS NO
1'S CARRYING FOR US AND NO 1 IS
PAYING ATTENTION TO OUR NEEDS
AND SO I THINK THERE THERE'S TBO
KINDS OF WORRIES ABOUT IF THE
DATA IS USED BUT FOR THE SAKE OF
CREATING DRUGS THAT ARE NOT
GOING TO BE HELPFUL TO
ENDOMETRIOSIS PATIENTS, THEY'RE
VERY WORRY BODY THAT AND GUARDED
ABOUT SHARING THEIR DATA.
SO, INDIVIDUAL WORRIES, YOU
KNOW, AS I WNL DO I WANT TO
SHARE INFORMATION ON MY
REPRODUCTION HEGHT AND THEN MORE
THE POPULATION BASED WORRY.
>> THANK YOU VERY MUCH.
>> DR. MELENZ, GOING BACK A BIT,
SORRY DEPARTMENT GET MY HAND UP
FAST ENOUGH BUT THIS IS A FOLLOW
UP ON DR. ANDERSON'S I THINK
QUESTION AND THIS 1 IS FOR
DR. MOORE, IT'S MORE SORT OF A
TERMINOLOGY CLARIFICATION, YOU
KNOW I'M NOT AN EXPERT IN THE
FIELD YOU'RE DISCUSSING BUT YOU
TALKED ABOUT 1 OF THE CHALLENGES
AS BEING, YOU KNOW YOU WANT AI
GENERAL, YOU WANT THE SAME FOR
ALL PEOPLE AND I DIDN'T HEAR YOU
USE THE TERM LYING ALGORITHMIC
FAIRNESS, AND WONDERED JUST SORT
OF FROM AN OPERATIONALLY
DEFINING SOME OF THESE NEWER
TERMS, DO YOU USE KIND OF AI
GENERAL IN ALGORITHMIC FAIRNESS
AND SIN NONE MOUSILY OR ANY
THOUGHTS THERE?
>> YEAH, THAT'S EXACTLY WHAT I
MEANT, YOU KNOW IN MACHINE
LEARNING WE OFTEN TALK ABOUT
GENERALIZATION, DOES THE MODEL
GENERALIZE TO ALL PEOPLE SO
THAT'S WHY I USE THAT WORD BUT
FAIRNESS IS ANOTHER WORD YOU
COULD USE MAKING SURE THE MODEL
IS MAKING PREDICTIONS EQUALLY IN
ALL PEOPLE REGARDLESS OF THEIR
BACKGROUND.
SO ABSOLUTELY IT'S VERY
IMPORTANT AND I WOULD SAY
UNDERSTUDIED AREA OF AI.
>> OKAY, YEAH, GREAT, I AM
WORKING WITH A DOCTORAL STUDENT
AND THERE ARE MORE EXPERTS IN
THE TEAM LOOKING FOR FENDOEE
TYPE AND FAIRNESS IN EHR DATA SO
IT WAS, ANYWAY, WONDERFUL TO
HEAR ALL YOUR TALKS TODAY, SO
THANK YOU.
>> HI, DAN WITH THE MEDICAL
CENTER, THIS WAS A QUESTION THAT
GOES OUT TO SPEAKERS HERE, I
THINK IT WOULD BE REALLY USEFUL
TO SORT OF YOU KNOW, WE HEARD
SOME EXAMPLES OF, YOU KNOW ARE
WHERE LLMs MIGHT PERFORM
WELL FROM IT IS PERSPECTIVE OF
USER THAT IS NOT NECESSARILY A
RESEARCHER, WONDERING IF YOU
COULD COMMENT ON YOUR
EXPERIENCES IN THE FIELD AND
WHAT AREAS MAYBE TO HEALTHCARE
RECORD SYSTEMS WHAT KIND OF
TASKS ARE LMM GOOD FOR AND AS
OPPOSED TO STAY AWAY FROM?
>> YOUR QUESTION IS GREAT, THE
PROBLEM APPLIES WHEN LLMs
TRAIN ON WHAT THEY HAVE ON THE
BRETT AND THEY ONLY KNOW WHAT
THEY'VE BEEN TRAINED ON AND IF
YOU'RE TRYING TO APPLY THEM TO A
VERY SPECIFIC TASK, THAT WASN'T
IN THE TRAINING SET, THAT'S
WHERE YOU WILL HAVE PROBLEMS AND
SO FOR THOSE OF YOU ON THE CALL
THAT AREN'T EXPERTS IN LARGE
LANGUAGE MODELS THERE'S
SOMETHING CALLED RETRIEVAL
AUGMENTED GENERATION OR RAG FOR
SHORT.
WHICH IS CREATING A DATABASE
WHERE YOU PUT INFORMATION AND
LANGUAGE THAT YOU MIGHT NOT HAVE
ACCESS TO AND THERE ARE TRICKS
YOU CAN DO TO WHEN YOU GIVE IT A
PROMPT TO MATCH IT TO THE
DATABASE AND THEN FEED THE RIGHT
INFORMATION TO CHAT GPT OR LARGE
LANGUAGE MODEL SO IT CAN CRAFT A
MORE ACCURATERY SPONSE BUT IN
THE END OF IT, THAT'S 1 OF THE
THINGS WE DO IS PUT
BIOMALKNOWLEDGE INTO A RAG
DATABASE AND GIVE CHAT GPT
ACCESS TO ALL THESE
RELATIONSHIPS BETWEEN GENES AND
DRUGS AND DISEASE, AND ONLY THEN
IN THE OTHER TRICKS IN PAPER,
ONLY THEN DOES CHAT GPT DO A
GOOD JOB SCWRING AND MUCH LESS
LIKELY TO HALLUCINATE.
SO I WOULD SAY OUT OF THE BOX
THEY DO MAKE MISTAKES AND THEY
ARE INACCURATE PLENTY OF TIMES.
AND JUST A FUNNY EXAMPLE, I WILL
SKIP IT BUT I DON'T WANT TO GET
INTO IT -- SO ANYWAY, I THINK
THERE ARE SPECIFIC THINGS CAN
YOU DO TO GET THEM TO WORK MUCH
BETTER ON RESEARCH TYPE
PROBLEMS, AND OTHER CLINICAL
PROBLEMS.
I CAN GIVE MY EXPERIENCE AS PART
OF OUR WORK AT THE NEW YORK
PRESCRIBING BI TERRION HOSPITAL
WHERE WE THINK OF LPLRKS Ms ON
CLINICAL DOCUMENTATION AND TEXT
BUT ALSO FOUNDATION MODELS ON
OTHER TYPE OF DATA TYPES, RIGHT,
SO WHENEVER WE SAY LARGE
LANGUAGE MODEL, IT'S THE
ORIGINAL TECHNOLOGY, BUT
LANGUAGE COULD BE REPLACED AND
WE FIND IN GENERAL THAT THESE
LANGUAGE, AND USE OTHER THINGS,
YOU CAN BUILD TECHNOLOGIES
THAT'S VERY HELPFUL TO ALL
STAKEHOLDERS IN THE HEALTH
SYSTEM.
SO WE'RE RIGHT NOW AND REALLY
HEAR THE QUESTION IS NOT EVEN
HOW WELL IS IT DOING BUT WE CAN
VALIDATE THAT TO SOME EXTENT BUT
IT'S REALLY WHAT DO PEOPLE ASK
ONCE THEY HAVE THE ABILITY TO
ASK ANY QUESTION OF A PATIENT
RECORD, RIGHT?
-- POEM DON'T WANT TO SHARE
THEIR MENSTRUAL HEALTH DATA BUT
APPROXIMATE WE ARE ABLE TO
GENERATE FAKE MENSTRUAL HEALTH
DATA THAT LOOKS A LOT LIKE WHAT
MEN STRAIGHTERS TELL US ABOUT
THEIR MENSTRUATION THEN THAT
COULD BE HELPFUL TO YOU KNOW
GIVE TO THE RESEARCH COMMUNITY
AND UNLOCK A LOT OF RESEARCH ON
A TOPIC THAT'S NOT CURRENTLY
VERY STUDIED.
>> -- INFORMATION YOU CAN BE
REASONABLY SURE THAT INFORMATION
IS CORRECT IS 1 THING, WE HAVE A
PROJECT WHERE WE'RE JUST TRYING
TO IDENTIFY INSTANCES OF DATA
REUSE IN THE LITERATURE WE WOULD
NECESSARILY RECOGNIZE AT THE
BEGINNING SO HUMANS CAN DO THAT,
TRADITIONAL STATISTICAL METHODS
CAN DO THAT, LENS LENS LENS LENS
MENTORSHIP SKILLS KIND OF MAKE
STUFF UP AND WE HAVE BEEN
TRAINING AND DOING IT AROUND
THIS BUT IT'S TRICKY, IT'S NOT
CLEAR TO ME THAT MAYBE IS LIKE
THE BEST FIT FOR THAT PROBLEM
SPACE.
AND O THE TYPE OF QUESTION YOU
HAVE DEPENDS ON THE DATA YOU
HAVE TO VALIDATE AND I WANT TO
EMPHASIZE ON THIS, THEY'RE NOT
THINKING, THEY'RE JUST
PREDICTING PROBABLISTICALLY WHAT
THEY'RE SAYING, AND YOU CAN
SPEND AS MUCH TIME CREATING
DATABASES TO MAKE SURE IT'S
PULLING IN SOMETHING CORRECT AS
YOU MIGHT JUST LIKE WRITING SOME
OTHER CODE OR STATISTICAL MODEL
TO SOLVING PROBLEMS SO IT GETS
LIKE TO BEING INTENTIONAL AND
THINKING THROUGH WHAT TOOLS ARE
THE RIGHT 1 FOR THE JOB THAT WE
ARE TRYING TO DO AND I THINK WE
WILL BE PHENOMENAL FOR DATA
RECOVERY AND RESEARCH.
AND THEN SOMEBODY I WORK WITH
HAS BUILT LIKE A IF YOU ARE ALL
WITH AGENTS AND LLMs PULLING
IN DATA FROM DIFFERENT SOURS
CONSTRUCTING A RELATIONAL SORT
OF KNOWLEDGE GRAPH SITTING
BEHIND IT THAT AND BED HOW THIS
RESOURCE IS THINKING ABOUT THESE
THINGS THAT ARE RELATED SO
THERE'S A HUMAN VALIDATING AND I
THINK THE NEXT GENERATION OF
TOOLS AND IRPT FACES TO DATA
THAT WE CAN BUILD WITH SOMETHING
SO POWERFUL IT'S SYNTHESIZING
AND BRINGING PEOPLE TOGETHER IS
SUPER EXCITING AND IT'S JUST
MAKING SURE IT'S BEING USED FOR
THE RIGHT PURPOSE.
THANKS FOR AGAIN ADVOCATING IF
ARE A HUMAN IN THE LIMITED
PARTNER AND MY QUESTION IS TO
DR. MOORE IS THAT IN CLINICAL
USAGE CLINICAL DECISION SUPPORT
IS SO IMPORTANT AND STILL TO
HAVE HUMAN IN THE LOOP TO BE THE
DECISION MAKER, YOU'RE NODDING
YOUR HEAD, I'M ASSUMING YOU'RE
AGREEING AND THEIR SITUATION I
THINK I CAN SIGN OUT OF THE LOOP
NOW.
ONE OF THE BOARD MEMBERS ASK
IFED WE WERE USING AND SO PUT
THAT TO BED VERY QUICKLY, AS A
HOSPITAL, WE FIRMLY BELIEVE THAT
OUR CLINICIANS ARE THE 1S THAT
MAKE THE DECISIONS AND WE SEE AI
AS ASSISTANCE TO GIVE ADVICE AND
HELP MAKE DECISIONS BUT NOT BE
THE DECISION MAKERS.
QUESTIONS FROM THE AUDIENCE, I
DON'T WANT TO DOMINATE THE
QUESTIONS.
>> WHILE WE'RE WAITING ON
QUESTIONS I WANT TO MENTION
AGENT AI AND FOR THOSE WHO
HAVEN'T HEARD IT, AGENETICALLYIC
AI IS SOMETHING THAT'S BECOMING
HOT AND USEFUL AND THE BASIC
IDEA IS TO HAVE MULTIPLE AI
AGENTS THAT TACKLE INDEPENDENTLY
INDEPENDENT PARTS OF A PROBLEM
AND SOLVE A BIGGER PROBLEM AND
EXAMPLE I WAS LISTENING TO A
PODCAST AND IT WAS A GREAT
EXAMPLE OF A HIGH SCHOOL STUDENT
CHEATING ON HOME WORK USING AI
AND HE DEVELOPED AN APPROACH
THAT WOULD WRITE THE ESSAY FOR
HIM AND ANOTHER AI THAT WOULD
EDIT IT AND ANOTHER AI WOULD
CHANGE THE LANGUAGE THAT A
LANGUAGE DETECTION ALGORITHM
WOULD BT KNOW IT WAS WRITTEN BY
AI AND WAS A CLEAR EXAMPLE OF
AGENETICALLYIC AI AND I WANT TO
SHOW IT OUT THERE BECAUSE MY THE
END OF YEAR AGENTIC AI, AND 2025
WILL BE THE YEAR OF AGENTIC AI
AND THEY WILL GIVE US AN
IMPROVED LEVEL OF PERFORMANCE
WITH LARGE LANGUAGE MODELS AND
EVEN DEEP LEARNING AND
REINFORCEMENT LEARNING AND OTHER
TYPES OF AI ABOVE AND BEYOND
WHAT WE'RE DOING NOW USING
SINGLE AI APPROACHES.
AND I WILL REFERENCE ANOTHER
ARTICLE THAT INVOLVES A COMPANY
SUGGESTING IT WAS USING AGENTIC
AI TO FILL IT OUT AND SELL IT
AND IT TURNS OUT IT WAS BEING
SOLD TO 700 PEOPLE IN ANOTHER
COUNTRY DOING THE WORK SO
THERE'S LOTS OF CRITICAL
THINKING AND READING TO DO AND
IT IS SUPER FUN.
MY OFFICE HAS A SIZABLE
INITIATIVE, AND MULTIMODAL AI,
AND IT IS STILL AT THE RESEARCH
STAGE, DO YOU SEE DO YOU SEE THE
QUESTION FOR ALL 3 OF YOU,
HAVING MULTIMODAL AI IN A
CLINICAL CONTEXT IN MEDICINE?
A LAB TEST THAT TIME SERIES IS
MULTIMODAL COMPARED TO CLINICAL
DOCUMENTATION, SO YOU KNOW I
THINK WE WANT TO BE BROADER,
WHEN WE THINK ABOUT MULTIMODAL,
BUT I THINK THAT'S A HOPE AND WE
KNOW THAT YOU KNOW THERE'S THIS
NEW DATA TYPES LIKE WEARABLES,
AND THINGS THAT ARE NOT EVEN YET
FULLY PART OF THE HEALTHCARE
SYSTEM, WE WANT TO BE ABLE TO
INTORPERATE THEM, BUT WE KNOW
THAT WHEN WE ASK HUMANS TO DO
SO, IT'S A WHOLE LOT OF WORK AND
SO, YOU KNOW IS IT SOMETHING
THAT AI CAN HELP WITH, AND I
THINK IT CAN, AND PROBABLY
FOUNDATION MODELS WILL BE YOU
KNOW A WAY TO GET THERE TO THIS
MULTIMODEL ASPECT WHERE IT CAN
LEARN A REPRESENTATION OF EACH
OF THESE MODALITIES AND BASED ON
THE TASK KIND OF BE SMART ABOUT
WHICH MODALITY TO PAY ATTENTION,
TO HOW TO INTEGRATE THEM, ET
CETERA.
BUT I THINK THE UNIFIER HERE OR
THE HARMONIZER WILL BE THE
FOUNDATION MODELS PROBABLY.
SO TALKING GENOMIC AND
HISTOPATHOLOGY, BUT YESTERDAY,
AT THE CONFERENCE HERE, I ALSO
HEARD THE USE OF MULTIMODAL,
APPLYING TO DIFFERENT DATA FROM
DIFFERENT CELL TYPES.
WITHIN AN ORGANISM SO YOU'RE
RIGHT IN POINTING OUT THAT WOULD
NOT HAVE NORMALLY THOUGHT OF
DIFFERENT DATA FROM SEQUENCING
DATA FROM THE SAMPLE FROM
DEFINITE CELLS WITHIN AN
ORGANISM AS MULTIMODAL BUT IT
OPENED MY EYES ABOUT WHAT WE
SHOULD THINK BROADLY ABOUT
MULTIMODAL.
LET ME SEE, I AM CONSCIOUS OF
NOT IGNORING QUESTIONS THAT MAY
BE IN THE CHAT.
I DON'T SEE ANY.
>> IT'S ACTUALLY JANINE'S TURN?
SO THERE YOU GO.
>> WHAT A FANTASTIC SET OF
PRESENTATIONS AND PANEL
DISCUSSIONS.
WE WERE REALLY EXCITED TO HAVE
THIS SESSION AND WE WERE ON
TARGET SO I APPRECIATE YOU
COMING TOGETHER AND COMING INTO
THIS MAYBE A LITTLE UNFAMILIAR
SPACE EXCEPT FOR THE THINGS WE
TALKED ABOUT BEFORE TO TALK
ABOUT THE POWER OF THE
POTENTIAL, THE PIT FALLS, THE
PRIVACY AND MANY OTHER PIECES
THAT WERE INVOLVED IN TRYING TO
THINK THROUGH ACCOUNTING FOR SEX
AS A BIOLOGICAL VARIABLE FROM MY
PERSPECTIVE IN AI AND PUTTING
SCIENCE AND TECHNOLOGY AND
INNOVATION TO WORK FOR THE
HEALTH OF WOMEN BECAUSE THAT'S
WHY WE ARE HERE, THAT'S OUR WHY
AND SO WE'RE GREATLY
APPRECIATIVE OF YOUR INPUT ON
THAT CONVERSATION TODAY AND WITH
THAT WE ACTUALLY ARE SUPPOSED TO
HAVE ANOTHER 5 MINUTES OF OPEN
DISCUSSION, THANK YOU SO MUCH
PANEL, WELCOME TO STAY BUT I
KNOW YOU'RE ALL BUSY
SOPHISTICATEDY WE WISH YOU WELL.
WE ARE SUPPOSED TO HAVE 5
MINUTES OF OPEN DISCUSSION FOR
ADVISORY MEMBERS AT THIS TIME
TELL 2:15 SO I WANT TO HOPE THE
FLOOR AGAIN FOR ADVISORY
COMMITTEE MEMBERS, PERHAPS YOU
THOUGHT ABOUT SOMETHING ON THE
BREAK OR LUNCH RATHER, ABOUT
THAT YOU WANTED TO BRING UP AS A
TOPIC FOR US TO CONSIDER FOR
FUTURE MEETINGS.
OR A QUESTION.
AND IF NOT I HAVE AN EXCITING
LATE BREAKING ANNOUNCEMENT FOR
YOU, WE ARE REALLY THRILLED TO
ANNOUNCE THAT WE'RE -- THROUGH
OUR COMMITMENT TO ADVANCING
WOMEN'S HEALTH HERE AT NIH,
THROUGH ROBUST, TRANSPARENT AND
ACCOUNTABLE SCIENTIFIC
INVESTMENT, THAT BEGINNING WITH
THE FY24 REPORTING CYCLE, NIH
HAS CONVERTED OUR RCDC SYSTEM,
IT STAND FIST ARE RESEARCH
CONDITION AND DISEASE
CATEGORIZATION, REPORTING
METHODOLOGY FOR THE WOMEN'S
HEALTH RESEARCH CATEGORY FOR A
MANUEL CODING TO A FULLY
AUTOMATED CODING.
TO ENHANCE OUR ACCURACY AND
CONSISTENCY.
SO THE PREVIOUS CATEGORIES, FOR
WOMEN'S HEALTH, MANUELLY,
CURATED, THE NEW CATTED GORY IS
CALLED WOMEN'S RESEARCH, AND
UNDER IT THERE WERE PROJECTS
ENCLUED THAD DID NOT DIRECTLY
FOCUS ON WOMEN'S HEALTH OUTCOMES
HOWEVER THE NEW AUTOMATED SYSTEM
INSURES A MORE RECISE REFLECTION
OF OUR RESEARCH EFFORTS AND
SUPPORTING A MORE EFFECTIVE USE
OF TAXPAYER DOLLARS, SO I DO
WANT TO SHARE WITH YOU THAT YOU
MAY NOTICE SOME DIFFERENCES IN
THE NUMBERS, WHILE THE UPDATED
METHODOLOGY MAY SHOW AN APPARENT
DECREASE IN THE REPORTED FUNDING
DOLLARS FROM FY23 TO FY24.
OVERALL FUNDING FOR WOMEN'S
HEALTH RESEARCH HAS NOT CHANGED.
THE SHIFT IS RELATED TO
PROVIDING A CLEAR AND MORE
ACCURATE REPRESENTATION OF OUR
SUSTAINED INVESTMENT IN THIS
CRITICAL INVESTMENT, AND IT'S
HOW IT'S REPORTED, NOT THE
AMOUNT THAT'S BEING FUNDED, IT'S
THE REPORTING METHODOLOGY, I DO
WANT TO SEE HOW RNT THIS IS, IN
RESEARCH SPENDING AND A PULLEY
AUTOMATED WOMEN'S HEALTH
RESEARCH CATEGORY THROUGH RCDC
IS SOMETHING WE HAVE BEEN
WORKING TOWARDS FOR SOMETIME.
SO ADVISORY COMMITTEE YOU ARE
IMPORTANT IN OUR EFFORTS AS YOU
MOVE FORWARD AND I WANTED TO
MAKE SURE YOU WERE AWARE OF THIS
EXCITING EVENTS AND THOSE
NUMBERS ARE NOW AVAILABLE WITH
THE RCDC WEBSITE AND LET ME JUST
PAUSE AND SEE IF THERE ARE
QUESTIONS OR COMMENTS.
OKAY, WE ARE GOING TO TAKE AN
EARLIER BREAK, WE WERE SUPPOSED
TO TAKE A BREAK FROM 2 2:15, WE
WILL TAKE A BREAK UNTIL 2:25 AND
WE WILL SEE YOU IN 10 OR 12
MINUTES.
THANKS EVERYONE.
WELCOME BACK, EVERYBODY.
HOME STRETCH.
PER THE FEDERAL ADVISORY
COMMITTEE ACT, OR FACA
REGULATIONS, ANY MEMBER OF THE
PUBLIC IS ALLOWED TO FILE A
LETTER AND STATEMENT IF
INTERESTED IN PRESENTING ORAL
COMMENT TO THE COMMITTEE AT THIS
TIME WE WANT TO ACKNOWLEDGE THE
WRITTEN COMMENTS RECEIVED BY THE
PHYSICIAN'S COMMITTEE FOR
RESPONSIBLE MEDICINE, AND OPEN
THE FLOOR FOR AN ORAL COMMENT
FROM THE AMERICAN GUIN
OICOLOGGIC SOCIETY WHICH WILL BE
PRESENTED BY DR. WINESTEIN,
CHIEF THE GYNECOLOGY AND PELVIC
SURGERY AND CO CHAIR OF THE
CENTER FOR PELVIC FLOOR DISORDER
AT MASS GENERAL HOSPITAL
ASSOCIATE PROFESSOR OF
OBSTETRICS AND PREPRODUCTIVE
BIOLOGY AT HARVARD MEDICAL
SCHOOL.
WELCOME.
THANK YOU SO MUCH IF ARE THIS
TIEWPT AND THANK YOU FOR THE
OPPORTUNITY TO PROPROVIDE
WRITTEN AND ALAL COMMENTS, I AM
WITH THE MASS GENERAL HOSPITAL
AND MY RESEARCH INTERESTS NEAR
COMBINED PELVIC FLOOR DISORDERS,
IMAGING AND PELVIC FLOOR
OUTCOMES.
TODAY I'M SPEAKING TO YOU IN A
ROLE AS A AMERICAN UROLOGICAL
SCIENTIFIC COMMITTEE.
AUGs, IT'S A NATIONAL MEDICAL
SOCIETY REPRESENTING OVER 2000
MEMBERS INCLUDING PRACTICING
PHYSICIANS NURSE PRACTITIONERS,
PHYSICAL THERAPY AND ACTIVITIES
AND PROJECTS IOF THEDS,
HEALTHCARE PROFESSIONALS AND
RESEARCHERS FROM MANY
DISCIPLINES DEDICATING TO TREATS
ANDING FEMALE PELVIC FLOOR
DISORDERS OR FFDs, WE WANT TO
UNDERSTAND THE IMPORTANCE OF
UNDERSTANDING AND EVALUATING
CONDITIONS WOMEN FACE THROUGHOUT
THEIR LIVES INCLUDING CONDITIONS
THAT BECOME MORE PREVALENT IN
POST REPRODUCTIVE YEARS.
IT'S NOTABLE THAT MOST FUNDING
DEVOTED TO HEALTH RESEARCH IS
FOCUSED ON REPRODUCTIVE AGE
SPANS INCLUDING THOSE THAT
WORSEN WITH THE MENOPAUSAL
CONDITION AND THOSE THAT
TRANSITION AND THOSE IN POST
PRODUCTION OF U.S. WOMEN.
AS SUCH AUG STRONGLY SUPPORTS
RESEARCH FUNDING DEDICATED TO
WHOLIC WOMEN'S HEALTH FOCUSING
ON STUDIES TO URO-GYNECOLOGIC
DISORDERS INCLUDING PFDs
AFFECT 25 MILLION INDIVIDUALS IN
NEARLY EVERY COMMON OLDER WOMEN
AND 1 IN 4 WOMEN WILL FACE
PELVIC FLOOR DISORDER IN THEIR
LIFETIME AND THE RATE IS LIKELY
HIGHER IN WOMEN OVER AGE 65.
SPFD IS DECREASED AFTER
MENOPAUSE, WE WILL SUFFER FROM
INCONTINENCE AND ONE-THIRD OF
WOMEN EXPERIENCE URINARY TRACT
INFECTIONS, MOST CONDITIONS STAY
FOR EXTENDED PERIODS OF TIME AND
REQUIRE ONGOING MEDICAL
CONDITION.
IN TWE 23, AUG RELEASED
INFORMATION FOR THE PUBLIC
DISORDERS, RCHT IDENTIFY
KNOWLEDGE GAPS IN RESEARCH
RIPORRITYS ACROSS 6 SPECIFIC
TOPICS, LOWER URINARY TRACT
SYMPTOMS, FECAL INCONTINENCE,
URINARY TRACT INFECTIONS, SEXUAL
DISTUNKZ IN WOMEN WITH PELVIC
DISORDERS AND MY O FACIAL SYSTEM
CONDITION AND MORE.
WITH THE TIME PERMITTING I WILL
FOCUS ON ON ONLY 1 OF 2 OF THIS
CONDITION, PELVIC ORGAN PROLAPSE
IS THE DESCENT OF 1 OF THE
PELVIC ORGANS INTO OR OUTSIDE OF
THE VARMIS BEGINNA AND IT
AFFECTS UP TO 50% OF ALL WOMEN.
THIS CONDITION CAN SEVERELY
IMPACT QUALITY OF LIFE PROMPTING
WOMEN IN THE UNITED STATES TO
UNDERGO SURGICAL PROLAPSE,
WORSENING PROLAPSE HAS BEEN
ASSOCIATED WITH FUNCTION,
ANXIOUS, DEPRESSION, SLEEP
DISTORTIONS AND LOWER
SATISFACTION PARTICIPATING IN
SOCIAL ROLES, OVERALL THE
PATHOPHYSIOLOGIC MECHANISM
UNDERLYING THIS DEVELOPMENT OF
PROGRESSION OF SEVERITY OF
PROLAPSE ARE MEDICALLY
UNDERSTOOD AND NO EFFECT
PREVENTATIVE STRATEGIES EXIST
AGAINST PROLAPSE IN CURRENT
TREATMENT MODALITIES ARE DELAYED
AND COMP PENSATORY.
IDENTIFYING THEMES THAT WE WANT
TO EXPLORE ARE NORMAL FUNCTIONAL
ANATOMY, CELLULAR GENETICS AND
BIOMECHANICAL FACTORS, THERAPIES
FOR PREVENTION TREATMENT AND
RECURRENCE, SOCIETAL IMPACT AND
FINANCIAL BURDEN ON TREATMENT OF
THIS MODALITIES, AH, G STRONGLY
SUPPORTS THE INCREASED RESEARCH
FUNDING ON THESE RESEARCH TOPIC
AREAS THAT ARE IN ADDRESS
RESEARCH GAPS AND INVEST IN THE
FULL FEMALE LIFE SPANS AND
IMPROVED CARE OF DELIVERY OF
PFDs IN CONDITION ANDS THANK
YOU VERY MUCH FOR YOUR WORK ON
WOMEN'S HEALTH RESEARCH FUNDING
AND FOR THEIR OPPORTUNITY TO PUT
THEM IN THE PUBLIC COMMENTS.
>> OKAY, THANK YOU ONCE MORE
DR. WINESTEIN, APPRECIATE YOUR
COMMENTS.
BEFORE WE CLOSE I WOULD LIKE TO
ASK, INVITE DR. OTA WANG TO
RESPOND TO ANY QUESTIONS SENT
FROM THE PUBLIC SENT TO THE
WRCHINBOX?
TLOOKS LIKE WE DON'T HAVE ANY
QUESTIONS SUBCOMMITTED COMMITTE-
SUBMITTED BUT IF THERE ARE
QUESTIONS AFTERWARDS WE WILL BE
MORE THAN HAPPY TO WORRY THEM.
SO WHAT I WILL NOW DO IS TURN IT
OVER TO DR. CLAYTON.
>> THANK YOU DR. OTA WANG.
FIRST I WANT TO THANK ALL OF THE
EXCELLENT PRESENTERS FOR
PARTICIPATING IN TODAY'S
ADVISORY COMMITTEE FOR RESEARCH
ON WOMEN'S HEALTH MEETING, WE
DEEPLY APPRECIATE THE CONTINUED
SUPPORT THAT THE ACRW H AS WELL
MEMBERS, PROVIDE TO OUR OFFICE
AND I WOULD LOAMACYIC TO ALSO
THANK THE OFFICE OF RESEARCH ON
WOMEN'S HEALTH, FEDERAL STAFF
AND OUR CONTRACTORS SUPPORT FOR
MAKING THIS MEETING POSSIBLE.
ON BEHALF OF ORWH, I THANK ALL
OF YOU AND LOOK FORWARD TO
SEEING YOU AT THE 64th MEETING
OF THE ADVISORY COMMITTEE ON
RESEARCH ON WOMEN'S HEALTH ON
OCTOBER 7th, 2025, WHICH WILL
BE AN IN-PERSON MEETING.
I HOPE YOU ALL REMAIN SAFE AND
HEALTHY AND TODAY'S MEETING IS
NOW ADJOURNED.
THANK YOU VERY MUCH.
EVERYONE.
APPRECIATE YOU BEING HERE.